

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajem1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * * * Welcome to STN International * * * * * * * * *

| | |
|-----------------------------|---|
| NEWS 1 | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 APR 02 | CAS Registry Number Crossover Limits Increased to
500,000 in Key STN Databases |
| NEWS 3 APR 02 | PATDPAFULL: Application and priority number formats
enhanced |
| NEWS 4 APR 02 | DWPI: New display format ALLSTR available |
| NEWS 5 APR 02 | New Thesaurus Added to Derwent Databases for Smooth
Sailing through U.S. Patent Codes |
| NEWS 6 APR 02 | EMBASE Adds Unique Records from MEDLINE, Expanding
Coverage back to 1948 |
| NEWS 7 APR 07 | CA/Caplus CLASS Display Streamlined with Removal of
Pre-IPC 8 Data Fields |
| NEWS 8 APR 07 | 50,000 World Traditional Medicine (WTM) Patents Now
Available in Caplus |
| NEWS 9 APR 07 | MEDLINE Coverage Is Extended Back to 1947 |
| NEWS 10 JUN 16 | WPI First View (File WPIFV) will no longer be
available after July 30, 2010 |
| NEWS 11 JUN 18 | DWPI: New coverage - French Granted Patents |
| NEWS 12 JUN 18 | CAS and FIZ Karlsruhe announce plans for a new
STN platform |
| NEWS 13 JUN 18 | IPC codes have been added to the INSPEC backfile
(1969-2009) |
| NEWS 14 JUN 21 | Removal of Pre-IPC 8 data fields streamline displays
in CA/Caplus, CASREACT, and MARPAT |
| NEWS 15 JUN 21 | Access an additional 1.8 million records exclusively
enhanced with 1.9 million CAS Registry Numbers --
EMBASE Classic on STN |
| NEWS 16 JUN 28 | Introducing "CAS Chemistry Research Report": 40 Years
of Biofuel Research Reveal China Now Atop U.S. in
Patenting and Commercialization of Bioethanol |
| NEWS 17 JUN 29 | Enhanced Batch Search Options in DGENE, USGENE,
and PCTGEN |
| NEWS 18 JUL 19 | Enhancement of citation information in INFADOC
databases provides new, more efficient competitor
analyses |
| NEWS 19 JUL 26 | CAS coverage of global patent authorities has
expanded to 61 with the addition of Costa Rica |
| NEWS EXPRESS FEBRUARY 15 10 | CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010. |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS LOGIN | Welcome Banner and News Items |

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 20:26:22 ON 17 AUG 2010

=> FIL REGISTRY
COST IN U.S. DOLLARS

| | SINCE FILE
ENTRY | TOTAL
SESSION |
|---------------------|---------------------|------------------|
| FULL ESTIMATED COST | 0.88 | 0.88 |

FILE 'REGISTRY' ENTERED AT 20:28:40 ON 17 AUG 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 AUG 2010 HIGHEST RN 1236252-88-2
DICTIONARY FILE UPDATES: 16 AUG 2010 HIGHEST RN 1236252-88-2

New CAS Information Use Policies. Enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stn/gen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10-542,759-2 quinoline.str



chain nodes :

21 22

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

chain bonds :

4-21 21-22

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16 15-17 16-20 17-18 18-19 19-20

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-21 5-6 5-7 6-10 7-8 8-9 9-10 21-22

normalized bonds :

11-12 11-16 12-13 13-14 14-15 15-16 15-17 16-20 17-18 18-19 19-20

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom


20:Atom 21:CLASS 22:CLASS 23:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 20:29:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1401 TO ITERATE

100.0% PROCESSED 1401 ITERATIONS
SEARCH TIME: 00.00.01

5 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 25775 TO 30265
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> s 11 sss full
FULL SEARCH INITIATED 20:29:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 27736 TO ITERATE

100.0% PROCESSED 27736 ITERATIONS
SEARCH TIME: 00.00.01

139 ANSWERS

L3 139 SEA SSS FUL L1

| | | |
|----------------------|------------|---------|
| => file caplus | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| FULL ESTIMATED COST | ENTRY | SESSION |
| | 192.03 | 192.91 |

FILE 'CAPLUS' ENTERED AT 20:29:49 ON 17 AUG 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Aug 2010 VOL 153 ISS 8
FILE LAST UPDATED: 16 Aug 2010 (20100816/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 18 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 18 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:969083 CAPLUS
DOCUMENT NUMBER: 149:443052
TITLE: The discovery of small molecule chemical probes of Bcl-XL and Mcl-1
AUTHOR(S): Prakesch, Michael; Denisov, Alexey Yu; Naim, Marwen; Gehring, Kalle; Arya, Prabhat
CORPORATE SOURCE: MaRS Centre, Ontario Institute for Cancer Research, Toronto, ON, M5G 1L7, Can.
SOURCE: Bioorganic & Medicinal Chemistry (2008), 16(15), 7443-7449
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 149:443052

AB A tetrahydroaminoquinoline-based library was generated with the goals of finding small mol. modulators of protein-protein interactions. Several library members as well as other related intermediates were tested for their ability to bind to Bcl-XL and Mcl-1 by *in silico* and ¹⁵N NMR studies. The NMR study led to the identification of the tetrahydroaminoquinoline-based nude scaffold, as a weak binder ($K_d = 200 \mu\text{M}$ for Bcl-XL and $K_d = 300 \mu\text{M}$ for Mcl-1) to both proteins. Using this scaffold as the starting material, the authors then synthesized a focused library of only 9 derivs. by applying the principles of a fragment-based approach. All these derivs. were then tested by NMR and this led to the discovery of a novel, small mol. (MIPRALDEN) as a binder to Mcl-1 and Bcl-XL ($K_d = 25$ and $70 \mu\text{M}$). This finding is novel because to the authors' knowledge there are not many small mols. known in the literature that bind to Mcl-1.


IT 1068149-12-1P 1068149-18-7P

RL: BUU (Biological use, unclassified); CPN (Combinatorial preparation); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); PROC (Process); USES (Uses)
(discovery of small mol. chemical probes of proteins Bcl-XL and Mcl-1)

RN 1068149-12-1 CAPLUS

CN 2-Quinolineacetic acid, 1,2,3,4-tetrahydro-3-hydroxy-6-[(2-methoxyethoxy)methoxy]-1-(2-naphthalenylcarbonyl)-4-[(2-propen-1-yloxy)carbonyl]amino-, (2S,3R,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1068149-18-7 CAPLUS


CN 2-Quinolineacetic acid, 1,2,3,4-tetrahydro-3-hydroxy-6-[(2-methoxyethoxy)methoxy]-1-(2-naphthalenylcarbonyl)-4-[(2-naphthalenylcarbonyl)amino]-, (2S,3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 1068149-23-4P 1068149-26-7P 1068149-64-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (discovery of small mol. chemical probes of proteins Bcl-XL and Mcl-1)
 RN 1068149-23-4 CAPLUS
 CN 2-Quinolineacetic acid, 3-(acetyloxy)-1,2,3,4-tetrahydro-6-[(2-methoxyethoxy)methoxy]-1-(2-naphthalenylcarbonyl)-4-[(2-propen-1-yloxy)carbonyl]amino]-, ethyl ester, (2S,3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1068149-26-7 CAPLUS
 CN 2-Quinolineacetic acid, 3-(acetyloxy)-1,2,3,4-tetrahydro-6-[(2-methoxyethoxy)methoxy]-1-(2-naphthalenylcarbonyl)-4-[(2-naphthalenylcarbonyl)(2-propen-1-yloxy)carbonyl]amino-, ethyl ester, (2S,3S,4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1068149-64-3 CAPLUS

CN 2-Quinolineacetic acid, 3-(acetoxy)-1,2,3,4-tetrahydro-6-[(2-methoxyethoxy)methoxy]-1-(2-naphthalenylcarbonyl)-4-[(2-naphthalenylcarbonyl)amino]-, ethyl ester, (2S,3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1193399 CAPLUS
DOCUMENT NUMBER: 143:440276
TITLE: Phenanthridine analogues, their preparation, pharmaceutical compositions, and uses as inhibitors of hyperproliferation of T cells and keratinocytes
INVENTOR(S): Pegeraro, Stefano; Lang, Martin; Feurle, Julianne; Krauss, Juergen
PATENT ASSIGNEE(S): 4SC AG, Germany; Switch Biotech AG
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2005105752 | A1 | 20051110 | WO 2004-EP11121 | 20041005 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, | | | |

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 EP 1652841 A1 20060503 EP 2004-10341 20040430
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 AU 2004319072 A1 20051110 AU 2004-319072 20041005
 CA 2562400 A1 20051110 CA 2004-2562400 20041005
 EP 1740548 A1 20070110 EP 2004-790131 20041005
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
 CN 1934087 A 20070321 CN 2004-80042522 20041005
 BR 2004018782 A 20071009 BR 2004-18782 20041005
 JP 2007538007 T 20071227 JP 2007-509886 20041005
 NZ 551399 A 20090828 NZ 2004-551399 20041005
 US 20050282801 A1 20051222 US 2005-118421 20050502
 US 7276606 B2 20071002
 IN 2006MN01096 A 20070622 IN 2006-MN1096 20060913
 MX 2006011763 A 20070413 MX 2006-11763 20061011
 PRIORITY APPLN. INFO.: EP 2004-10341 A 20040430
 US 2004-566820P P 20040430
 WO 2004-EP11121 W 20041005

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:440276; MARPAT 143:440276


GI



AB The invention relates to phenanthridine analogs, e.g., general formula I, which are inhibitors of T cell hyperproliferation and keratinocyte hyperproliferation. In compds. I, A is SO₂ or substituted C; R1 is alkyl, alkoxy, OH, SH, acyl, carboxy, aryl, heteroaryl, etc.; and X and Y are independently N or (un)substituted C. The invention also relates to the preparation of I, pharmaceutical compns. containing I, optionally with appropriate adjuvants and additives, as well as to the use of the compns. for the inhibition of T cell or keratinocyte hyperproliferation. Addition of indole to phenanthridine and acylation with 2-furoyl chloride gave phenanthridine analog II. Several compds. of the invention express more than 50% inhibition of keratinocyte proliferation and seven of those compds., e.g., II, also express EC₅₀ value below 25 μM in a T cell proliferation assay.
IT 868853-64-9P, [6-(1-Indol-3-yl)-6H-phenanthridin-5-yl]naphthalen-1-ylmethanone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of phenanthridine analogs as inhibitors of hyperproliferation of T cells and keratinocytes)

RN 868853-64-9 CAPLUS
CN Methanone, [6-(1H-indol-3-yl)-5(6H)-phenanthridinyl]-1-naphthalenyl- (CA
INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1012143 CAPLUS
DOCUMENT NUMBER: 143:398877
TITLE: Perhydroquinolylbenzamides as Novel Inhibitors of
11 β -Hydroxysteroid Dehydrogenase Type 1
AUTHOR(S): Coppola, Gary M.; Kukkola, Paivi J.; Stanton, James
L.; Neubert, Alan D.; Marcopoulos, Nicholas; Bilci,
Natalie A.; Wang, Huai; Tomaselli, Hollis C.; Tan,
Jenny; Aicher, Thomas D.; Knorr, Douglas C.; Jeng,
Arco Y.; Dardik, Beatriz; Chatelain, Ricardo E.
CORPORATE SOURCE: Department of Metabolic and Cardiovascular Diseases,
Novartis Institutes for Biomedical Research,
Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2005), 48(21),
6696-6712
PUBLISHER: CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: American Chemical Society
LANGUAGE: Journal
OTHER SOURCE(S): English
AB High-throughput screening identified 5 as a weak inhibitor of
11 β -HSD1. Optimization of the structure led to a series of
perhydroquinolylbenzamides, some with low nanomolar inhibitory potency. A
tertiary benzamide is required for biol. activity and substitution of the
terminal benzamide with either electron-donating or -withdrawing groups is
tolerated. The majority of the compds. show selectivity of >20 to
>700-fold over 11 β -HSD2. Analogs which showed >50% inhibition of
11 β -HSD1 at 1 μ M in an cellular assay were screened in an ADX
mouse model. A maximal response of >70% reduction of liver corticosterone
levels was observed for three compds.; 9m, 25 and 49.
IT 867288-49-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid
dehydrogenase)


RN 867288-49-1 CAPLUS
CN Benzanide, 2,4-dichloro-N-[4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-1-naphthalenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 867288-60-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)
RN 867288-60-6 CAPLUS
CN Methanone, (4-nitro-1-naphthalenyl)[(4aR,8aS)-octahydro-1(2H)-quinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 867288-61-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)
RN 867288-61-7 CAPLUS
CN Methanone, (4-amino-1-naphthalenyl)[(4aR,8aS)-octahydro-1(2H)-quinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
 REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:696877 CAPLUS
 DOCUMENT NUMBER: 143:211847
 TITLE: Preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity
 Potashman, Michele; Kim, Tae-Seong; Bellon, Steven; Booker, Shon; Cheng, Yuan; Kim, Joseph L.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Harmange, Jean-Christophe; Borg, George; Weiss, Matthew; Hodous, Brian L.; Graceffa, Russell; Buckner, William H.; Masse, Craig E.; Choquette, Deborah; Martin, Matthew W.; Germain, Julie; Dipietro, Lucian V.; Chaffee, Stuart C.; Nunes, Joseph J.; Buchanan, John L.; Habgood, Gregory J.; McGowan, David C.; Whittington, Douglas A.

PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 444 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2005070891 | A2 | 20050804 | WO 2005-US2326 | 20050124 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2005206571 | A1 | 20050804 | AU 2005-206571 | 20050124 |

| | | | | |
|---|----|----------|------------------|-------------|
| CA 2553423 | A1 | 20050804 | CA 2005-2553423 | 20050124 |
| EP 1713484 | A2 | 20061025 | EP 2005-722533 | 20050124 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU | | | | |
| US 20060241115 | A1 | 20061026 | US 2005-42634 | 20050124 |
| US 7435823 | B2 | 20081014 | | |
| CN 1933839 | A | 20070321 | CN 2005-80006839 | 20050124 |
| BR 2005007373 | A | 20070710 | BR 2005-7373 | 20050124 |
| JP 2007518824 | T | 20070712 | JP 2006-551404 | 20050124 |
| MX 2006008327 | A | 20060929 | MX 2006-8327 | 20060721 |
| IN 2006CN02683 | A | 20070608 | IN 2006-CN2683 | 20060721 |
| NO 2006003693 | A | 20061023 | NO 2006-3693 | 20060817 |
| ZA 2006005941 | A | 20080227 | ZA 2006-6941 | 20060821 |
| US 20090176774 | A1 | 20090709 | US 2008-157303 | 20080609 |
| PRIORITY APPLN. INFO.: | | | US 2004-538691P | P 20040123 |
| | | | US 2005-42634 | A3 20050124 |
| | | | WO 2005-US2326 | W 20050124 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:211847; MARPAT 143:211847

GI



II

AB The title compds. I [R1XAYR; R = (un)substituted aryl, heterocyclyl, cycloalkyl, etc.; R1 = (un)substituted quinolinyl, quinazolinyl, pyrimidinyl, etc.; A = (un)substituted naphthalenediyI, etc.; X = O, S, (un)substituted NH, CH2; Y = NHCO, CONH, etc.] which are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases, were prepared. E.g., a multi-step synthesis of II, starting from 6-hydroxy-2-naphthoic acid, was given. The compds. I showed inhibition of LcK kinase, c-Met kinase, and VEGFR kinase at less than 10 μ M. The invention encompasses novel compds. I, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutically compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.


IT 861876-16-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity)

RN 861876-16-6 CAPLUS

CN 2-Pyridinecarboxamide, 4-[(5-[[3,4-dihydro-7-(trifluoromethyl)-1-(2H)-quinolinyl]carbonyl]-2-naphthalenyl]oxy]-N-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:633903 CAPLUS

DOCUMENT NUMBER: 141:173975

TITLE: Preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1

INVENTOR(S): Coppola, Gary Mark; Damon, Robert Edson; Kukkola, Paivi Jaana; Stanton, James Lawrence

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH

SOURCE: PCT Int. Appl., 145 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2004065351 | A1 | 20040805 | WO 2004-EP571 | 20040123 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ | | | | |
| CA 2513349 | A1 | 20040805 | CA 2004-2513349 | 20040123 |
| EP 1590319 | A1 | 20051102 | EP 2004-704554 | 20040123 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2004006938 | A | 20060103 | BR 2004-6938 | 20040123 |
| CN 1741986 | A | 20060301 | CN 2004-80002540 | 20040123 |
| JP 2006517199 | T | 20060720 | JP 2006-500009 | 20040123 |
| US 20060205772 | A1 | 20060914 | US 2005-542759 | 20050816 |
| PRIORITY APPLN. INFO.: | | | US 2003-442532P | P 20030124 |
| | | | WO 2004-EP571 | W 20040123 |

OTHER SOURCE(S): MARPAT 141:173975

GI



AB The title compds. [I; R1, R2 = H, CN, halo, NO₂, etc.; or R1 and R2 together with the carbon atoms they are attached to form an optionally substituted 5-7 membered (hetero)aromatic ring; R3 = alkyl; or R3 and R2 together with the amide group to which R3 is attached and the carbon atoms to which R2 and the amide are attached form (un)substituted 5-7 membered carbocyclic or heterocyclic ring; R4 = alkyl, cycloalkyl, heterocyclyl, aryl, (hetero)aralkyl; or NR4R3 = (un)substituted 5-8 membered ring, 8-12 membered fused bicyclic ring (both ring systems may contain another heteroatom selected from O, N and S); W = NR5COR6, NR5CO2R6, NR5CONR6R7, etc.; R5, R7 = H, alkyl, aralkyl; R6 = alkyl, cycloalkyl, heterocyclyl, aryl, (hetero)aralkyl; X, Y = CH, N; or X:Y = CH₂, O, S, NR10 (R10 = H, alkyl)] which lower intracellular glucocorticoid concns. in mammals, in particular, intracellular cortisol levels in humans, were prepared. E.g., two alternative routes for preparation of the amide II were given. The compds. I were tested for inhibition of 11 β -HSD1 (specific data given for representative compds. I). The compds. I improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compds. I lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration

in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compds. I may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compds. I may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compds. I for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.

| | | | |
|----|--------------|--------------|--------------|
| IT | 735347-02-1P | 735347-03-2P | 735347-04-3P |
| | 735347-05-4P | 735347-06-5P | 735347-07-6P |
| | 735347-08-7P | 735347-09-8P | 735347-10-1P |
| | 735347-11-2P | 735347-12-3P | 735347-13-4P |
| | 735347-14-5P | 735347-15-6P | 735347-16-7P |
| | 735347-17-8P | 735347-18-9P | 735347-19-0P |
| | 735347-20-3P | 735347-21-4P | 735347-22-5P |
| | 735347-23-6P | 735347-24-7P | 735347-25-8P |

| | | |
|--------------|--------------|--------------|
| 735347-26-9P | 735347-27-0P | 735347-28-1P |
| 735347-29-2P | 735347-30-5P | 735347-31-6P |
| 735347-32-7P | 735347-33-8P | 735347-34-9P |
| 735347-35-0P | 735347-36-1P | 735347-37-2P |
| 735347-38-3P | 735347-39-4P | 735347-40-7P |
| 735347-41-8P | 735347-42-9P | 735347-43-0P |
| 735347-44-1P | 735347-45-2P | 735347-46-3P |
| 735347-47-4P | 735347-48-5P | 735347-49-6P |
| 735347-50-9P | 735347-51-0P | 735347-54-3P |
| 735347-56-5P | 735347-57-6P | 735347-58-7P |


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1)

RN 735347-02-1 CAPLUS


CN Benzamide, 3,4-dimethoxy-N-[4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-1-naphthalenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735347-03-2 CAPLUS

CN Benzamide, 4-(hexyloxy)-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-04-3 CAPLUS

CN Benzamide, 4-hexyl-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-05-4 CAPLUS


CN Benzamide, 4-fluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 735347-06-5 CAPLUS
CN Benzamide, 2-chloro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-07-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-08-7 CAPLUS

CN Benzamide, 4-butyl-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-09-8 CAPLUS

CN Benzamide, 2,4-difluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-10-1 CAPLUS

CN Benzamide, 3,4-difluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-11-2 CAPLUS

CN Benzamide, 3-fluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-12-3 CAPLUS

CN Benzamide, 2-fluoro-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]-4-(trifluoromethyl)- (CA INDEX NAME)




RN 735347-13-4 CAPLUS

CN Benzamide, N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]-4-pentyl- (CA INDEX NAME)




RN 735347-14-5 CAPLUS

CN Benzamide, 2-methoxy-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 735347-15-6 CAPLUS

CN Benzamide, N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]-4-phenoxy- (CA INDEX NAME)



RN 735347-16-7 CAPLUS


CN Benzamide, 4-methoxy-N-[4-[(octahydro-1(2H)-quinolinyl)carbonyl]-1-naphthalenyl]- (CA INDEX NAME)



RN 735347-17-8 CAPLUS

CN 1-Naphthalenecarboxamide, N-(4-fluorophenyl)-4-[[^{4aR,8aS}]-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-18-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2-methylpropyl)-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-19-0 CAPLUS

CN 1-Naphthalenecarboxamide, N-cyclohexyl-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-20-3 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(4-methoxyphenyl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-21-4 CAPLUS

CN 1-Naphthalenecarboxamide, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-[1-(phenylmethyl)-4-piperidinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-22-5 CAPLUS

CN 1-Naphthalenecarboxamide, N-decyl-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-23-6 CAPLUS

CN 1-Naphthalenecarboxamide, N-[(4-chlorophenyl)methyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-24-7 CAPLUS

CN 1-Naphthalene carboxamide, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-(phenylmethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-25-8 CAPLUS

CN 1-Naphthalene carboxamide, N-methyl-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-(2-phenylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-26-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(4-ethoxyphenyl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-27-0 CAPLUS

CN 1-Naphthalenecarboxamide, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-[2-(4-phenoxyphenyl)ethyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-28-1 CAPLUS

CN 1-Naphthalene carboxamide, N-[2-(2,4-dichlorophenyl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-29-2 CAPLUS

CN 1-Naphthalene carboxamide, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-[2-(4-pyridinyl)ethyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-30-5 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(3-chlorophenyl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-31-6 CAPLUS


CN 1-Naphthalenecarboxamide, N-[{(2-fluorophenyl)methyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735347-32-7 CAPLUS
 CN 1-Naphthalenecarboxamide, N-(2-methylbutyl)-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735347-33-8 CAPLUS
 CN 1-Naphthalenecarboxamide, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-[2-(2-pyridinyl)ethyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-34-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(2-chlorophenyl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-35-0 CAPLUS

CN 1-Naphthalenecarboxamide, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-(2-phenylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-36-1 CAPLUS

CN 1-Naphthalene carboxamide, N-(4-cyanophenyl)-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-37-2 CAPLUS

CN 1-Naphthalene carboxamide, N-(4-butylphenyl)-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-38-3 CAPLUS

CN 1-Naphthalenecarboxamide, N-[1,1'-biphenyl]-4-yl-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-39-4 CAPLUS

CN Quinoline, decahydro-1-[(4-(1-piperidinyl)carbonyl)-1-naphthalenyl]carbonyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735347-40-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2,4-dichlorophenyl)-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carboxyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-41-8 CAPLUS

CN 1-Naphthalenecarboxamide, N-hexyl-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carboxyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-42-9 CAPLUS

CN 1-Naphthalene carboxamide, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-(3-phenylpropyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-43-0 CAPLUS

CN 1-Naphthalene carboxamide, N-[2-(3-methoxyphenyl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-44-1 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(2-methoxyphenyl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-45-2 CAPLUS

CN 1-Naphthalenecarboxamide, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-N-[2-(3-pyridinyl)ethyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-46-3 CAPLUS

CN Quinoline, decahydro-1-[(4-[(4-phenyl-1-piperidinyl)carbonyl]-1-naphthalenyl)carbonyl]-, (4aR,8aS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735347-47-4 CAPLUS

CN 1-Naphthalene carboxamide, N-[2-(1,3-benzodioxol-5-yl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-48-5 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(3,4-dichlorophenyl)ethyl]-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-49-6 CAPLUS

CN 1-Naphthalenecarboxamide, N-(2-chlorophenyl)-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-50-9 CAPLUS

CN 1-Naphthalenecarboxamide, N-(3,4-dimethoxyphenyl)-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carboxylic acid, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-51-0 CAPLUS

CN 1-Naphthalenecarboxamide, N-(4-methoxyphenyl)-4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carboxylic acid, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-54-3 CAPLUS

CN Methanone, [6-(acetyloxy)-2-naphthalenyl][(4aR,8aR)-octahydro-1(2H)-quinolinyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-56-5 CAPLUS

CN Methanone, 2-naphthalenyl[(4aR,8aS)-octahydro-1(2H)-quinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735347-57-6 CAPLUS

CN 2-Naphthalenecarboxamide, N-(2-methylpropyl)-6-[[(4aR,8aS)-octahydro-1(2H)-

quinolinyl]carbonyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735347-58-7 CAPLUS

CN Methanone, [6-(acetyloxy)-2-naphthalenyl][(4aR,8aS)-octahydro-1(2H)-quinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 735351-65-2P 735351-66-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1)

RN 735351-65-2 CAPLUS

CN 1-Naphthalenecarboxylic acid, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl]-, methyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735351-66-3 CAPLUS

CN 1-Naphthalene carboxylic acid, 4-[(4aR,8aS)-octahydro-1(2H)-quinolinyl]carbonyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:1006774 CAPLUS

DOCUMENT NUMBER: 140:35993

TITLE: Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex

INVENTOR(S): Michelotti, Enrique L.; Tice, Colin M.; Palli, Subba Reddy; Thompson, Christine S.; Dhadialla, Tarlochan S.

PATENT ASSIGNEE(S): Rheogene, Inc., USA

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003105849 | A1 | 20031224 | WO 2003-US18796 | 20030613 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20050228016 | A1 | 20051013 | US 2003-460820 | 20030612 |
| CA 2486407 | A1 | 20031224 | CA 2003-2488407 | 20030613 |
| AU 2003236529 | A1 | 20031231 | AU 2003-236529 | 20030613 |
| EP 1513530 | A1 | 20050316 | EP 2003-737088 | 20030613 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2006052977 | T | 20060126 | JP 2004-512752 | 20030613 |
| MX 2004012391 | A | 20050419 | MX 2004-12391 | 20041209 |
| PRIORITY APPLN. INFO.: | | | US 2002-388353P | P 20020613 |
| | | | US 2003-460820 | A 20030612 |
| | | | WO 2003-US18796 | W 20030613 |

OTHER SOURCE(S): MARPAT 140:35993


AB This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of 4-tetrahydroquinolines.

IT 300718-72-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex)

RN 300718-72-3 CAPLUS

CN Methanone, [3,4-dihydro-2-methyl-4-(phenylamino)-1(2H)-quinolinyl]-1-naphthalenyl- (CA INDEX NAME)




| | | |
|----------------------|---|--|
| OS.CITING REF COUNT: | 2 | THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS) |
| REFERENCE COUNT: | 4 | THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT |

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2002:408625 CAPLUS
 DOCUMENT NUMBER: 137:6003
 TITLE: Preparation of naphthalene derivatives as cannabinoid CB1 receptor ligands.
 INVENTOR(S): Brain, Christopher Thomas; Culshaw, Andrew James;
 Dziadulewicz, Edward Karol; Schopfer, Ulrich
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Erfindungen
 Verwaltungsgesellschaft m.b.H.
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-----------------|------------------|----------|
| WO 2002042248 | A2 | 20020530 | WO 2001-EP13605 | 20011122 |
| WO 2002042248 | A3 | 20021219 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| TW 314140 | B | 20090901 | TW 2001-90128718 | 20011120 |
| CA 2427844 | A1 | 20020530 | CA 2001-2427844 | 20011122 |
| AU 2002026350 | A | 20020603 | AU 2002-26350 | 20011122 |
| EP 1339663 | A2 | 20030903 | EP 2001-995657 | 20011122 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2001015605 | A | 20030916 | BR 2001-15605 | 20011122 |
| HU 2003002125 | A2 | 20031028 | HU 2003-2125 | 20011122 |
| HU 2003002125 | A3 | 20070529 | | |
| JP 2004514663 | T | 20040520 | JP 2002-544387 | 20011122 |
| CN 1224598 | C | 20051026 | CN 2001-819438 | 20011122 |
| NZ 548553 | A | 20080328 | NZ 2001-548553 | 20011122 |
| RU 2354646 | C2 | 20090510 | RU 2003-117459 | 20011122 |
| KR 810948 | B1 | 20080310 | KR 2003-705038 | 20030410 |
| ZA 2003002916 | A | 20040423 | ZA 2003-2916 | 20030411 |
| US 20040053890 | A1 | 20040318 | US 2003-432120 | 20030519 |
| US 7045533 | B2 | 20060516 | | |
| IN 2003CN00781 | A | 20050415 | IN 2003-CN781 | 20030521 |
| IN 222611 | A1 | 20081121 | | |
| NO 2003002327 | A | 20030718 | NO 2003-2327 | 20030522 |
| MX 2003004593 | A | 20030904 | MX 2003-4593 | 20030523 |
| AU 2006200813 | A1 | 20060316 | AU 2006-200813 | 20060224 |
| JP 2008050361 | A | 20080306 | JP 2007-236718 | 20070912 |
| AU 2009240832 | A1 | 20091217 | AU 2009-240832 | 20091125 |
| PRIORITY APPLN. INFO.: | | | | |
| | | GB 2000-28702 | A 20001124 | |
| | | AU 2002-26350 | T0 20011122 | |
| | | JP 2002-544387 | A3 20011122 | |
| | | WO 2001-EP13605 | W 20011122 | |
| | | AU 2002-226350 | A3 20020630 | |
| | | AU 2006-200813 | A3 20060224 | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 137:6003



AB Title compds. [I; X = S, SO, SO₂, SO₂NH, P(O)(OMe), P(O)(OH), NH, NMe, NHCONH, CO, CO₂, NHCO, CH(OH), CH:N, CH:CH, CH₂NH, C:(NH); R₁ = aryl, heteroaryl; R₂ = H, OR₄, NR₅R₆; R₄ = alkyl, alkenyl; R₅ R₆ = H, alkyl, alkylcarbonyl; R₃ = H, cyano, heteroaryl, heterocycloalkyl, COR₇, OR₈, NR₉R₁₀; R₇ = OH, alkoxy, NH₂, NHCH₂CO₂H, aryl; R₈ = H, alkyl, alkylcarbonyl, arylcarbonyl; R₉, R₁₀ = H, alkyl, alkenyl; with the proviso that when X = CO and R₂ and R₃ = H or R₂ = H and R₃ = 4-MeO, R₁ = neither 1-naphthyl nor 4-methoxy-1-naphthyl], were prepared Thus, (naphthalen-1-yl)(4-hydroxynaphthalen-1-yl)methanone was refluxed 22 h with K₂CO₃ and 1-bromopentane in acetone to give (naphthalen-1-yl)(4-pentyloxy)naphthalen-1-yl)methanone. I showed IC₅₀ values of 1-100 μ M in a CB₁ receptor binding assay.


IT 432048-51-6P 432048-52-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naphthalene derivs. as cannabinoid CB1 receptor ligands)


RN 432048-51-6 CAPLUS

CN Methanone, (3,4-dihydro-8-hydroxy-1(2H)-quinolinyl)[4-(pentyloxy)-1-naphthalenyl]- (CA INDEX NAME)



RN 432048-52-7 CAPLUS

CN Methanone, (3,4-dihydro-1(2H)-quinolinyl)[4-(pentyloxy)-1-naphthalenyl]-
(CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (8 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2001:603689 CAPLUS
 DOCUMENT NUMBER: 135:182179
 TITLE: Storage stable aqueous ink compositions and image formation method therewith
 INVENTOR(S): Oya, Hidenobu
 PATENT ASSIGNEE(S): Konica Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 21 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------------------------|---|----------|-----------------|----------|
| JP 2001226614 | A | 20010821 | JP 2000-39360 | 20000217 |
| JP 3915364 | B2 | 20070516 | | |
| EP 1125995 | A2 | 20010822 | EP 2001-301325 | 20010215 |
| EP 1125995 | A3 | 20011205 | | |
| R: AT, BE, CH,
IE, SI, LT, | DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
LV, FI, RO | | | |
| US 20010023652 | A1 | 20010927 | US 2001-785001 | 20010216 |
| US 6676737 | B2 | 20040113 | | |

PRIORITY APPLN. INFO.: JP 2000-39360 A 20000217

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:182179


AB Title compns. are characterized in that precursors, which are converted to insol. pigments by chemical, thermal, photodecompr., and/or radiation methods, are dissolved in aqueous medium. The compns. have good storage stability and form images with good gloss, light resistance, and no blur after 30 days at 60° and 80% relative humidity.

IT 355015-58-6

RL: PEP (Physical, engineering or chemical process); TEM (Technical or engineered material use); PROC (Process); USES (Uses)
 (pigment precursors in storage stable aqueous ink compns. giving images with good quality and storage stability)

RN 355015-58-6 CAPLUS

CN 2-Naphthalenesulfonic acid, 3,3'-(7,14-dihydro-2,9-dimethyl-7,14-dioxoquinol[2,3-b]acridine-5,12-diyl)dicarbonyl]bis-, disodium salt (9CI)
 (CA INDEX NAME)



● 2 Na

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2001:247327 CAPLUS
DOCUMENT NUMBER: 1341:280860
TITLE: Preparation of piperazine derivatives as 5-HT1B antagonists
INVENTOR(S): Marshall, Howard; Thompson, Mervyn; Wyman, Paul Adrian
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2001023374 | A1 | 20010405 | WO 2000-EP9442 | 20000921 |
| W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2385737 | A1 | 20010405 | CA 2000-2385737 | 20000921 |
| BR 2000014279 | A | 20020521 | BR 2000-14279 | 20000921 |
| EP 1216239 | A1 | 20020626 | EP 2000-967803 | 20000921 |
| EP 1216239 | B1 | 20040211 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL | | | | |
| TR 2002000795 | T2 | 20020722 | TR 2002-795 | 20000921 |
| HU 2002002787 | A2 | 20021228 | HU 2002-2787 | 20000921 |
| HU 2002002787 | A3 | 20031229 | | |
| JP 2003510317 | T | 20030318 | JP 2001-526526 | 20000921 |
| AU 765020 | B2 | 20030904 | AU 2000-77836 | 20000921 |
| NZ 517865 | A | 20031128 | NZ 2000-517865 | 20000921 |

| | | | | |
|------------------------|----|----------|----------------|-------------|
| AT 259363 | T | 20040215 | AT 2000-967803 | 20000921 |
| PT 1216239 | E | 20040531 | PT 2000-967803 | 20000921 |
| ES 2211624 | T3 | 20040716 | ES 2000-967803 | 20000921 |
| CN 1190432 | C | 20050223 | CN 2000-816269 | 20000921 |
| IN 2002MN00325 | A | 20050318 | IN 2002-MN325 | 20020318 |
| NO 2002001459 | A | 20020322 | NO 2002-1459 | 20020322 |
| ZA 2002002319 | A | 20021121 | ZA 2002-2319 | 20020322 |
| MX 2002003175 | A | 20020930 | MX 2002-3175 | 20020325 |
| US 6747030 | B1 | 20040608 | US 2002-89013 | 20020325 |
| HK 1046909 | A1 | 20041203 | HK 2002-108463 | 20021121 |
| US 20040176388 | A1 | 20040909 | US 2004-802236 | 20040317 |
| PRIORITY APPLN. INFO.: | | | GB 1999-22831 | A 19990925 |
| | | | GB 2000-1936 | A 20000127 |
| | | | GB 2000-13873 | A 20000607 |
| | | | WO 2000-EP9442 | W 20000921 |
| | | | US 2002-89013 | A1 20020325 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:280860

GI



AB Piperazine derivs. I [Ra = R1aP1 where P1 = Ph, naphthyl, heteroaryl and R1 = halo, alkyl, cycloalkyl, etc.; Rb = H, halo, OH, alkyl, etc.; Rc = H, alkyl; Rd, Re = alkyl; Y = bond, CH2, O, NR5; W = (CR9R10)t where t = 2-4 and R9 and R10 = H, alkyl or W = CH:CH], 5-HT1B antagonists, were prepared. All examples tested in the radioligand binding assay were found to have a pKi > 7.3 at 5-HT1B receptors with many demonstrating a pKi in the higher range of 8.0-9.2. E.g., cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline was prepared.


IT 332397-35-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazine derivs. as 5-HT1B antagonists)

RN 332397-35-0 CAPLUS

CN Methanone, [3,4-dihydro-6-methoxy-7-[(3R,5S)-3,4,5-trimethyl-1-piperazinyl]-1(2H)-quinolinyl][4-(6-methyl-2-pyridinyl)-1-naphthalenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1995:69737 CAPLUS
 DOCUMENT NUMBER: 122:177364
 ORIGINAL REFERENCE NO.: 122:32240h,32241a
 TITLE: Enantiomer separation by high-performance liquid chromatography on polysiloxane-based chiral stationary phases
 AUTHOR(S): Schleimer, Michael; Pirkle, William H.; Schurig, Volker
 CORPORATE SOURCE: Institut fuer Organische Chemie der Universitaet, Auf der Morgenstelle 18, Tuebingen, 7400, Germany
 SOURCE: Journal of Chromatography, A (1994), 679(1), 23-34
 DOCUMENT TYPE: CODEN: JCRAEY; ISSN: 0021-9673
 LANGUAGE: Journal
 English
 AB The synthesis of two polysiloxane-based chiral stationary phases (CSPs) derived from a π -acidic N-(3,5-dinitrobenzoyl)- β -amino acid (JEM-1) and a π -basic N-(1-naphthyl)leucine selector is described as is their systematic comparison with the corresponding brush-type CSPs. The enantioselectivity of the polysiloxane-based CSPs is higher under both normal- and reversed-phase conditions. In the normal-phase mode, the greater enantioselectivity stems from smaller retention factors for the least retained enantiomers, presumably because of a reduction of analyte interactions with the support silanols owing to effective shielding of the surface by the polymer. The retention factors of the 2nd-eluted enantiomers are shifted to higher values on the π -basic CSP and to lower values on the π -acidic CSP. The latter CSP shows but a small increase in enantioselectivity relative to the corresponding brush-type CSP having a comparable selector loading. The silanophilic interactions can be further reduced by end-capping with hexamethyldisilazane (HMDS). When lower amounts of polar modifier were used, the resolution of the polymeric CSPs approaches that of the corresponding brush-type CSP. Under reversed-phase conditions enantioselectivity is reduced but not to the extent generally found for brush-type CSPs. The presence of the nonpolar polymeric backbone can introduce hydrophobic interactions which may alter enantioselectivity. It would seem advantageous to use

dimethylpolysiloxanes having a high selector concentration to reduce the extent of any nonchiral contribution by the polysiloxane backbone to analyte retention while enhancing the favorable chiral recognition properties of the polymer.

IT 90133-16-7, (R)-N-(1-Naphthoyl)-1,2,3,4-tetrahydro-5,6-benzo- α -picoline 90133-17-8,
(S)-N-(1-Naphthoyl)-1,2,3,4-tetrahydro-5,6-benzo- α -picoline
123824-35-1, (\pm)-N-(1-Naphthoyl)-1,2,3,4-tetrahydro-5,6-benzo- α -picoline
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(enantiomer separation by HPLC on polysiloxane-based chiral stationary phases)


RN 90133-16-7 CAPLUS
CN Methanone, [(2R)-3,4-dihydro-2-methyl-1(2H)-quinolinyl]-1-naphthalenyl-
(CA INDEX NAME)

Absolute stereochemistry.




RN 90133-17-8 CAPLUS
CN Methanone, [(2S)-3,4-dihydro-2-methyl-1(2H)-quinolinyl]-1-naphthalenyl-
(CA INDEX NAME)

Absolute stereochemistry.



RN 123824-35-1 CAPLUS
CN Methanone, (3,4-dihydro-3-methyl-1(2H)-quinolinyl)-1-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1994:499785 CAPLUS
 DOCUMENT NUMBER: 121:99785
 ORIGINAL REFERENCE NO.: 121:17707a,17710a
 TITLE: Apoptosis regulator
 INVENTOR(S): Nakai, Satoru; Aihara, Koutoku; Tanaka, Hideo; Iba, Hitomi; Kawai, Kazuyoshi; Ichikawa, Hiroyuki; Akamatsu, Seiji; Saito, Fumio; Tominaga, Michiaki; Adachi, Masakazu
 PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------------|-----------------|----------|
| WO 9404504 | A1 | 19940303 | WO 1993-JP1144 | 19930812 |
| W: AU, CA, JP, KR, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| AU 9347615 | A | 19940315 | AU 1993-47615 | 19930812 |
| AU 666577 | B2 | 19960215 | | |
| EP 623598 | A1 | 19941109 | EP 1994-908099 | 19930812 |
| R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE | | | | |
| US 5464833 | A | 19951107 | US 1994-211818 | 19940419 |
| US 5691341 | A | 19971125 | US 1995-520478 | 19950829 |
| PRIORITY APPLN. INFO.: | | | | |
| | | JP 1992-220373 | A 19920819 | |
| | | WO 1993-JP1144 | W 19930812 | |
| | | US 1994-211818 | A3 19940419 | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 121:99785

AB Carbostyryl derivs. such as 6- [4-(4-ethylbenzoyl)-1-piperazinyl]-3,4-dihydrocarbostyryl (I) and 1-benzyl-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydrocarbostyryl(II) are apoptosis regulators useful as neoplasm inhibitors and other therapeutic agents. Thus, I markedly (71.1%) inhibited the growth of human premyelogenic leukemia cells in cultures. Tablets were prepared containing II 150, Avicel 40, corn starch 30, Mg stearate 2, hydroxypropyl Me cellulose 10, PEG 6000 3, castor oil 40, and methanol 40 g.

IT 104797-10-6


RL: BIOL (Biological study)

(as apoptosis regulator, for cancer and other disease treatment)

RN 104797-10-6 CAPLUS


CN 2(1H)-Quinolinone, 6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydro-

1-(1-naphthalenylcarbonyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (11 CITINGS)
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1994:163035 CAPLUS
 DOCUMENT NUMBER: 120:163035
 ORIGINAL REFERENCE NO.: 120:28747a,28750a
 TITLE: Regioselectivity in forming dipole-stabilized anions.
 Sites of metalation of indolines,
 tetrahydroquinolines, and benzazepines activated by
 N-formimidoyl or N-Boc groups
 AUTHOR(S): Meyers, A. I.; Milot, Guy
 CORPORATE SOURCE: Dep. Chem., Colorado State Univ., Fort Collins, CO,
 80523, USA
 SOURCE: Journal of Organic Chemistry (1993), 58(24), 6538-40
 DOCUMENT TYPE: CODEN: JOCEAH; ISSN: 0022-3263
 LANGUAGE: Journal
 English
 OTHER SOURCE(S): CASREACT 120:163035
 GI




AB Metalation of the title compds. indicated that the formamidine-equipped indolines or 1,2,3,4-tetrahydroquinolines give rise solely to C-2 alkylation products whereas the corresponding N-tert-BOC systems give only ortho aryl alkylation. When the (iminomethyl)benzazepine system I was examined, metalation occurred at both sites albeit the major product was derived from C-2 alkylation. Use of bifunctional dihalides led to good yields of the 1-azabicyclo systems. Deuteration studies also showed that the formamidine moiety totally inhibits ring metalation even though both C-2 protons are deuterated.


IT 153254-69-4P 153254-71-8P 153254-72-9P
 153254-73-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 153254-69-4 CAPLUS
CN Methanone, (3,4-dihydro-2-methyl-1(2H)-quinolinyl)-2-naphthalenyl- (CA INDEX NAME)




RN 153254-71-8 CAPLUS
CN Methanone, (2-butyl-3,4-dihydro-1(2H)-quinolinyl)-2-naphthalenyl- (CA INDEX NAME)



RN 153254-72-9 CAPLUS
CN Methanone, (3,4-dihydro-2-(2-propen-1-yl)-1(2H)-quinolinyl)-2-naphthalenyl- (CA INDEX NAME)




RN 153254-73-0 CAPLUS
CN Methanone, (3,4-dihydro-2-propyl-1(2H)-quinolinyl)-2-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 27 THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1990:54475 CAPLUS
 DOCUMENT NUMBER: 112:54475
 ORIGINAL REFERENCE NO.: 112:9351a,9354a
 TITLE: An improved chiral stationary phase for the facile separation of enantiomers
 AUTHOR(S): Pirkle, William H.; McCune, John E.
 CORPORATE SOURCE: Sch. Chem. Sci., Univ. Illinois, Urbana, IL, 61801, USA
 SOURCE: Journal of Chromatography (1988), 441(2), 311-22
 CODEN: JOCRAM; ISSN: 0021-9673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A chiral stationary phase (CSP) derived from cis-3-(1,1-dimethylethyl)-4-phenyl-2-azetidinone is quite effective for the chromatog. separation of the enantiomers of a variety of compds. This CSP has two stereogenic centers. For many enantiomers, it exhibits superior performance to that of a widely used phenylglycine-derived CSP.
 IT 123824-35-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (chromatog. resolution of, azetidinone-derived stationary phase for)
 RN 123824-35-1 CAPLUS
 CN Methanone, (3,4-dihydro-3-methyl-1(2H)-quinolinyl)-1-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
 (8 CITINGS)


L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1988:204508 CAPLUS
 DOCUMENT NUMBER: 108:204508
 ORIGINAL REFERENCE NO.: 108:33601a,33604a
 TITLE: Preparation of dihydroquinolinone-4-oximes as diuretics
 INVENTOR(S): Mochida, Ei; Uemura, Akio; Kato, Kazuo; Tokunaga, Hiroki; Haga, Akinori
 PATENT ASSIGNEE(S): Mochida Pharmaceutical Co., Ltd., Japan; Hodogaya Chemical Co., Ltd.
 SOURCE: Eur. Pat. Appl., 91 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|----------|
| EP 243982 | A1 | 19871104 | EP 1987-106373 | 19870430 |

| | | | | |
|---|----|----------|-----------------|-------------|
| EP 243982 | B1 | 19910417 | | |
| R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | A | 19881005 | JP 1987-92788 | 19870415 |
| JP 63239270 | B | 19920731 | | |
| JP 04046951 | A | | | |
| US 4839368 | A | 19890613 | US 1987-42784 | 19870427 |
| ZA 8703133 | A | 19871230 | ZA 1987-3133 | 19870430 |
| AT 62679 | T | 19910515 | AT 1987-106373 | 19870430 |
| ES 2036542 | T3 | 19930601 | ES 1987-106373 | 19870430 |
| AU 8772441 | A | 19871105 | AU 1987-72441 | 19870501 |
| AU 596657 | B2 | 19900510 | | |
| WO 8706580 | A1 | 19871105 | WO 1987-JP276 | 19870501 |
| W: DK, FI, HU, KR, LK, NO, SU | | | | |
| HU 47912 | A2 | 19890428 | HU 1987-2931 | 19870501 |
| HU 199803 | B | 19900328 | | |
| IL 82399 | A | 19920621 | IL 1987-82399 | 19870501 |
| IL 97150 | A | 19920621 | IL 1987-97150 | 19870501 |
| CA 1314888 | C | 19930323 | CA 1987-536174 | 19870501 |
| FI 8705771 | A | 19871230 | FI 1987-5771 | 19871230 |
| FI 90071 | B | 19930915 | | |
| FI 90071 | C | 19931227 | | |
| NO 8705495 | A | 19880301 | NO 1987-5495 | 19871230 |
| NO 174465 | B | 19940131 | | |
| NO 174465 | C | 19940511 | | |
| DK 8706944 | A | 19880302 | DK 1987-6944 | 19871230 |
| DK 171379 | B1 | 19961007 | | |
| SU 1722227 | A3 | 19920323 | SU 1987-4203894 | 19871230 |
| SU 1779246 | A3 | 19921130 | SU 1988-4613166 | 19881223 |
| US 5077410 | A | 19911231 | US 1989-301125 | 19890125 |
| AU 9058618 | A | 19901115 | AU 1990-58618 | 19900702 |
| AU 630716 | B2 | 19921105 | | |
| JP 05262737 | A | 19931012 | JP 1992-27135 | 19920118 |
| JP 08000812 | B | 19960110 | | |
| CA 1333286 | C | 19941129 | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | | CA 1992-616521 | 19921130 |
| | | | JP 1986-102847 | A 19860502 |
| | | | JP 1987-92788 | A 19870415 |
| | | | US 1987-42784 | A3 19870427 |
| | | | EP 1987-106373 | A 19870430 |
| | | | CA 1987-536174 | A3 19870501 |
| | | | IL 1987-82399 | A 19870501 |
| | | | WO 1987-JP276 | W 19870501 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 108:204508; MARPAT 108:204508

GI




AB The title compds. [I; R1 = alkyl, haloalkyl, cycloalkyl, alkoxy, MeOCH2, MeO2CCH2CH2, PhCH2, PhCH:CH, naphthyl, pyridyl, thieryl, pyrazinyl, (un)substituted Ph; R2, R3 = H, Me; R5, R6 = H, halo, OH, MeS, MeS(O), MeSO2, NM2, NO2, Ac, Me, CF3, CO2Me, MeO; X = NOR4; R4 = CH2CO2Me, SO3H, MeSO2, P(O)(OMe)OH] were prepared. 2,4-C12C6H3COCl was added to 7-chloro-2,3-dihydro-4H-quinolinone in dioxane containing pyridine and the mixture stirred 3 h to give I (R1 = 2,4-C12C6H3, R2 = R3 = R5 = R6 = H, X =

O) to which, in MeOH, was added H₂NOSO₃H to give, on workup, I (R1 = 2,4-C₁₂C₆H₃, R2 = R3 = R5 = R6 = H, X = NOSO₃K) (II) which, at 0.1 mg/kg i.v., increased urine output of anesthetized dogs by 518%. II 100, lactose 890, and Mg stearate 10 g were mixed to give a 10% powder.

IT 114404-54-5P 114404-55-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of diuretics)


RN 114404-54-5 CAPLUS

CN 4(1H)-Quinolinone, 7-chloro-2,3-dihydro-1-(1-naphthalenylcarbonyl)- (CA INDEX NAME)



RN 114404-55-6 CAPLUS


CN 4(1H)-Quinolinone, 7-chloro-2,3-dihydro-1-(2-naphthalenylcarbonyl)- (CA INDEX NAME)



IT 114427-56-4P 114448-59-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as diuretic)

RN 114427-56-4 CAPLUS


CN Hydroxylamine-O-sulfonic acid, N-[7-chloro-2,3-dihydro-1-(2-naphthalenylcarbonyl)-4(1H)-quinolinylidene]-, potassium salt (9CI) (CA INDEX NAME)



● K

RN 114448-59-8 CAPLUS

CN Hydroxylamine-O-sulfonic acid, N-[7-chloro-2,3-dihydro-1-(naphthalenylcarbonyl)-4(1H)-quinolinylidene]-, potassium salt (9CI) (CA INDEX NAME)



● K

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1986:572312 CAPLUS

DOCUMENT NUMBER: 105:172312

ORIGINAL REFERENCE NO.: 105:27769a,27772a

TITLE: Carbostyryl compounds

INVENTOR(S): Tominaga, Michiaki; Fujioka, Takafumi; Nagami, Kazuyoshi; Nakagawa, Kazuyuki

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 68 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|----------|
| EP 187322 | A1 | 19860716 | EP 1985-116129 | 19851218 |
| EP 187322 | B1 | 19900314 | | |

| | | | | |
|------------------------|--------------------------------|----------------|------------|----------|
| R: | CH, DE, FR, GB, IT, LI, NL, SE | | | |
| JP 61267556 | A 19861127 | JP 1985-272086 | | 19851203 |
| JP 07100696 | B 19951101 | | | |
| US 4760064 | A 19880726 | US 1985-808420 | | 19851213 |
| DK 8505861 | A 19860619 | DK 1985-5861 | | 19851217 |
| DK 168522 | B1 19940411 | | | |
| PRIORITY APPLN. INFO.: | | JP 1984-268189 | A 19841218 | |
| | | JP 1985-272086 | A 19851203 | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 105:172312; MARPAT 105:172312
 GI




AB The title compds. I [R1 = alkanoyl, alkoxy carbonyl, (un)substituted phenylalkyl, (un)substituted Bz, etc.; R2 = (un)substituted Bz] and their salts, useful as cardiotonic agents, were prepared. Thus, I [R1 = H; R2 = 3,4-(MeO)2C6H3CO] was added to NaH followed by AcCl to give I [R1 = Ac; R2 = 3,4-(MeO)2C6H3CO] (II). In tests for inotropic effect in dogs II at 1 μmol showed 20% in contraction of papillary muscle. Pharmaceutical formulations containing I are given.

IT 104797-10-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as cardiotonic)

RN 104797-10-6 CAPLUS


CN 2(1H)-Quinolinone, 6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-3,4-dihydro-1-(1-naphthalenylcarbonyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1984:423295 CAPLUS
 DOCUMENT NUMBER: 101:23295
 ORIGINAL REFERENCE NO.: 101:3689a,3692a
 TITLE: Chromatographic separation of the enantiomers of N-acylated heterocyclic amines
 AUTHOR(S): Pirkle, William H.; Welch, Christopher J.; Mahler, George S.; Meyers, A. I.; Fuentes, Lelia M.; Boes,

CORPORATE SOURCE: Michael
 Sch. Chem. Sci., Univ. Illinois, Urbana, IL, 61801,
 USA
 SOURCE: Journal of Organic Chemistry (1984), 49(13), 2504-6
 DOCUMENT TYPE: CODEN: JOCEAH; ISSN: 0022-3263
 LANGUAGE: Journal
 English
 OTHER SOURCE(S): CASREACT 101:23295
 GI




AB Racemic heterocyclic amines were chromatog. resolved as their N- α -naphthoyl derivs. with chiral stationary phases derived from (R)-N-(3,5-dinitrobenzoyl)phenylglycine. Resolved by this technique were, e.g., pyrrolidines I ($n = 0$, R = Me, Bu), piperidines I ($n = 1$, R = Me, Et, Pr, Bu, Ph), isoindolines II ($n = 0$, R = Me, Et), tetrahydroisoquinolines II ($n = 1$, R = Me, Bu, Me₂CHCH₂, PhCO, PhCH₂CH₂), and tetrahydroquinoline III. Morphinan IV ($R_1 = \alpha$ -naphthoyl) and dibenzoquinolinizinone V were also resolved; the latter required no prior derivatization.

IT 90133-16-7P 90133-17-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 90133-16-7 CAPLUS

CN Methanone, [(2R)-3,4-dihydro-2-methyl-1(2H)-quinolinyl]-1-naphthalenyl-
 (CA INDEX NAME)


Absolute stereochemistry.



RN 90133-17-8 CAPLUS

CN Methanone, [(2S)-3,4-dihydro-2-methyl-1(2H)-quinolinyl]-1-naphthalenyl-
(CA INDEX NAME)

Absolute stereochemistry.



IT 90132-79-9 90132-81-3 90132-82-4


RL: PROC (Process)

(resolution of, by chiral stationary phase chromatog.)

RN 90132-79-9 CAPLUS

CN Methanone, [(4aR,10bR)-2,3,4a,5,6,10b-hexahydro-7,8-dimethoxybenzo[f]quinolin-4(1H)-yl]-1-naphthalenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 90132-81-3 CAPLUS

CN Methanone, [(2R)-3,4-dihydro-2-[(R)-hydroxyphenylmethyl]-1(2H)-quinolinyl]-1-naphthalenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 90132-82-4 CAPLUS

CN Methanone, [(2R)-3,4-dihydro-2-[(S)-hydroxyphenylmethyl]-1(2H)-quinolinyl]-

1-naphthalenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1971:552988 CAPLUS

DOCUMENT NUMBER: 75:152988

ORIGINAL REFERENCE NO.: 75:24129a

TITLE: Light-sensitive photographic material with at least one silver halide emulsion layer containing a cyan coupler

INVENTOR(S): Kunitz, Friedrich W.; Maeder, Helmut; Otto, Rigobert

PATENT ASSIGNEE(S): Agfa-Gevaert A.-G.

SOURCE: Ger. Offen., 26 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|------------|
| DE 1922628 | A | 19701105 | DE 1969-1922628 | 19690503 |
| CH 528103 | A | 19720915 | CH 1970-528103 | 19700422 |
| BE 749373 | A | 19701023 | BE 1970-749373 | 19700423 |
| US 3632347 | A | 19720104 | US 1970-32725 | 19700428 |
| FR 2047197 | A5 | 19710312 | FR 1970-16024 | 19700430 |
| GB 1277542 | A | 19720614 | GB 1970-1277542 | 19700430 |
| PRIORITY APPLN. INFO.: | | | DE 1969-1922628 | A 19690503 |

GI For diagram(s), see printed CA Issue.

AB Light-sensitive photog. materials with ≥ 1 Ag halide emulsion layer containing an indole, isoindole, or quinoline cyan coupler and a red-masking azo coupler were prepared. Tetrahydroquinoline (266 g) was nitrated with 85.6 ml 98% HNO₃ in H₂SO₄ to give 7-nitro-1,2,3,4-tetrahydroquinoline (I). A THF solution of 141 g I was treated with 203 ml. Et₃N and then with 282 g stearoyl chloride and the product was reduced (Raney Ni) to give 1-stearoyl-7-amino-1,2,3,4-tetrahydroquinoline (II). II (210 g) was treated with 141 g 1,2-HOC₁₀H₆CO₂Ph and 215 g of the product was dissolved in AcOH and treated with SO₂C₁₂ to form 157 g III. An addnl. 21 couplers of related structure were prepared.


IT 34228-38-1P

RL: IMP (Industrial manufacture); PREP (Preparation)
(preparation of)

RN 34228-38-1 CAPLUS

CN Octadecanamide, N-[1,2,3,4-tetrahydro-1-(1-hydroxy-2-

naphthalenyl)carbonyl]-7-quinolinyl)- (CA INDEX NAME)



L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1971:498444 CAPLUS
DOCUMENT NUMBER: 75:98444
ORIGINAL REFERENCE NO.: 75:15564h,15565a
TITLE: Antiinflammatory
1,1a,2,6b-tetrahydrocycloprop[b]indole-1-carboxylic
compounds
INVENTOR(S): Welstead, John W., Jr.
PATENT ASSIGNEE(S): A. H. Robins Co., Inc.
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|------------|
| DE 2103295 | A | 19710805 | DE 1971-2103295 | 19710125 |
| US 3654304 | A | 19720404 | US 1970-5897 | 19700126 |
| NL 7100384 | A | 19710728 | NL 1971-384 | 19710112 |
| GB 1304232 | A | 19730124 | GB 1971-1498 | 19710112 |
| CA 948208 | A1 | 19740528 | CA 1971-102689 | 19710113 |
| ZA 7100473 | A | 19711027 | ZA 1971-473 | 19710125 |
| FR 2081458 | A5 | 19711203 | FR 1971-2364 | 19710125 |
| FR 2081458 | A1 | 19711203 | | |
| CH 531508 | A | 19730131 | CH 1971-1079 | 19710125 |
| PRIORITY APPLN. INFO.: | | | US 1970-5897 | A 19700126 |

GI For diagram(s), see printed CA Issue.


AB Title compds. (I, R = Et or H), useful as antiinflammatory agents or as intermediates for indole-3-acetic acids, were prepared from 1-substituted indoles by reaction with N2CHCO2Et (II) to give ET exo- and endo-1,1a,2,6b-tetrahydrocycloprop[b]indole-1-carboxylates, separation of exo and endo isomers by chromatog., and hydrolysis to give I (R = H). Thus, 1-benzoylindole treated with II in the presence of CuCN .apprx.1 hr at 50-60° gave 20% exo-I and 10% endo-I (R = Et, R1 = R3 = H, R2 = Ph) (III). exo-III was refluxed in 5N NaOH and 95% EtOH 1 hr to give 62% I (R = R1 = R3 = H, R2 = Ph). Similarly prepared were .apprx.15 I, e.g. I (R = H) (R1-R3 given): Me, p-C1C6H4, H; H, m-CF3C6H4, 5-MeO; H, 1-naphthoyl, H; H, p-ClC6H4NH, H.

IT 33375-48-3P 33375-49-4P 33383-22-1P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 33375-48-3 CAPLUS


CN Cycloprop[b]indole-1-carboxylic acid,
1,1a,2,6b-tetrahydro-2-(1-naphthoyl)-, ethyl ester, exo- (8CI) (CA INDEX
NAME)



RN 33375-49-4 CAPLUS
 CN Cycloprop[b]indole-1-carboxylic acid,
 1,1a,2,6b-tetrahydro-2-(1-naphthoyl)-, ethyl ester, endo- (8CI) (CA INDEX NAME)



RN 33383-22-1 CAPLUS
 CN Cycloprop[b]indole-1-carboxylic acid,
 1,1a,2,6b-tetrahydro-2-(1-naphthoyl)-, exo- (8CI) (CA INDEX NAME)



=> FIL REGISTRY
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE

| SINCE FILE ENTRY | TOTAL SESSION |
|------------------|---------------|
| 107.58 | 300.49 |
| SINCE FILE ENTRY | TOTAL SESSION |
| -15.30 | -15.30 |

FILE 'REGISTRY' ENTERED AT 20:33:38 ON 17 AUG 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 AUG 2010 HIGHEST RN 1236252-88-2
DICTIONARY FILE UPDATES: 16 AUG 2010 HIGHEST RN 1236252-88-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10-542,759-2 isoquinoline.str




```
chain nodes :  
21 22  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  
chain bonds :  
3-21 21-22  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14  
14-15 15-16 15-17 16-20 17-18 18-19 19-20  
exact/norm bonds :  
1-2 1-6 2-3 3-4 3-21 4-5 5-6 5-7 6-10 7-8 8-9 9-10 21-22  
normalized bonds :  
11-12 11-16 12-13 13-14 14-15 15-16 15-17 16-20 17-18 18-19 19-20
```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:Atom

L5 STRUCTURE UPLOADED

=> d 15
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15 sss sam
SAMPLE SEARCH INITIATED 20:34:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1948 TO ITERATE

100.0% PROCESSED 1948 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 36313 TO 41607
PROJECTED ANSWERS: 7 TO 298

L6 7 SEA SSS SAM L5

=> s 15 sss full
FULL SEARCH INITIATED 20:34:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 39835 TO ITERATE

100.0% PROCESSED 39835 ITERATIONS 141 ANSWERS
SEARCH TIME: 00.00.01

L7 141 SEA SSS FUL L5

| | | |
|--|------------|---------|
| => fil caplus | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| FULL ESTIMATED COST | ENTRY | SESSION |
| | 191.54 | 492.03 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE | TOTAL |
| CA SUBSCRIBER PRICE | ENTRY | SESSION |
| | 0.00 | -15.30 |

FILE 'CAPLUS' ENTERED AT 20:34:14 ON 17 AUG 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Aug 2010 VOL 153 ISS 8
FILE LAST UPDATED: 16 Aug 2010 (20100816/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 17
L8 35 L7

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 35 ANSWERS - CONTINUE? Y/(N):y

L8 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2010:682824 CAPLUS
DOCUMENT NUMBER: 153:11891
TITLE: Preparation of 2-(N-substituted piperazinyl)steroid derivatives as anticancer agents
INVENTOR(S): Poirier, Donald; Roy, Jenny; Maltais, Rene
PATENT ASSIGNEE(S): Universite Laval, Can.
SOURCE: PCT Int. Appl., 121pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------------------|----------|-----------------|------------|
| WO 2010060215 | A1 | 20100603 | WO 2009-CA1726 | 20091125 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| PRIORITY APPLN. INFO.: | | | US 2008-117837P | P 20081125 |
| OTHER SOURCE(S): | MARPAT 153:11891 | | | |
| GI | | | | |



AB 2-(N-substituted piperazinyl)pregnane and 2-(N-substituted piperazinyl)androstane derivs. of formula I [Y, Y1 = OH, alkoxy, acyloxy, etc.; Z = H, alkyl, C.tpbond.CH, etc.; R = H, alkyl; V = amino acid; W = CO, SO2, CH2, CONH, CSNH; X = alkyl, alkylthio, alkoxy, aryl, etc.] are prepared which exhibit cytotoxicity on a variety of cancer cell lines. Thus, II was prepared, and had IC50 = 1.9 μ M against HL-60 cancer cell line.

IT 1228038-04-7P


RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); PRPH (Prophetic); THU (Therapeutic use); BIOL (Biological study); CMPI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of piperazinyl androstanes and pregnanes as anticancer agents)

RN 1228038-04-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2010:490738 CAPLUS

DOCUMENT NUMBER: 152:501637

TITLE: Preparation of 2,3,11,12-tetrahydrobenzo[h]pyrimido[4,5-c]isoquinoline-2,11-dione nucleosides or nucleotides and polynucleotides containing the same for nucleic acid hybridization probe

INVENTOR(S): Saito, Isao; Okamoto, Akimichi; Tainaka, Kazuki; Iida, Mitsuhiro; Kato, Teruhisa

PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Tokyo Koho, 19pp.

CODEN: JTXXFF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|---|--|
| JP 4454218 | B2 | 20100421 | JP 2002-333326 | 20021118 |
| JP 2004168672 | A | 20040617 | | |
| WO 2004046147
W: AU, CA, US
AU 2003262008 | A1 | 20040603 | WO 2003-JP11472 | 20030909 |
| PRIORITY APPLN. INFO.: | A1 | 20040615 | AU 2003-262008
JP 2002-333326
JP 2002-333353
WO 2003-JP11472 | 20030909
A 20021118
A 20021118
W 20030909 |

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title nucleoside analogs or nucleotide analogs (I; R5 = H, OH; n = an integer of 0-3) and polynucleotides having 1 or 2 \geq nucleotides replaced with the nucleotide (II; R5 = same as above) were prepared. There are also disclosed (1) the use of the polynucleotides for nucleic acid hybridization probes, (2) DNA chips having the polynucleotides immobilized

or adsorbed on a substrate, and (3) method for identification of nucleotides in a target nucleic acid which comprises the following steps: (a) hybridization of a target nucleic acid with the polynucleotide described above, (b) measurement of the phosphorescent spectra of the hybridization products, and (c) identification of the nucleotides at the specific position of the target nucleic acid by comparing the phosphorescent spectrum of the polynucleotide before and after the hybridization. Thus, O-silylation of 5-ido-2'-deoxycytidine by tert-butylidimethylsilyl chloride in the presence of imidazole in DMF at room temperature for 90 min gave 99%

2',5'-di-O-(tert-butylidimethylsilyl)-5-ido-2'-deoxycytidine which underwent N-acylation by 1-naphthoyl chloride in pyridine at room temperature for 5 h to give 70% N,N-di(2-naphthoyl)-2',5'-di-O-(tert-butylidimethylsilyl)-5-ido-2'-deoxycytidine (III). Photochem. cyclization of III in the presence of 2-methyloxirane in benzene under irradiation with a mercury lamp for 7 min gave 8% 3-[2',5'-di-O-(tert-butylidimethylsilyl)-2'-deoxy- β -D-ribofuranosyl]-12-(1-naphthoyl)-2,3,11,12-tetrahydrobenzo[h]pyrimido[4,5-c]isoquinoline-2,11-dione (IV). Ammonolysis of IV with a mixture of 30% aqueous

NH₃ solution, MeOH, and CHCl₃ at 50° for 20 h gave

3-[2',5'-di-O-(tert-butylidimethylsilyl)-2'-deoxy- β -D-ribofuranosyl]-2,3,11,12-tetrahydrobenzo[h]pyrimido[4,5-c]isoquinoline-2,11-dione which underwent desilylation by treatment with Bu₄NF/THF at room temperature for 2 h to give 83% 3-(2'-deoxy- β -D-ribofuranosyl)-2,3,11,12-tetrahydrobenzo[h]pyrimido[4,5-c]isoquinoline-2,11-dione (V).

5'-O-tritylation of V by 4,4'-dimethoxytrityl chloride in pyridine at room temperature for 10 h followed by condensation with N,N,N',N'-tetraisopropyl-2-cyanoethylidiphosphoramidite in the presence of tetrazole in MeCN at room temperature for 2 h gave the phosphoramidite (VI). Oligodeoxypyronucleotide analog 5'-CGCAATXTAACCG-3' (VII; X = Q) was prepared by the phosphoramidite method using an Applied Biosystem 392DNA/RNA synthesizer and the phosphoramidite VI. VII formed stable duplexes with 5'-GCGTAGATTGCG-3', 5'-GCGTAAATTGCG-3', 5'-GCGTTACATTGCG-3', and 5'-GCGTTATATTGCG-3' with melting temperature of 56.1, 55.3, 52.0, and 50.4°, resp.

IT 610303-49-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of

2,3,11,12-tetrahydroBenzo[h]pyrimido[4,5-c]isoquinoline-2,11-dione nucleoside and oligonucleotides containing them for nucleic acid hybridization probe)

RN 610303-49-6 CAPLUS

CN Benzo[h]pyrimido[4,5-c]isoquinoline-2,11(3H,12H)-dione,
3-[2'-deoxy-3,5-bis-O-[(1,1-dimethylethyl)dimethylsilyl]- β -D-erythro-pentofuranosyl]-12-(1-naphthalenylcarbonyl)-(CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 200911531063 CAPLUS

DOCUMENT NUMBER: 152137904

TITLE: Preparation of new substituted arylsulphonylglycines as inhibitors of the interaction between glycogen phosphorylase and GL subunit of glycogen-associated protein phosphatase 1 and their pharmaceutical compositions useful for treating diabetes

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany
SOURCE: Ger. Offen., 160pp.; Chemical Indexing Equivalent to

1511491399 (WO)

CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|----------------------|----------|
| DE 102008019838 | A1 | 20091210 | DE 2008-102008019838 | 20080419 |
| WO 2009127723 | A1 | 20091022 | WO 2009-EP54593 | 20090417 |
| W: AB, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NC, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN,
TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: DE 2008-102008019838A 20080419
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the preparation of substituted arylsulfonylglycines I [R1 = H, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, (un)substituted alkyl; R2, R3 = independently H, halo, perfluoroalkyl, etc.; A = CH, N, while a total of not more than 4 N atoms may be present in the bicyclic system; Z = CH, CF, N; R4, R5 = independently H, CN, (hetero)aryl, NH2 and derivs., etc.; R6 = H, halo, (un)substituted alk(en/ynyl), etc.] and their physiol. acceptable salts which have the ability to suppress the interaction of glycogen phosphorylase with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and to their pharmaceutical compns. useful for treating diabetes mellitus. Thus, a multi-step synthesis was given for arylsulfonylglycine II. In a binding test, arylsulfonylglycines I inhibited the interaction of human liver glycogen phosphorylase with protein PP1R3 (GL subunit of glycogen-associated PP1) with IC50 values < 5 μ M.

IT 1192209-19-0P, [(3,5-Dichlorophenylsulfonyl)[5-[(3,4-dihydro-1H-isoquinolin-2-yl)carbonyl]naphthalen-2-yl]amino]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of substituted arylsulfonylglycines as inhibitors of interaction between glycogen phosphorylase and GL subunit of glycogen-associated protein phosphatase 1 for treating diabetes mellitus)

RN 1192209-19-0 CAPLUS


CN Glycine, N-[(3,5-dichlorophenyl)sulfonyl]-N-[5-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)



IT 1192207-56-9P, tert-Butyl 2-[(3,5-dichlorophenylsulfonyl)[5-[(3,4-dihydro-1H-isoquinolin-2-yl)carbonyl]naphthalen-2-yl]amino]acetate
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of substituted arylsulfonylglycines as inhibitors of interaction between glycogen phosphorylase and GL subunit of glycogen-associated protein phosphatase 1 for treating diabetes mellitus)

RN 1192207-56-9 CAPLUS

CN Glycine, N-[(3,5-dichlorophenyl)sulfonyl]-N-[5-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-2-naphthalenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



L8 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1298655 CAPLUS

DOCUMENT NUMBER: 151:491399

TITLE: Preparation of new substituted arylsulfonylglycines as inhibitors of the interaction between glycogen phosphorylase and GL subunit of glycogen-associated protein phosphatase 1 and their pharmaceutical compositions useful for treating diabetes

INVENTOR(S): Langkopf, Elke; Himmelsbach, Frank; Mack, Juergen; Pautsch, Alexander; Schoelch, Corinna; Schuler-Metz, Annette; Streicher, Ruediger; Wagner, Holger

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany
SOURCE: PCT Int. Appl., 227pp.; Chemical Indexing Equivalent to 152:37904 (DE)

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--------|------------|-----------------------|----------|
| WO 2009127723 | A1 | 20091022 | WO 2009-EP54593 | 20090417 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| DE 102008019838 | A1 | 20091210 | DE 2008-102008019838 | 20080419 |
| PRIORITY APPLN. INFO.: | | | DE 2008-102008019838A | 20080419 |
| OTHER SOURCE(S): | MARPAT | 151:491399 | | |
| GI | | | | |

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is related to the preparation of substituted arylsulfonylglycines I [R1 = H, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl, (un)substituted alkyl; R2, R3 = independently H, halo, perfluoroalkyl, etc.; A = CH, N, while a

total of not more than 4 N atoms may be present in the bicyclic system; Z = CH, CF, N; R4, R5 = independently H, CN, (hetero)aryl, NH2 and derivs., etc.; R6 = H, halo, (un)substituted alk(en/yn)yl, etc.;] and their physiol. acceptable salts which have the ability to suppress the interaction of glycogen phosphorylase with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and to their pharmaceutical compns. useful for treating diabetes mellitus. Thus, a multi-step synthesis was given for arylsulfonylglycines II. In a binding test, arylsulfonylglycines I inhibited the interaction of human liver glycogen phosphorylase with protein PP1R3 (GL subunit of glycogen-associated PP1) with IC₅₀ values < 5 μ M.


IT 1192209-19-0P, [(3,5-Dichlorophenylsulfonyl)[5-[(3,4-dihydro-1H-isoquinolin-2-yl)carbonyl]naphthalen-2-yl]amino]acetic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted arylsulfonylglycines as inhibitors of interaction between glycogen phosphorylase and GL subunit of glycogen-associated protein phosphatase 1 for treating diabetes mellitus)

RN 1192209-19-0 CAPLUS

CN Glycine, N-[(3,5-dichlorophenyl)sulfonyl]-N-[5-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-2-naphthalenyl]- (CA INDEX NAME)



IT 1192207-56-9P, tert-Butyl


2-[(3,5-dichlorophenylsulfonyl)[5-[(3,4-dihydro-1H-isoquinolin-2-yl)carbonyl]naphthalen-2-yl]amino]acetate

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of substituted arylsulfonylglycines as inhibitors of interaction between glycogen phosphorylase and GL subunit of glycogen-associated protein phosphatase 1 for treating diabetes mellitus)

RN 1192207-56-9 CAPLUS

CN Glycine, N-[(3,5-dichlorophenyl)sulfonyl]-N-[5-[(3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-2-naphthalenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1107812 CAPLUS
DOCUMENT NUMBER: 151:358768
TITLE: Oxadiazooanthracene derivatives as GLP-1 receptor agonists and their preparation, pharmaceutical compositions and use in the treatment of diabetes
INVENTOR(S): Mjalli, Adnan M.M.; Polisetti, Dharma Rao; Yukum, Thomas Scott; Kalpathy, Santhosh; Guzel, Mustafa; Behme, Christopher; Davis, Stephen Thomas
PATENT ASSIGNEE(S): TransTech Pharma, Inc., USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|--|---------------------------------------|
| WO 2009111700 | A2 | 20090911 | WO 2009-US36333 | 20090306 |
| WO 2009111700 | A3 | 20100304 | | |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| US 20090306063 | A1 | 20091210 | US 2009-399504 | 20090306 |
| US 7727983 | B2 | 20100601 | | |
| US 20100197677 | A1 | 20100805 | US 2010-759010
US 2008-34599P
US 2009-399504 | 20100413
P 20080307
A3 20090306 |
| PRIORITY APPLN. INFO.: | | | | |


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:358768

GI



I



II

AB The invention provides oxadiazanthracene derivs. of formula I and the pharmaceutical compns. comprising oxadiazanthracene derivs., use of the oxadiazanthracene derivs. for the preparation of pharmaceutical compns., methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazanthracene derivs. of formula I. Compds. of the formula I wherein R is -(CH₂)₀₋₂-G1-L1-G2; L1 is a direct bond, CH₂, O, NH and derivs., CO, CONH and derivs., NHCO and derivs., NHSO₂ and derivs., etc.; G1 is (un)substituted alkynylene, (un)substituted (hetero)arylene, (un)substituted fused cycloalkyl(hetero)arylene, etc.; G2 is (un)substituted (hetero)aryl, (un)substituted fused arylcycloalkyl, (un)substituted fused cycloalkyl(hetero)aryl, etc.; R1 is CO₂H and derivs., CONH₂ and derivs., tetroazole, and acid isostere; R2 is H, (un)substituted alkyl, (un)substituted Ph, (un)substituted cycloalkyl, (un)substituted alkylene-cycloalkyl and (un)substituted alkylene-phenyl; R3 and R4 are independently H, SO₁₋₂H and derivs., SO₃H and derivs., SO₁₋₂NH₂ and derivs., CHO, CO-C₁₋₁₀ alkyl, etc.; R5 is -G3-L2-Q2-L3-G4; L2 and L3 are independently a direct bond, CH₂, O, NH and derivs., CO, CONH and derivs., NHCO and derivs., etc.; Q2 is a direct bond, C₁₋₁₀ alkylene, C₂₋₁₀ alkenylene and C₂₋₁₀ alkynylene; G3 and R4 are independently (un)substituted (hetero)arylene, (un)substituted cycloalkylene, (un)substituted heterocyclylene, (un)substituted fused arylcycloalkylene, etc.; ring B and ring C are optionally substituted; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared via cross-coupling of (S)-3-[4-(3,4-dichlorobenzyl)oxy]phenyl]-1-methyl-2-oxo-6-[(S)-1-phenylpropyl]-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diazaanthracene-7-carboxylic acid with (S)-2-amino-3-(4'-cyanobiphenyl-4-yl)-2-methylpropionic acid Me ester followed by hydrolysis. All the invention compds. were evaluated for their GLP-1 receptor agonistic activity. From the assay, it was determined that II exhibited the EC₅₀ value of 38.2 nM.

IT 1187061-00-2P 1187061-01-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)


(drug candidate; preparation of oxadiazanthracene derivs. as GLP-1 receptor agonists useful in the treatment of diabetes)

RN 1187061-00-2 CAPLUS


CN [*1,1'*-Biphenyl]-4-propanoic acid, 4'-cyano- α -[[[(8*S*)-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-2,3,6,7,8,9-hexahydro-7-(1-naphthalenylcarbonyl)-2-oxo-1*H*-pyrido[4,3-*g*][1,4]benzoxazin-8-yl]carbonyl]amino]-, (*αS*)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



RN 1187061-01-3 CAPLUS

CN [*1,1'*-Biphenyl]-4-propanoic acid, 4'-cyano- α -[[[(8*S*)-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-2,3,6,7,8,9-hexahydro-7-(2-naphthalenylcarbonyl)-2-oxo-1*H*-pyrido[4,3-*g*][1,4]benzoxazin-8-yl]carbonyl]amino]-, (*αS*)- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:521298 CAPLUS
 DOCUMENT NUMBER: 149:145824
TITLE: Constrained dansyl derivatives reveal bacterial specificity of highly conserved thymidylate synthases
AUTHOR(S): Calo, Samuele; Tondi, Donatella; Ferrari, Stefania;
 Venturelli, Alberto; Ghelli, Stefano; Costi, Maria
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita
 degli Studi di Modena e Reggio Emilia, Modena, 41100,
 Italy
SOURCE: ChemBioChem (2008), 9(5), 779-790
PUBLISHER: CODEN: CBCHFX; ISSN: 1439-4227
 Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S):

CASREACT 149:145824

AB The elucidation of the structural/functional specificities of highly conserved enzymes remains a challenging area of investigation, and enzymes involved in cellular replication are important targets for functional studies and drug discovery. Thymidylate synthase (TS, ThyA) governs the synthesis of thymidylate for use in DNA synthesis. The present study focused on Lactobacillus casei TS (LcTS) and Escherichia coli TS (EcTS), which exhibit 50% sequence identity and strong folding similarity. The authors have successfully designed and validated a chemical model in which linear, but not constrained, dansyl derivs. specifically complement the LcTS active site. Conversely, chemical constrained dansyl derivs. showed up to 1000-fold improved affinity for EcTS relative to the inhibitory activity of linear derivs. This study demonstrates that the accurate design of small ligands can uncover functional features of highly conserved enzymes.

IT 1038452-86-6


RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(inhibitor; constrained dansyl derivs. preparation and inhibition of highly conserved thymidylate synthases of Escherichia coli and Lactobacillus casei)

RN 1038452-86-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyloxy]-1,2,3,4-tetrahydro-2-(2-naphthalenylcarbonyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

37

THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN



ACCESSION NUMBER: 2008:465942 CAPLUS

DOCUMENT NUMBER: 149:44260

TITLE: 4-Biphenyl and 2-naphthyl substituted
6,7-dimethoxytetrahydroisoquinoline derivatives as
potent P-gp modulators

AUTHOR(S): Colabufo, Nicola Antonio; Berardi, Francesco; Cantore, Mariangela; Perrone, Maria Grazia; Contino, Marialessandra; Inglese, Carmela; Niso, Mauro; Perrone, Roberto; Azzariti, Amalia; Grazia

CORPORATE SOURCE: Maria; Paradiso, Angelo
 Dipartimento Farmacochimico, Universita degli Studi di
 Bari, Bari, 70125, Italy
 SOURCE: Bioorganic & Medicinal Chemistry (2008), 16(7),
 3732-3743
 PUBLISHER: CODEN: BMECEP; ISSN: 0968-0896
 Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:44260
 GI



AB Starting from lead compound 1 (EC50 = 1.64 μ M), its non-basic nucleus has been conformationally restricted by 4-biphenyl and 2-naphthyl moieties. In each series we investigated if the presence of H-bond donor or acceptor substituents, the basicity and the lipophilicity ($c \log P$) were correlated with the P-gp inhibiting activity of tested compds. In the biphenyl series, derivative 4d (II) displayed the best results (EC50 = 0.05 μ M). The corresponding amide 3d was found less active (EC50 = 3.5 μ M) (III) ascertaining the importance of basicity in this series while the presence of hydroxy or methoxy substituents seems to be negligible. In the naphthyl series, both the basicity and the presence of H-bond donor or acceptor groups seem to be negligible. Moreover, the lipophilicity did not influence the P-gp inhibition activity of each series. Specific biol. assays have been carried out to establish the P-gp interacting mechanism of tested compds. discriminating between substrates and inhibitors. Moreover, compound 4d displayed a potent P-gp inhibition activity with good selectivity towards BCRP pump.

IT 1001580-26-2P 1031367-73-3P 1031367-75-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(4-Biphenyl and 2-naphthyl substituted


6,7-dimethoxytetrahydroisoquinoline derivs. as potent P-gp modulators)

RN 1001580-26-2 CAPLUS


CN Methanone, (3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-2-naphthalenyl- (CA INDEX NAME)



RN 1031367-73-3 CAPLUS
 CN Methanone, (3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)(6-hydroxy-2-naphthalenyl)- (CA INDEX NAME)



RN 1031367-75-5 CAPLUS
 CN Methanone, (3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)(6-methoxy-2-naphthalenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)
 REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:1086611 CAPLUS
 DOCUMENT NUMBER: 147:406705
 TITLE: Preparation of bicycloheteroaryl compounds as P2X₇
 modulators
 INVENTOR(S): Kelly, Michael G.; Kincaid, John; Fang, Yunfeng; Cao,
 Yeyu; Kaub, Carl; Gowlugari, Sumithra; Wang, Zhan
 Renovis, Inc., USA
 PATENT ASSIGNEE(S): PCT Int. Appl., 149 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2007109182 | A2 | 20070927 | WO 2007-US6721 | 20070316 |
| WO 2007109182 | A3 | 20071129 | | |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN,
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | |
| RW: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, | | | |


IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:


| | |
|-----------------|------------|
| US 2006-782782P | P 20060316 |
| US 2006-782973P | P 20060316 |
| US 2006-783304P | P 20060316 |
| US 2007-918124P | P 20070315 |

OTHER SOURCE(S):
 GI

MARPAT 147:406705



I



II

AB The title compds. I [A = (un)substituted CH; B and Y = (un)substituted CH and CH2; W, W1 and Z = CR4 and N, provided that all three of W, W1 and Z can not be N at the same time; L1 = CO, SO, SO2, (un)substituted alkylene; n = 0-4; R1 = (un)substituted 5-13 membered (hetero)aryl; R21, R22 = H, halo, (un)substituted alkyl; or R21 and R22 join together to form a cycloalkyl or cycloheteroalkyl; R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl, acyl, etc.] which may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others, were prepared and formulated. E.g., a multi-step synthesis of II, starting from 4-chlorobenzaldehyde, was given. II showed IC50 of 49.28 nM when tested in IL-1 β release assay.


IT 950988-57-5P 950989-23-8P 950989-82-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel bicycloheteroaryl compds. as P2X7 modulators useful in prevention and treatment of diseases)


RN 950988-57-5 CAPLUS

CN Benzeneacetamide, N-[6-chloro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-5-isquinolinyl]-3-fluoro-4-(trifluoromethyl)- (CA INDEX NAME)




RN 950989-23-8 CAPLUS

CN Benzeneacetamide, N-[6-chloro-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-5-isoquinolinyl]-2-fluoro-3-(trifluoromethyl)- (CA INDEX NAME)



RN 950989-82-9 CAPLUS

CN Benzeneacetamide, 3-fluoro-N-[1,2,3,4-tetrahydro-6-methyl-2-(1-naphthalenylcarbonyl)-5-isoquinolinyl]-4-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L8 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:846100 CAPLUS
DOCUMENT NUMBER: 147:212293
TITLE: Preparation of 1-[2'-(N-acylamino)acyl]-2-pyrrolidine and 1-[2'-(N-carbamoylamino)acyl]-2-pyrrolidine carbonitriles, boronic acids, carbaldehydes and analogs as fibroblast activation protein alpha inhibitors for treating cancer
INVENTOR(S): Evans, David Michael; Horton, John; Trim, Julie Elizabeth
PATENT ASSIGNEE(S): Ferring B.V., Neth.
SOURCE: PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2007085895 | A2 | 20070802 | WO 2006-IB3512 | 20060831 |
| WO 2007085895 | A3 | 20080417 | | |
| W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| EP 1760076 | A1 | 20070307 | EP 2005-108049 | 20050902 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| AU 2006336854 | A1 | 20070802 | AU 2006-336854 | 20060831 |
| CA 2627607 | A1 | 20070802 | CA 2006-2627607 | 20060831 |

| | | | | |
|--|--|---|-----------------|------------|
| EP 1919864 | A2 | 20080514 | EP 2006-849433 | 20060831 |
| R: AT, BE, BG,
IS, IT, LI,
BA, HR, MK, | CH, CY, CZ, DE,
LT, LU, LV, MC,
RS | DK, EE, ES, FI,
NL, PL, PT, RO,
SE, SI, SK, TR, AL, | | |
| JP 2009507011 | T | 20090219 | JP 2008-528601 | 20060831 |
| IN 2008BDN02735 | A | 20080725 | IN 2008-DN2735 | 20080401 |
| KR 2008043383 | A | 20080516 | KR 2008-707975 | 20080402 |
| NO 2008001636 | A | 20080529 | NO 2008-1636 | 20080402 |
| US 20100081701 | A1 | 20100401 | US 2009-991286 | 20090515 |
| PRIORITY APPLN. INFO.: | | | EP 2005-108049 | A 20050902 |
| | | | US 2005-713324P | P 20050902 |
| | | | WO 2006-IB3512 | W 20060831 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 147:212293

GI



AB Di peptide nitriles, boronic acids, aldehydes, and analogs I [X = a bond, CH₂, S, CF₃, COF, SO, SO₂, CH₂CH₂ and Y = CH₂; or XY = CH:CH; Q1 = CN, B(OH)₂, COX1; X1 = H, alk(en)yl, heteroaryl, CH₂NR4R5, CH₂OR6, etc.; R4, R5, R6 = independently H, alk(en)yl, heteroaryl, arylalkyl, heteroaryalkyl; or R4R5 = (CH₂)_m; m = 2-7; Z = O, S; when Z = O, R = H, aryl/alkyl, NR4R5, aryl, etc.; when Z = S, R = NR4R5; R1 = H, alk(en)yl, aryl, (CH₂)_aNHW1, CH(Me)OW4, etc.; a = 2-5; W1 = H, COW6, CO₂W6, SO₂W6; W4 = H, W6, W6 = alkyl, benzyl, heteroaryl; R2 = H, alkyl; R3 = H, alkyl, arylalkyl, etc.; or R1R3 = (CH₂)_p; p = 3-4; R1R2 = (CH₂)_q; q = 3-6; R1R3 = 1,2-phenylene, 2,3-pyrrolidinylene, 1,2-cyclopentylene, etc.; and their tautomers, stereoisomers, and their pharmaceutically acceptable salts] were prepared as fibroblast activation protein alpha (FAP α) inhibitors for treating especially cancer. Thus, amine II was prepared from N-(tert-butoxycarbonyl)-L-proline, L-prolinamide, and 3-anisoyl chloride. Preferred I were competitive inhibitors with IC₅₀<1 μ M for FAP α and IC₅₀>1 μ M for DPIV, DP8 and DP9 in a fluorogenic assay.

IT 928371-48-6P 928371-51-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(drug candidates; preparation of N-acyl- and N-carbamoylaminoacyl pyrrolidine carbonitriles, boronic acids, carbaldehydes and analogs as FAP α inhibitors for treating cancer)

RN 928371-48-6 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[(3S)-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-3-isoquinolinyl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 928371-51-1 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[(3S)-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-3-isoquinolinyl]carbonyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L8 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:247921 CAPLUS

DOCUMENT NUMBER: 146:317223

TITLE: Preparation of 1-[2'-(N-acylamino)acyl]-2-pyrrolidine and 1-[2'-(N-carbamoylamino)acyl]-2-pyrrolidine carbonitriles, boronic acids, carbaldehydes and analogs as fibroblast activation protein alpha inhibitors for treating cancer

INVENTOR(S): Evans, David Michael

PATENT ASSIGNEE(S): Ferring B.V., Neth.

SOURCE: Eur. Pat. Appl., 192pp.

CODEN: EPXXDW



DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| EP 1760076 | A1 | 20070307 | EP 2005-108049 | 20050902 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU | | | | |
| AU 2006336854 | A1 | 20070802 | AU 2006-336854 | 20060831 |
| CA 2627607 | A1 | 20070802 | CA 2006-2627607 | 20060831 |
| WO 2007085895 | A2 | 20070802 | WO 2006-IB3512 | 20060831 |
| WO 2007085895 | A3 | 20080417 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| EP 1919864 | A2 | 20080514 | EP 2006-849433 | 20060831 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, RS | | | | |
| JP 2009507011 | T | 20090219 | JP 2008-528601 | 20060831 |
| IN 2008DN02735 | A | 20080725 | IN 2008-DN2735 | 20080401 |
| ZA 2008002867 | A | 20081231 | ZA 2008-2867 | 20080401 |
| KR 2008043383 | A | 20080516 | KR 2008-707975 | 20080402 |
| NO 2008001636 | A | 20080529 | NO 2008-1636 | 20080402 |
| US 20100081701 | A1 | 20100401 | US 2009-991286 | 20090915 |
| PRIORITY APPLN. INFO.: | | | EP 2005-108049 | A 20050902 |
| | | | US 2005-713324P | P 20050902 |
| | | | WO 2006-IB3512 | W 20060831 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 146:317223

GI



AB Dipeptide nitriles, boronic acids, aldehydes, and analogs I [$X =$ a bond, CH₂, S, CF₂, CHF, SO, SO₂, CH₂CH₂ and $Y =$ CH₂; or XY = CH:CH; Q1 = CN, B(OH)₂, COX1; X1 = H, alk(en)yl, hetero/aryl, CH₂NR4R5, CH₂OR6, etc.; R4, R5, R6 = independently H, alk(en)yl, hetero/aryl, arylalkyl, heteroarylalkyl; or R4R5 = (CH₂)_m; m = 2-7; Z = O, S; when Z = O, R = H, aryl/alkyl, NR4R5, aryl, etc.; when Z = S, R = NR4R5; R1 = H, alk(en)yl, aryl, (CH₂)_aNHW1, CH(Me)OW4, etc.; a = 2-5; W1 = H, COW6, CO₂W6, SO₂W6; W4 = H, W6; W6 = alkyl, benzyl, hetero/aryl; R2 = H, alkyl; R3 = H, alkyl, arylalkyl, etc.; or R1R3 = (CH₂)_p; p = 3-4; R1R2 = (CH₂)_q; q = 3-6; R1R3 = 1,2-phenylene, 2,3-pyrrolidinylene, 1,2-cyclopentylene, etc.; and their tautomers, stereoisomers, and their pharmaceutically acceptable salts] were prepared as fibroblast activation protein alpha (FAP α) inhibitors for treating especially cancer. Thus, amide II was prepared from N-(text-butoxycarbonyl)-L-proline, L-prolinamide, and 3-anisoyl chloride. Preferred I were competitive inhibitors with IC₅₀<1 μ M for FAP α and IC₅₀>1 μ M for DPIV, DP8 and DP9 in a fluorogenic assay.

IT 928371-48-6P 928371-51-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidates; preparation of N-acyl- and N-carbamoylaminoacyl pyrrolidine carbonitriles, boronic acids, carbaldehydes and analogs as FAP α inhibitors for treating cancer)

RN 928371-48-6 CAPLOS

CN 2-Pyrrolidinecarbonitrile, 1-[(3S)-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-3-isooquinolinyl]carbonyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 928371-51-1 CAPLUS

CN 2-Pyrrolidinecarbonitrile, 1-[(3S)-1,2,3,4-tetrahydro-2-(2-naphthalenyl)carbonyl]-3-isoquinolinyl]carbonyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:365100 CAPLUS

DOCUMENT NUMBER: 144:390755

TITLE: Preparation of quinolinecarboxamides as histamine H3R receptor antagonists and/or inverse agonists.

INVENTOR(S): McArthur, Silvia Gatti; Hertel, Cornelia; Nettekoven, Matthias Heinrich; Raab, Susanne; Richter, Hans; Roche, Olivier; Rodriguez-Sarmiento, Rosa Maria; Schuler, Franz

PATENT ASSIGNEE(S): Hoffman-La Roche Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 28 pp.

DOCUMENT CODEN: USXXCO

TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----------------|------|----------|-----------------|----------|
| US 20060084679 | A1 | 20060420 | US 2005-251509 | 20051014 |
| US 7534891 | B2 | 20090519 | | |

| | | | |
|---|-------------|------------------|------------|
| AU 2005299018 | A1 20060504 | AU 2005-299018 | 20051007 |
| CA 2584318 | A1 20060504 | CA 2005-2584318 | 20051007 |
| WO 2006045416 | A1 20060504 | WO 2005-EP10814 | 20051007 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
YU, ZA, ZM, ZW | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | |
| EP 1805166 | A1 20070711 | EP 2005-798160 | 20051007 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | |
| CN 101044135 | A 20070926 | CN 2005-80035690 | 20051007 |
| JP 2008517003 | T 20080522 | JP 2007-537151 | 20051007 |
| BR 2005018222 | A 20081104 | BR 2005-18222 | 20051007 |
| RU 2391338 | C2 20100610 | RU 2007-118538 | 20051007 |
| MX 2007004465 | A 20070507 | MX 2007-4465 | 20070413 |
| KR 2007059155 | A 20070611 | KR 2007-708809 | 20070418 |
| KR 867071 | B1 20081104 | | |
| IN 2007DN03162 | A 20070831 | IN 2007-DN3162 | 20070427 |
| PRIORITY APPLN. INFO.: | | EP 2004-105145 | A 20041019 |
| | | WO 2005-EP10814 | W 20051007 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 144:390755

GI



AB Title compds. [I; R1, R2 = H, alkyl, alkenyl, cycloalkyl, hydroxalkyl, alkoxyalkyl, (substituted) cycloalkylalkyl, heterocyclylalkyl, etc.; R1R2N = atoms to form (substituted) 4-7 membered heterocyclyl; A = (substituted) azetidinyl(alkyl), pyrrolidinyl(alkyl), piperidinyl(alkyl)], were prepared Thus, azetidin-1-yl[6-(1-isopropylpiperidin-4-yloxy)quinolin-2-yl]methanone (preparation outlined) showed H3R inverse agonist activity with Ki = 78 nM.

IT 871119-91-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of quinolinecarboxamides as histamine H3R receptor antagonists and/or inverse agonists)

RN 871119-91-4 CAPLUS

CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[3-(1-piperidinyl)propoxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1314324 CAPLUS

DOCUMENT NUMBER: 144:51333

TITLE: Preparation of naphthalene derivatives as histamine-3 receptor ligands

INVENTOR(S): Gatti McArthur, Silvia; Hertel, Cornelia; Nettekoven, Matthias Heinrich; Plancher, Jean-Marc; Raab, Susanne; Roche, Olivier; Rodriguez-Sarmiento, Rosa Maria; Schuler, Franz

PATENT ASSIGNEE(S): F. Hoffmann-La Roche AG, Switz.

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2005117865 | A1 | 20051215 | WO 2005-EP5594 | 20050524 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BN, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2005249196 | A1 | 20051215 | AU 2005-249196 | 20050524 |
| CA 2566526 | A1 | 20051215 | CA 2005-2566526 | 20050524 |
| EP 1755593 | A1 | 20070228 | EP 2005-775021 | 20050524 |
| EP 1755593 | B1 | 20080116 | | |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV | | | | |
| CN 1960727 | A | 20070509 | CN 2005-80017816 | 20050524 |
| BR 2005011778 | A | 20080115 | BR 2005-11778 | 20050524 |
| JP 20080501649 | T | 20080124 | JP 2007-513783 | 20050524 |
| AT 383857 | T | 20080215 | AT 2005-775021 | 20050524 |
| PT 1755593 | E | 20080317 | PT 2005-775021 | 20050524 |
| ES 2299074 | T3 | 20080516 | ES 2005-775021 | 20050524 |
| NZ 550764 | A | 20090925 | NZ 2005-550764 | 20050524 |

| | | | | |
|------------------------|----|----------|------------------|-------------|
| RU 2387638 | C2 | 20100427 | RU 2006-146621 | 20050524 |
| AR 49433 | A1 | 20060802 | AR 2005-102236 | 20050531 |
| TW 299992 | B | 20080821 | TW 2005-94117927 | 20050531 |
| US 20060009449 | A1 | 20060112 | US 2005-142738 | 20050601 |
| US 7259158 | B2 | 20070821 | | |
| ZA 2006009678 | A | 20080625 | ZA 2006-9678 | 20061121 |
| IN 2006DN06979 | A | 20070803 | IN 2006-DN6979 | 20061122 |
| MX 2006014017 | A | 20070208 | MX 2006-14017 | 20061130 |
| KR 2007020057 | A | 20070216 | KR 2006-725300 | 20061130 |
| KR 854212 | B1 | 20080826 | | |
| NO 2006005733 | A | 20061219 | NO 2006-5733 | 20061212 |
| US 20070265254 | A1 | 20071115 | US 2007-821263 | 20070622 |
| US 7608617 | B2 | 20091027 | | |
| PRIORITY APPLN. INFO.: | | | EP 2004-102460 | A 20040602 |
| | | | WO 2005-EP5594 | W 20050524 |
| | | | US 2005-142738 | A3 20050601 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:51333; MARPAT 144:51333

GI



AB Title compds. represented by the formula I [wherein R1 = H, alkyl, (un)substituted phenyl(alkyl) or alkoxyalkyl; R2 = H, (cyclo)alkyl, alkylsulfanylalkyl, etc.; or R1R2 = (un)saturated heterocyclyl; A = (un)substituted piperidinyl, pyrrolidinyl, piperazinyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as histamine-3 (H3) receptor ligands. For example, reaction of (6-hydroxynaphthalen-2-yl)piperidin-1-ylmethanone (preparation given) with 3-(piperidin-1-yl)propan-3-ol gave II•HCl in 46% yield. II showed binding affinity with 3H-(R)-α-methylhistamine ($K_i = 26$ nM). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.


IT 871119-91-4P 871119-92-5P 871119-93-6P
 871120-21-7P 871120-22-8P 871120-23-9P
 871120-24-0P 871120-25-1P 871121-91-4P
 871121-92-5P 871121-99-2P 871122-00-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of naphthalene derivs. as histamine-3 receptor ligands)

RN 871119-91-4 CAPLUS


CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[3-(1-piperidinyl)propoxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 871119-92-5 CAPLUS


CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[3-(2-methyl-1-piperidinyl)propoxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 871119-93-6 CAPLUS


CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[2-(1-methyl-2-piperidinyl)ethoxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 871120-21-7 CAPLUS

CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 871120-22-8 CAPLUS
 CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[(1-(1-methylethyl)-3-pyrrolidinyl)oxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 871120-23-9 CAPLUS
 CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[(1-(1-methylethyl)-4-piperidinyl)oxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 871120-24-0 CAPLUS
 CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[(1-(2-methylpropyl)-4-piperidinyl)oxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 871120-25-1 CAPLUS
CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[(1-methyl-3-piperidinyl)methoxy]-2-naphthalenyl]-, hydrochloride (1:1) (CA INDEX NAME)




● HCl


RN 871121-91-4 CAPLUS
CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[3-(1-piperidinyl)propoxy]-2-naphthalenyl]- (CA INDEX NAME)




RN 871121-92-5 CAPLUS
CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[3-(2-methyl-1-piperidinyl)propoxy]-2-naphthalenyl]- (CA INDEX NAME)



RN 871121-99-2 CAPLUS
CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-2-naphthalenyl]- (CA INDEX NAME)



RN 871122-00-8 CAPLUS
CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)[6-[[1-(1-methylethyl)-4-piperidinyl]oxy]-2-naphthalenyl]- (CA INDEX NAME)




IT 871121-74-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of naphthalene derivs. as histamine-3 receptor ligands)

RN 871121-74-3 CAPLUS

CN Methanone, (3,4-dihydro-2(1H)-isoquinolinyl)(6-hydroxy-2-naphthalenyl)-(CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1193399 CAPLUS

DOCUMENT NUMBER: 143:440276

TITLE: Phenanthridine analogues, their preparation, pharmaceutical compositions, and uses as inhibitors of hyperproliferation of T cells and keratinocytes

INVENTOR(S): Pegeraro, Stefano; Lang, Martin; Feurle, Juliane; Krauss, Juergen

PATENT ASSIGNEE(S): ASC AG, Germany; Switch Biotech AG

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2005105752 | A1 | 20051110 | WO 2004-EP11121 | 20041005 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1652841 | A1 | 20060503 | EP 2004-10341 | 20040430 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR | | | | |

| | | | | |
|--|----|----------|------------------|------------|
| AU 2004319072 | A1 | 20051110 | AU 2004-319072 | 20041005 |
| CA 2562400 | A1 | 20051110 | CA 2004-2562400 | 20041005 |
| EP 1740548 | A1 | 20070110 | EP 2004-790131 | 20041005 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| CN 1934087 | A | 20070321 | CN 2004-80042522 | 20041005 |
| BR 2004018782 | A | 20071009 | BR 2004-18782 | 20041005 |
| JP 2007538007 | T | 20071227 | JP 2007-509886 | 20041005 |
| NZ 551399 | A | 20090828 | NZ 2004-551399 | 20041005 |
| US 20050282801 | A1 | 20051222 | US 2005-118421 | 20050502 |
| US 7276606 | B2 | 20071002 | | |
| IN 2006MNN01096 | A | 20070622 | IN 2006-MN1096 | 20060913 |
| MX 2006011763 | A | 20070413 | MX 2006-11763 | 20061011 |
| PRIORITY APPLN. INFO.: | | | EP 2004-10341 | A 20040430 |
| | | | US 2004-566820P | P 20040430 |
| | | | WO 2004-EP11121 | W 20041005 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:440276; MARPAT 143:440276
GT




AB The invention relates to phenanthridine analogs, e.g., general formula I, which are inhibitors of T cell hyperproliferation and keratinocyte hyperproliferation. In compds. I, A is SO₂ or substituted C; R1 is alkyl, alkoxy, OH, SH, acyl, carboxy, aryl, heteroaryl, etc.; and X and Y are independently N or (un)substituted C. The invention also relates to the preparation of I, pharmaceutical compns. containing I, optionally with appropriate

adjuvants and additives, as well as to the use of the compns. for the inhibition of T cell or keratinocyte hyperproliferation. Addition of indole to phenanthridine and acylation with 2-furoyl chloride gave phenanthridine analog II. Several compds. of the invention express more than 50% inhibition of keratinocyte proliferation and seven of those compds., e.g., II, also express EC₅₀ value below 25 μ M in a T cell proliferation assay.

IT 868853-64-9P, [6-(1H-Indol-3-yl)-6H-phenanthridin-5-yl]naphthalen-1-ylmethanone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of phenanthridine analogs as inhibitors of hyperproliferation of T cells and keratinocytes)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:735326 CAPLUS
 DOCUMENT NUMBER: 143:229730
 TITLE: Preparation of tetrahydroisoquinoline derivatives for
 treating diseases mediated by protein trafficking or
 chloride channel activity
 INVENTOR(S): Pregele, Marko J.; Hirth, Bradford H.; Kane, John L.;
 Qiao, Shuang; Gregory, Jill; Cuff, Lisa
 PATENT ASSIGNEE(S): Genzyme Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 52 pp.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|--|----------|-----------------|------------|
| US 20050176761 | A1 | 20050811 | US 2004-6042 | 20041207 |
| US 7541466 | B2 | 20090602 | US 2003-531873P | P 20031223 |
| PRIORITY APPLN. INFO.: | | | | |
| OTHER SOURCE(S): | CASREACT 143:229730; MARPAT 143:229730 | | | |
| GI | | | | |



AB Tetrhydroisoquinoline derivs. I (variables defined below), pharmaceutical compns. comprising them and methods of treating disease are disclosed herein. The disclosed compds. are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like. For I the variables are: X1 = CH2, CO, SO, SO2; X2 = CH2, CO, COCH2, CO2, COS, O, S, SO; X3, X4, X5, X6 = N, CH, wherein at least 1 of

X₃, X₄, X₅, X₆ = CH; Ring B is optionally substituted in any substitutable carbon; R1 and R2 = H or an optionally substituted aliphatic, aryl, heteroaryl, heterocyclic, cycloalkyl, peptide, or amino acid group, provided that R1 and R2 are not both H; or, R1 and R2, taken together with the nitrogen to which they are bonded, are an optionally substituted heterocyclic group; R3 = optionally substituted aryl, heteroaryl, cycloalkyl, or heterocyclic group; m = 0-2; each R4 = halogen, OH, SH, Ra, ORa, SRa, NH₂, NHRa, NRa₂, C(O)NRa₂, CF₃, CN, or NO₂; and Ra = C1-C5 branched or linear alkyl group.

IT 862504-24-3P, 2-[(Naphthalen-2-yl)carbonyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid N-(4-chlorophenyl)amide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of tetrahydroisoquinoline derivs. for treating diseases mediated by protein trafficking or chloride channel activity)
 RN 862504-24-3 CAPLUS
 CN 3-Isoquinolinelcarboxamide, N-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-(2-naphthalenylcarbonyl)-(CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:612285 CAPLUS
 DOCUMENT NUMBER: 143:133293
 TITLE: Preparation of spiroindoline and spiroisoquinoline compounds as Mas receptor ligands
 INVENTOR(S): Boatman, Douglas P.; Adams, John W.; Moody, Jeanne V.; Babych, Eric D.; Schrader, Thomas O.
 PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 224 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|--|----------|-----------------|----------|
| WO 2005063745 | A2 | 20050714 | WO 2004-US43609 | 20041222 |
| WO 2005063745 | A3 | 20060316 | | |
| WO 2005063745 | A9 | 20070201 | | |
| W: | AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM | | | |
| RW: | BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, | | | |

| | | | | |
|---|----|-----------------|------------------|----------|
| AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG | | | | |
| AU 2004309419 | A1 | 20050714 | AU 2004-309419 | 20041222 |
| CA 2546147 | A1 | 20050714 | CA 2004-2546147 | 20041222 |
| EP 1716148 | A2 | 20061102 | EP 2004-815636 | 20041222 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU | | | | |
| CN 1972944 | A | 20070530 | CN 2004-80038166 | 20041222 |
| JP 2007516298 | T | 20070621 | JP 2006-547461 | 20041222 |
| IN 2006KN02015 | A | 20070518 | IN 2006-KN2015 | 20060718 |
| US 20070254903 | A1 | 20071101 | US 2007-583839 | 20070308 |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 2003-532546P | P | 20031223 |
| | | US 2004-539554P | P | 20040126 |
| | | US 2004-565251P | P | 20040423 |
| | | WO 2004-US43609 | W | 20041222 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:133293; MARPAT 143:133293

GT



AB Title compds. I [wherein R1 = H, halo, OH, NO₂, (un)substituted alkyl, etc.; A, B = (un)substituted alkylene; E = bond or (un)substituted alkylene; G = H, (un)substituted aryl, etc.; W, X, Y, Z = N or (un)substituted CH; n = 0 or 1, or pharmaceutically acceptable salts, free bases, solvates, hydrates or stereoisomers thereof] were prepared as Mas receptor ligands. For instance, I₂ was synthesized and had IC₅₀ of 297.67 nM in the Mas receptor IP₃ assay. Therefore, I and their pharmaceutical compns. are useful for treating, preventing and/or managing vascular, cardiovascular or neurol. diseases or disorders.

IT 858350-88-6P 858350-89-7P 858350-90-0P

858350-99=9P


BL: PAC (Phan)

RE: PAC (Pharmacological activity); SYN (Synthetic preparation); THER (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of spiroindoline and spiroisoquinoline compds. as Mas receptor ligands)

RN 858350-88-6 CAPLUS


CN Methanone, (1'-butyl-2,3-dihydrospiro[isoquinoline-4(1H),4'-piperidin]-2-yl)-1-naphthalenyl- (CA INDEX NAME)




RN 858350-89-7 CAPLUS
CN Methanone, [1'-(1,3-benzodioxol-4-ylmethyl)-2,3-dihydrospiro[isoquinoline-4(1H), 4'-piperidin]-2-yl]-1-naphthalenyl- (CA INDEX NAME)



RN 858350-90-0 CAPLUS
CN Methanone, [1'-[2,4-dimethylphenyl]methyl]-2,3-dihydrospiro[isoquinoline-4(1H), 4'-piperidin]-2-yl]-1-naphthalenyl- (CA INDEX NAME)




RN 858350-99-9 CAPLUS
CN Methanone, (2,3-dihydrospiro[isoquinoline-4(1H), 4'-piperidin]-2-yl)-1-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (8 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:284144 CAPLUS
 DOCUMENT NUMBER: 142:355176
 TITLE: Preparation of 6,8-dimethoxyisoquinolines as novel potassium channels modulators
 INVENTOR(S): Garcia, Gabriel; Saeb, Wael; Kramer, Bernd
 PATENT ASSIGNEE(S): 4SC AG, Germany
 SOURCE: U.S. Pat. Appl. Publ., 54 pp.
 CODEN: USXKCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| US 20050070570 | A1 | 20050331 | US 2004-869914 | 20040618 |
| PRIORITY APPLN. INFO.: | | | US 2003-479159P | P 20030618 |
| ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT | | | | |
| OTHER SOURCE(S): MARPAT 142:355176 | | | | |
| GI | | | | |



AB The invention relates to compds. I [Z = carbonyl, thiocarbonyl or sulfonyl; R1 = alkyl, alkenyl, alkynyl, aryl, H, halo, etc.; R2 = H, OH, CH₂SO₂alkyl, CH₂SO₂cycloalkyl, etc.; R5 = alkyl, alkenyl or alkynyl] which are useful for the prevention, alleviation or treatment of diseases, conditions or disorders which are associated with, or dependent on the membrane potential or conductance of cells in mammals, including a human. The general methods for synthesis of compds. I are described. One hundred sixty five compds. I (such as II) were prepared. Biol. data were given for representative compds. I. The pharmaceutical composition comprising the compound

I is claimed.
IT 808753-91-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6,8-dimethoxyisoquinolines as novel potassium channels modulators)
RN 808753-91-5 CAPLUS
CN Methanone, [3,4-dihydro-1-(4-hydroxyphenyl)-6,8-dimethoxy-2(1H)-isoquinolinyl]-1-naphthalenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)


L8 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:1118825 CAPLUS
DOCUMENT NUMBER: 142:56196
TITLE: Preparation of N-substituted 3,4-dihydro-1H-isoquinolines as potassium channel modulators
INVENTOR(S): Garcia, Gabriel; Saeb, Wael; Kramer, Bernd; Rauer, Heiko; Vincak, Adam
PATENT ASSIGNEE(S): 4SC AG, Germany
SOURCE: Eur. Pat. Appl., 31 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| EP 1489071 | A1 | 20041222 | EP 2003-13842 | 20030618 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CA 2524700 | A1 | 20041229 | CA 2004-2524700 | 20040617 |
| WO 2004113302 | A1 | 20041229 | WO 2004-EP6552 | 20040617 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BV, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, | | | | |

SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 EP 1663983 A1 20060607 EP 2004-740010 20040617
 EP 1663983 B1 20090121
 R: AI, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 AT 421503 T 20090215 AT 2004-740010 20040617
 PRIORITY APPLN. INFO.: EP 2003-13842 A 20030618
 WO 2004-EP6552 W 20040617
 OTHER SOURCE(S): CASREACT 142:56196; MARPAT 142:56196
 GI



AB Title compds. I [Z = CO, SO₂; R1 = alk(en/yn)yl, aryl, H, etc.; R2 = CH₂SO₂alkyl, CH₂SO₂aryl, etc.; R5 = alk(en/yn)yl] are prepared. General synthetic procedures and data are provided for 40 example compds. I are useful for the treatment of asthma, cystic fibrosis, etc.
 IT 808753-91-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-substituted 3,4-dihydro-1H-isoquinolines as potassium channel modulators)
 RN 808753-91-5 CAPLUS
 CN Methanone, [3,4-dihydro-1-(4-hydroxyphenyl)-6,8-dimethoxy-2(1H)-isoquinolinyl]-1-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:857399 CAPLUS
 DOCUMENT NUMBER: 141:343478
 TITLE: Use of small molecule compounds for immunopotentiation
 INVENTOR(S): Valiante, Nicholas

PATENT ASSIGNEE(S): Chiron Corporation, USA
 SOURCE: PCT Int. Appl., 146 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2004087153 | A2 | 20041014 | WO 2004-US10331 | 20040329 |
| WO 2004087153 | A3 | 20050317 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG | | | | |
| CA 2520124 | A1 | 20041014 | CA 2004-2520124 | 20040329 |
| US 20050136065 | A1 | 20050623 | US 2004-814480 | 20040329 |
| EP 1608369 | A2 | 20051228 | EP 2004-758593 | 20040329 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| PRIORITY APPLN. INFO.: US 2003-458888P P 20030328
WO 2004-US10331 W 20040329 | | | | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:343478
 GI




AB The invention provides immunostimulatory compns. comprising a small mol. immunopotentiator (SMIP) compound and methods of administration thereof. Also provided are methods of administering a SMIP compound in an effective amount to enhance the immune response of a subject to an antigen. Further provided are compns. and methods of administering SMIP compds. alone or in combination with another agent for the treatment of cancer, infectious diseases and/or allergies/asthma. Preparation of selected compds., e.g. I, is included.

IT 190274-318

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (small mol. compds. for immunopotentiation)


RN 190274-31-8 CAPLUS
CN Methanone, (3,4-dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl)-2-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:627033 CAPLUS
DOCUMENT NUMBER: 139:302587
TITLE: Synthesis and properties of a novel fluorescent nucleobase, naphthopyridopyrimidine
AUTHOR(S): Okamoto, Akimitsu; Tainaka, Kazuki; Saito, Isao
CORPORATE SOURCE: Faculty of Engineering, Department of Synthetic Chemistry and Biological Chemistry, Kyoto University and SORST, Japan Science and Technology Corporation, Kyoto, 606-8501, Japan
SOURCE: Tetrahedron Letters (2003), 44(36), 6871-6874
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new base-discriminating fluorescent nucleoside, NPP, that can sharply distinguish between A and G bases opposite NPP is described. The hybridization of an ODN probe containing NPP with a target DNA facilitates the judgment of the type of purine base located at a specific site on the target DNA.
IT 610303-49-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and properties of a fluorescent nucleobase, naphthopyridopyrimidine)
RN 610303-49-6 CAPLUS
CN Benzo[h]pyrimido[4,5-c]isoquinoline-2,11(3H,12H)-dione, 3-[2-deoxy-3,5-bis-O-[(1,1-dimethylethyl)dimethylsilyl]-β-D-erythro-pentofuranosyl]-12-(1-naphthalenylcarbonyl)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 36 THERE ARE 36 CAPLUS RECORDS THAT CITE THIS RECORD (36 CITINGS)
 REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:491215 CAPLUS
 DOCUMENT NUMBER: 139:69277
 TITLE: Preparation of 3,4-dihydro-1h-isoquinolin-2-yl derivatives as NK2 antagonists.
 INVENTOR(S): Kehler, Jan; Poulsen, Anders; Bjornholm, Berith;
 Kroll, Friedrich; Bang Norgaard, Morten
 H. Lundbeck A/S, Den.
 PATENT ASSIGNEE(S): PCT Int. Appl., 89 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2003051869 | A1 | 20030626 | WO 2002-DK858 | 20021216 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2470723 | A1 | 20030626 | CA 2002-2470723 | 20021216 |
| AU 2002351733 | A1 | 20030630 | AU 2002-351733 | 20021216 |
| EP 1458714 | A1 | 20040922 | EP 2002-787450 | 20021216 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| BR 2002015037 | A | 20041214 | BR 2002-15037 | 20021216 |
| HU 2004002643 | A2 | 20050428 | HU 2004-2643 | 20021216 |


| | | | | |
|----------------|----|----------|----------------|----------|
| CN 1620452 | A | 20050525 | CN 2002-828152 | 20021216 |
| CN 100509805 | C | 20090708 | | |
| JP 2005518378 | T | 20050623 | JP 2003-552753 | 20021216 |
| NZ 533358 | A | 20070531 | NZ 2002-533358 | 20021216 |
| ZA 2004004333 | A | 20050602 | ZA 2004-4333 | 20040602 |
| MX 2004005988 | A | 20040927 | MX 2004-5988 | 20040618 |
| IN 2004CN01546 | A | 20060210 | IN 2004-CN1546 | 20040712 |
| IN 222647 | A1 | 20081121 | | |
| NO 2004002980 | A | 20040714 | NO 2004-2980 | 20040714 |
| US 20050070713 | A1 | 20050331 | US 2004-499880 | 20041028 |
| US 7384957 | B2 | 20080610 | | |

PRIORITY APPLN. INFO.:

| | | |
|-----------------|---|----------|
| DK 2001-1916 | A | 20011219 |
| US 2001-341905P | P | 20011219 |
| WO 2002-DK858 | W | 20021216 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 139:69277
GI



AB The title compds. I [R1 = R11CO, R11CS, R11SO₂, R11OCO, R11SCO, or R11COCR12R13; R11 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R2 = H, CF₃, alkyl; R3-R6, R7a, R7b, R8a, R8b are independently selected from H, halo, CN, NO₂, alkyl, alkenyl, etc.; m = 2-6; R9 = (un)substituted PhCH₂, benzoyl, 2,3-dihydrobenzofuranyl, or mono- or bicyclic aryl or heteroaryl; Q = C, N, or CR10, wherein R10 = H, halo, CN, NO₂, alkyl, cycloalkyl, etc.; or R9 and R10 taken together form a heterocyclic structure] and their pharmaceutically acceptable acid salts are prepared as NK2 antagonists. Two method were applied for preparation of these compds.: (a) alkylating a piperidine derivative with (RS)-1-(2-bromoethyl)-3,4-dihydro-1H-isquinoline-2-carboxylic acid-tert-Bu ester, and (b) acylating an amine derivative by using a carboxylic acid, a coupling reagent, an activated ester, an acid chloride or an isocyanate. In assays of I to determine inhibition of binding of ¹²⁵I-NKA to human NK2 receptors, the majority of the compds. possessed IC₅₀ values of 50 nM or less, and for a large group of the compds. the IC₅₀ values were 10 nM or less.


IT 551962-72-2P 551962-88-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of substituted dihydroisoquinolinyl derivs. via alkylation and acylation methods and their inhibition activities as NK2 antagonists)

RN 551962-72-2 CAPLUS

CN Acetamide, N-[4-(3-fluorophenyl)-1-[2-[1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-1-isoquinolinyl]ethyl]-4-piperidinyl] - (CA INDEX NAME)



RN 551962-88-0 CAPLUS
 CN Acetanide, N-[4-phenyl-1-{2-[1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-1-isoquinolinyl]ethyl}-4-piperidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:396659 CAPLUS
 DOCUMENT NUMBER: 138:401613
 TITLE: Preparation of tetrahydroisoquinoline analogs as
 modulators of chemokine receptor activity for
 treatment of inflammatory diseases
 INVENTOR(S): Hermsmeier, Mark Alden; Rawlins, David B.; Wityak,
 John
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003041641 | A2 | 20030522 | WO 2002-US35779 | 20021107 |
| WO 2003041641 | A3 | 20040304 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MD, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2002357692 | A1 | 20030526 | AU 2002-357692 | 20021107 |
| US 6649606 | B1 | 20031118 | US 2002-289671 | 20021107 |
| PRIORITY APPLN. INFO.: | | | US 2001-346377P | P 20011109 |
| | | | WO 2002-US35779 | W 20021107 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:401613
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein R1 = (un)substituted (aryl)alkyl, (aryl)alkenyl, alkynyl, aryl, (aryl)cycloalkyl, cycloalkylalkyl, cycloalkylalkoxy, alkoxyalkyl, alkylthioalkyl, aryloxyalkyl, arylalkoxyalkyl, heterocyclyl(alkyl), or heteroaryl(alkyl); R2 = H or (un)substituted (aryl)alkyl, (aryl)alkenyl, alkynyl, aryl, cycloalkyl(alkyl), alkoxyalkyl, cycloalkylalkoxy, aryloxyalkyl, arylalkoxyalkyl, heterocyclyl(alkyl), or heteroaryl(alkyl); X = a bond, O, or NR4; R3 and R3a = independently H, alkoxy, halo, CF3, alkyl, or aryl; R4 = independently alkyl or aryl; m, n, and p = independently 0-1; Y = a bond, (CH2)xC6H4(CH2)y, (CH2)xCR5R5a(CH2)y, or (CH2)xCR4=CR4(CH2)z; x and y = independently 0-3; z = 1-3; R5 and R5a = independently H, (cyclo)alkyl, alkoxy, OH, halo, CF3, or (alk)aryl; or R5 and R5a may be independently joined to R6 and R7 to form an alkylene bridge; or CR5R5a = cycloalkyl; X2 = (un)substituted aryl, heterocyclyl, pyridinyl, NR6R7, or (un)substituted imidazolyl; R6 and R7 = independently H or (un)substituted alkyl; or NR6R7 = heterocyclyl; X3 = a bond, CO, CO2, CONR4, SO2, or SO2NR4; X4 = a bond, O, OCO, NR4, NR4CO, NR4CONR4, NR4SO2, NR4SO2NR4, OCONR4, CO, CONR4, S, SO2, or SO2NR4; with provisos; and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof] were prepared as modulators of chemokine receptor activity (no data). For example, reaction of 3-methoxyphenethylamine with HBr gave 3-(2-aminoethyl)phenol•HBr (100%). Cyclization with glyoxylic acid monohydrate in a 5% HCl solution, followed by esterification with MeOH provided Me. Cyclization with glyoxylic acid monohydrate in a 5% HCl solution, followed by esterification with MeOH provided Me. N-protection with di-tert-Bu dicarbonate in THF, etherification with benzyl bromide using K2CO3 in DMF (93%), and saponification using NaOH in H2O and MeOH afforded 6-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate (35%). N-protection with di-tert-Bu dicarbonate in THF, etherification with benzyl bromide using K2CO3 in DMF (93%), and saponification using NaOH in H2O and MeOH afforded 6-(benzyloxy)-1,2,3,4-tetrahydroisoquinoline-1-carboxylate (35%). Amidation with

diisopropylethylenediamine in the presence of 1-hydroxy-7-azabenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl in DMF gave II (79%). Thus, I and compns. containing I are useful for the treatment of inflammatory diseases, such as asthma, COPD, allergic disease, allergic rhinitis, rheumatoid arthritis, atherosclerosis, psoriasis, solid organ transplant rejection, osteoarthritis, and inflammatory bowel syndrome (no data).


IT 373635-89-3P 373635-91-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antiinflammatory; preparation of tetrahydroisoquinoline analogs as modulators of chemokine receptor activity for treatment of inflammatory diseases)


RN 373635-89-3 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-1,2,3,4-tetrahydro-2-(naphthalenylcarbonyl)-6-(phenylmethoxy)- (CA INDEX NAME)



RN 373635-91-7 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-1,2,3,4-tetrahydro-2-(naphthalenylcarbonyl)-6-(phenylmethoxy)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:833285 CAPLUS

DOCUMENT NUMBER: 135:371650

TITLE: Preparation of tetrahydroisoquinoline analogs for therapeutic use in stimulating endogenous production or release of growth hormone

INVENTOR(S): Li, James J.; Tino, Joseph A.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2001085695 | A1 | 20011115 | WO 2001-US14709 | 20010507 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ,UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2408486 | A1 | 20011115 | CA 2001-2408486 | 20010507 |
| EP 1280777 | A1 | 20030205 | EP 2001-933145 | 20010507 |
| EP 1280777 | B1 | 20051123 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2001010638 | A | 20030325 | BR 2001-10638 | 20010507 |
| JP 2004057456 | T | 20040311 | JP 2001-582296 | 20010507 |
| AU 2001259592 | B2 | 20050224 | AU 2001-259592 | 20010507 |
| AT 310728 | T | 20051215 | AT 2001-933145 | 20010507 |
| CN 1244561 | C | 20060308 | CN 2001-809334 | 20010507 |
| ES 2252230 | T3 | 20060516 | ES 2001-933145 | 20010507 |
| US 20020022637 | A1 | 20020221 | US 2001-852565 | 20010510 |
| US 6469024 | B2 | 20021022 | | |
| MX 2002010452 | A | 20030606 | MX 2002-10452 | 20021023 |
| | | | US 2000-203335P | P 20000511 |
| PRIORITY APFLN. INFO.: | | | WO 2001-US14709 | W 20010507 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:371650

GT



AB Tetrahydroisoquinoline analogs, such as I and II [R1 = alkyl, alkenyl, alkyl, aryl cycloalkyl, etc.; R2 = alkyl, alkenyl, alkynyl, aryl cycloalkyl, etc.; X = bond, linking group, such as O, NR4; Y = linking group, such as alkylphenylenealkyl, alkylene, alkenylene, etc.; X2 = NR6R7, N-bonded-heterocyclic; X3 = bond, linking group, such as CO, COO, CONR4, etc.; X4 = bond, linking group, such as O, OC(O), SO2, S, NR4, NR4CO, etc.; R4 = H, alkyl, aryl; R6, R7 = H, alkyl], were prepared for


pharmaceutical use in stimulating endogenous production or release of growth hormone and, therefore, useful in treating obesity, osteoporosis, i.e. improving bone density, and in improving muscle mass and muscle strength (no biol. testing data presented). Thus, tetrahydroisoquinoline II was prepared via a series of synthetic steps which included cyclocondensation of HO-3-C6H4(CH2)2NH2.HBr with OHCCO2H using 5% HCl solution and MeOH in toluene to form 1,2,3,4-tetrahydro-6-hydroxy-1-isouquinolinecarboxylic acid Me ester in 35% yield, followed by N-carboxylation with (Me3CO)2CO, O-alkylation with PhCH2Br, ester hydrolysis with NaOH, and amidation with H2N(CH2)2N(CHMe2)2.

IT 373635-89-3P 373635-91-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tetrahydroisoquinoline analogs for therapeutic use in stimulating endogenous production or release of growth hormone)


RN 373635-89-3 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-1,2,3,4-tetrahydro-2-(2-naphthalenylcarbonyl)-6-(phenylmethoxy)- (CA INDEX NAME)



RN 373635-91-7 CAPLUS

CN 1-Isoquinolinecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-1,2,3,4-tetrahydro-2-(2-naphthalenylcarbonyl)-6-(phenylmethoxy)- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2001:488632 CAPLUS

DOCUMENT NUMBER: 135:92550

TITLE: Preparation of tetrahydroisoquinolines as estrogen agonists/antagonists


INVENTOR(S): Chesworth, Richard; Cameron, Kimberly O'Keefe; Da Silva-Jardine, Paul Andrew; Day, Robert Francis; Lefker, Bruce Allen; Zawistoski, Michael Paul

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: Eur. Pat. Appl., 66 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| EP 1113007 | A1 | 20010704 | EP 2000-311197 | 20001214 |
| R: AT, BE, CH,
DE, DK, ES, FR,
GB, GR, IT, LI,
LU, NL, SE,
MC, PT,
IE, SI, LT,
LV, FI, RO | | | | |
| US 20010039285 | A1 | 20011108 | US 2000-745396 | 20001221 |
| US 6608203 | B2 | 20030819 | | |
| CA 2329516 | A1 | 20010624 | CA 2000-2329516 | 20001222 |
| JP 2001294575 | A | 20011023 | JP 2000-389883 | 20001222 |
| BR 2000006265 | A | 20020305 | BR 2000-6265 | 20001222 |
| MX 2001000150 | A | 20020806 | MX 2001-150 | 20010108 |
| US 20030220494 | A1 | 20031127 | US 2003-405308 | 20030402 |
| US 20040192685 | A1 | 20040930 | US 2004-820277 | 20040408 |
| PRIORITY APPLN. INFO.: | | | US 1999-173063P | P 19991224 |
| | | | US 2000-745396 | A3 20001221 |
| | | | US 2003-405308 | B1 20030402 |


OTHER SOURCE(S): MARPAT 135:92550
 GI



AB The title compds. [I; A1 = H, OH, alkoxy, etc.; A2-A4 = H, OH, alkoxy, halo; R1 = (un)substituted Ph, pyridyl, piperidinyl, etc.; X = a bond, (CH_2)n (n = 1-3), CO₂, etc.; R2 = alkyl, alkenyl, benzhydryl, etc.; p = 0-2], useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, prostatic disease, and the like, were prepared Thus, hydrogenation of 1-[1-(4-benzyloxyphenyl)-6-methoxy-3,4-dihydro-1H-isoquinolin-2-yl]-2,2-trifluoroethanone over 10% Pd/C in EtOH afforded 88% I [A1 = OMe; A2-A4 = H; R1 = 4-HOC₆H₄; p = 0; X = CO; R2 = CF₃].


IT 347978-24-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetrahydroisoquinolines as estrogen agonists/antagonists)
 RN 347978-24-9 CAPLUS
 CN Methanone, [3,4-dihydro-6-hydroxy-1-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2(1H)-isoquinoliny]-1-naphthalenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
 REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:580342 CAPLUS
 DOCUMENT NUMBER: 129:316128
 ORIGINAL REFERENCE NO.: 129:64511a,64514a
 TITLE: Asymmetric synthesis and enantioselectivity of binding of 1-aryl-1,2,3,4-tetrahydroisoquinolines at the PCP site of the NMDA receptor complex
 Wanner, Klaus T.; Beer, Herbert; Hoefner, Georg;
 Ludwig, Matthias
 AUTHOR(S):
 CORPORATE SOURCE: Inst. Pharmazie, Zentrum Pharmaforschung, Univ.
 Muenchen, Munich, D-80333, Germany
 SOURCE: European Journal of Organic Chemistry (1998), (9), 2019-2029
 PUBLISHER: Wiley-VCH Verlag GmbH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 129:316128
 GI



I



II

AB A new method for the asym. synthesis of 1-substituted tetrahydroisoquinolines is presented. It is based on stereoselective addition reactions of organometallic compds. to the intermediate N-acyliminium ion I, which is provided with an N-acyl group as a chiral auxiliary. In addition reactions with organomagnesium and organozinc reagents, diastereoselectivities from 70:30 to 95:5 were observed with the Zn reagents, in general leading to markedly improved stereoselectivities. By catalytic hydrogenation and after removal of the chiral auxiliary, the target compds. II and ent-II (R = Ph, 4-MeOC₆H₄, 4-ClC₆H₄, 2-thienyl, 2-naphthyl) were obtained (>99% ee). Enantiomerically pure II and ent-II were evaluated for their affinity to the PCP [1-(1-phenylcyclohexyl)piperidine] binding site of the NMDA (N-Me D-aspartate) receptor. In each case, II exhibited a higher affinity than ent-II, with the potencies of the enantiomers differing by a factor of 4-27. The absolute configuration of more potent II is in accordance with the stereochem. requirement found for FR 115427 which is a close analog.


IT 90133-03-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis and enantioselectivity of binding of
aryltetrahydroisoquinolines with methylaspartate receptor)

RN 90133-03-2 CAPLUS

CN Isoquinoline, 1,2,3,4-tetrahydro-1-methyl-2-(1-naphthalenylcarbonyl)-,
(1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

L8 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1997:241430 CAPLUS

DOCUMENT NUMBER: 127:12695

ORIGINAL REFERENCE NO.: 127:2441a,2444a

TITLE: Liquid chromatographic resolution of racemic cyclic amines

AUTHOR(S): Hyun, Myung Ho; Jin, Jong Sung; Lee, Wonjae

CORPORATE SOURCE: Dep. Chem., Pusan National Univ., Pusan, 609-735, S. Korea

SOURCE: Bulletin of the Korean Chemical Society (1997), 18(3), 336-339

CODEN: BKCSDE; ISSN: 0253-2964

PUBLISHER: Korean Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The (S,S)-Wheik-O chiral stationary phase was used to resolve enantiomers of racemic cyclic amines as their N- α - or N- β -naphthoyl derivs.


A possible chiral recognition mechanism was proposed based on the chromatog. resolution results and study of CPK mol. models. Resolution of the corresponding derivs. of cyclic amino esters, which are structurally

similar to cyclic amines, is also reported.

| | | | |
|----|-------------|-------------|-------------|
| IT | 190273-18-8 | 190273-21-3 | 190273-25-7 |
| | 190274-19-2 | 190274-24-9 | 190274-30-7 |
| | 190274-31-8 | 190274-33-0 | 190274-34-1 |


RL: ANT (Analyte); ANST (Analytical study)
 (racemic cyclic amines resolution by liquid chromatog. on (S,S)-Whelk-O chiral stationary phase using N- α - or N- β -naphthoyl derivs.)

RN 190273-18-8 CAPLUS
 CN Methanone, (3,4-dihydro-1-phenyl-2(1H)-isoquinolinyl)-1-naphthalenyl- (CA INDEX NAME)




RN 190273-21-3 CAPLUS
 CN Methanone, [(1R)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinyl]-1-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 190273-25-7 CAPLUS
 CN Methanone, [(1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinyl]-1-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 190274-19-2 CAPLUS
 CN Methanone, (3,4-dihydro-1-phenyl-2(1H)-isoquinolinyl)-2-naphthalenyl- (CA INDEX NAME)



RN 190274-24-9 CAPLUS

CN Methanone, [(1R)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinyl]-2-naphthalenyl-
(CA INDEX NAME)


Absolute stereochemistry.



RN 190274-30-7 CAPLUS


CN Methanone, [(1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinyl]-2-naphthalenyl-
(CA INDEX NAME)

Absolute stereochemistry.



RN 190274-31-8 CAPLUS


CN Methanone, (3,4-dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl)-2-
naphthalenyl- (CA INDEX NAME)



RN 190274-33-0 CAPLUS


CN Methanone, [(1R)-3,4-dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl]-2-
naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 190274-34-1 CAPLUS
 CN Methanone, [(1S)-3,4-dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl]-2-naphthalenyl- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1996:26681 CAPLUS
 DOCUMENT NUMBER: 124:202688
 ORIGINAL REFERENCE NO.: 124:37481a,37484a
 TITLE: Total Synthesis of (-)-Tetrahydropalmatine via Chiral Formamidine Carbanions: Unexpected Behavior with Certain Ortho-Substituted Electrophiles
 AUTHOR(S): Matulenko, Mari A.; Meyers, A. I.
 CORPORATE SOURCE: Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA
 SOURCE: Journal of Organic Chemistry (1996), 61(2), 573-80
 CODEN: JOCREA; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 124:202688
 AB A method has been developed by alkylation of chiral lithioformamidines to construct protoberberine alkaloids with a C(9) and C(10) D-ring substitution pattern. This ring pattern was established using an ortho-substituted hydroxymethylbenzene electrophile protected as a silyl ether to ultimately provide (-)-tetrahydropalmatine in 88% ee. Limitations with ortho-substituted electrophiles in the asym. formamidine alkylation were discussed. These electrophiles have the potential to disrupt the lithium formamide chelate and cause the selectivity in the alkylation to be uncharacteristically low. The total synthesis of (+)-canadine and (-)-tetrahydropalmatine along with the limitations to the formamidine alkylation technol. are delineated herein.

IT 173737-59-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (total synthesis of (-)-tetrahydropalmatine via chiral formamidine carbanions)
 RN 173737-59-2 CAPLUS


CN Isoquinoline, 1-[(2-[(1,1-dimethylethyl)dimethylsilyl]oxy)-3,4-dimethoxyphenyl]methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-(1-naphthalenylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 38 THERE ARE 38 CAPLUS RECORDS THAT CITE THIS RECORD (38 CITINGS)

L8 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1995:540977 CAPLUS
DOCUMENT NUMBER: 123:9739
ORIGINAL REFERENCE NO.: 123:2047a,2050a
TITLE: Catalytic iron-mediated enediene carbocyclizations: the enantioselective synthesis of a homolog of the alkaloid (-)-protoemetinol
AUTHOR(S): Takacs, James M.; Boito, Scott C.
CORPORATE SOURCE: Dep. Chem., Univ. Nebraska, Lincoln, NE, 68588-0304, USA
SOURCE: Tetrahedron Letters (1995), 36(17), 2941-4
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:9739
GI




AB The efficient enantioselective synthesis of the benzoquinolizidine I highlights the utility of the stereoselective iron-catalyzed cyclization of enediens and affords the opportunity to prepare analogs of protoemetinol, psychotrine, and related natural products.

IT 163814-77-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (enantioselective synthesis of a homolog of the alkaloid protoemetinol
 via catalytic iron-mediated enediene carbocyclizations)
 RN 163814-77-5 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-2-(1-naphthalenylcarbonyl)-
 1-[4-(phenylmethoxy)-2-butenyl]-, [S-(Z)]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.
 Double bond geometry as shown.



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

L8 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1994:656334 CAPLUS
 DOCUMENT NUMBER: 121:256334
 ORIGINAL REFERENCE NO.: 121:46815a
 TITLE: CCK and/or gastrin receptor ligands
 INVENTOR(S): Ryder, Hamish; Kendrick, David Alan; Semple, Graeme;
 Miyata, Keiji; Batt, Andrzej Roman; Mathews, Elizabeth
 Alice; Rooker, David Philip; Nishida, Akito
 PATENT ASSIGNEE(S): Ferring B. V., Neth.; Yamanouchi Pharmaceutical Co.
 Ltd.
 SOURCE: PCT Int. Appl., 282 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--------|------------|-----------------|------------|
| WO 9320099 | A2 | 19931014 | WO 1993-GB614 | 19930325 |
| WO 9320099 | A3 | 19931125 | | |
| W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP,
KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE,
SK, UA, US, VN | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| AU 9337645 | A | 19931108 | AU 1993-37645 | 19930325 |
| PRIORITY APPLN. INFO.: | | | GB 1992-6757 | A 19920327 |
| | | | WO 1993-GB614 | A 19930325 |
| OTHER SOURCE(S): GI | MARPAT | 121:256334 | | |



AB Peptide analogs ABC [A = aromatic, azaarom., aromatic amino acid, aralkyl, azaaralkyl, aralkanoyl, azaaralkanoyl; B = amino, aminoalkyl; C = amino] (175 compds.) were prepared. Thus, the threonine derivative I was prepared from D-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, Me₃CO₂C-Thr(OCH₂Ph)-OH, and 3-ClC₆H₄NCO in 6 steps. I had binding affinities for cholecystokinin A and B receptors of 170 and 20 nM resp. Selective cholecystokinin B receptor antagonists also inhibit pentagastrin-stimulated gastric secretion; the indole derivative II had an ED₅₀ of 0.20 μmole/kg in rats.

IT 158457-41-1 158457-42-2 158457-43-3


158457-44-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation as intermediate in preparation of cholecystokinin antagonist peptide analogs)

RN 158457-41-1 CAPLUS

CN 3-Isoquinolineacetic acid, 1,2,3,4-tetrahydro-2-[(3-[(phenylmethoxy)carbonyl]amino)-2-naphthalenyl]carbonyl-, methyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158457-42-2 CAPLUS

CN 3-Isoquinolineacetic acid, 2-[(3-[(1-(1,1-dimethylethoxy)carbonyl)-2,3-dihydro-1H-indol-2-yl]carbonyl]amino)-2-naphthalenyl]carbonyl]-1,2,3,4-tetrahydro-, methyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158457-43-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2,3,4-tetrahydro-2-[(3-[(phenylmethoxy)carbonyl]amino)-2-naphthalenyl]carbonyl-, methyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158457-44-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[(3-[[1-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-1H-indol-2-yl]amino)-2-naphthalenyl]carbonyl]-1,2,3,4-tetrahydro-, methyl ester, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 158460-20-9P 158460-21-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 158460-20-9 CAPLUS

CN 3-Isoquinolineacetic acid, 2-[{3-[[1-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-1H-indol-2-yl]carbonyl]amino]-2-naphthalenyl]carbonyl]-1,2,3,4-tetrahydro-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158460-21-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[{3-[[1-[(1,1-dimethylethoxy)carbonyl]-2,3-dihydro-1H-indol-2-yl]carbonyl]amino]-2-naphthalenyl]carbonyl]-1,2,3,4-tetrahydro-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1990:54475 CAPLUS
 DOCUMENT NUMBER: 112:54475
 ORIGINAL REFERENCE NO.: 112:9351a,9354a
 TITLE: An improved chiral stationary phase for the facile separation of enantiomers
 AUTHOR(S): Pirkle, William H.; McCune, John E.
 CORPORATE SOURCE: Sch. Chem. Sci., Univ. Illinois, Urbana, IL, 61801,
 USA
 SOURCE: Journal of Chromatography (1988), 441(2), 311-22
 CODEN: JOCRAM; ISSN: 0021-9673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A chiral stationary phase (CSP) derived from cis-3-(1,1-dimethylethyl)-4-phenyl-2-azetidinone is quite effective for the chromatog. separation of the enantiomers of a variety of compds. This CSP has two stereogenic centers. For many enantiomers, it exhibits superior performance to that of a widely used phenylglycine-derived CSP.
 IT 123880-09-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (chromatog. resolution of, azetidinone-derived stationary phase for)
 RN 123880-09-1 CAPLUS
 CN Methanone, [3,4-dihydro-1-(phenylmethyl)-2(1H)-isoquinolinyl]-1-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

(8 CITINGS)

L8 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1989:172405 CAPLUS
 DOCUMENT NUMBER: 110:172405
 ORIGINAL REFERENCE NO.: 110:28589a,28592a
 TITLE: Chiral dipole-stabilized anions: experiment and theory in benzylic and allylic systems. Stereoselective deprotonations, pyramidal inversions, and stereoselective alkylations of lithiated (tetrahydroisoquinolyl)oxazolines
 AUTHOR(S): Rein, Kathleen; Goicoechea-Pappas, Marta; Anklekar, Tarakeshwar V.; Hart, Georgina C.; Smith, Gregory A.; Gawley, Robert E.
 CORPORATE SOURCE: Dep. Chem., Univ. Miami, Coral Gables, FL, 33124, USA
 SOURCE: Journal of the American Chemical Society (1989), 111(6), 2211-17
 DOCUMENT TYPE: CODEN: JACSAT; ISSN: 0002-7863
 LANGUAGE: Journal English
 OTHER SOURCE(S): CASREACT 110:172405
 GI




AB The mechanism of the stereoselective alkylation of chiral (tetrahydroisoquinolyl)oxazolines was examined. The following details are discussed: the effect of temperature and oxazoline substituent structure on the alkylation diastereoselectivity, a comparison of monodentate vs. bidentate chelation of the organolithium, an evaluation of the effect of solvent and chelating solvent additives, the regiochem. of alkylation of (3,4-dehydropiperidino)oxazolines, lithiation-alkylation expts. on stereoselectively deuterated monodentate and bidentate isoquinolinylloxazolines, and semiempirical MO calcns. on the organolithium diastereomers I ($S =$ solvent mols.). There are two distinct stereoselective processes involved in the overall transformation. The proposed mechanism includes an oxazoline-alkyllithium coordination complex that controls the selectivity of the deprotonation step; the selectivity of the electrophilic quench is governed by Curtin-Hammett kinetics.

IT 90133-02-1P 90133-04-3P 119110-19-9P
 119110-20-2P 119110-21-3P 119110-22-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 90133-02-1 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-1-methyl-2-(1-naphthalenylcarbonyl)-,
 (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-04-3 CAPLUS
 CN Isoquinoline, 1-butyl-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-, (R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 119110-19-9 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-1-propyl-,
 (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 119110-20-2 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-1-(phenylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 119110-21-3 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-1-[(2-methoxyphenyl)methyl]-2-(1-naphthalenylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 119110-22-4 CAPLUS
 CN Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



OS.CITING REF COUNT: 35 THERE ARE 35 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)

L8 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1988:529406 CAPLUS
 DOCUMENT NUMBER: 109:129406
 ORIGINAL REFERENCE NO.: 109:21577a,21580a
 TITLE: Asymmetric synthesis of isoquinoline alkaloids
 AUTHOR(S): Meyers, A. I.; Dickman, Daniel A.; Boes, Michael
 CORPORATE SOURCE: Dep. Chem., Colorado State Univ., Ft. Collins, CO,
 80523, USA

SOURCE: Tetrahedron (1987), 43(21), 5095-108
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 109:129406
GI




AB The use of chiral formamidines affixed to variously substituted tetrahydroisoquinolines, e.g. I, allows asym. C-C bond forming reactions to occur α - to the amino group. In this manner, a wide variety of (S)-1-alkyl-1,2,3,4-tetrahydroisoquinolines were constructed in >90% enantiomeric excess. Choosing the proper substituents and skeletal features, an efficient entry into the benzylisoquinoline, tetrahydroprotoberberine, aporphine, and isopavine class of alkaloids was achieved.

IT 107485-94-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 107485-94-9 CAPLUS

CN 1,3-Dioxolo[4,5-g]isoquinoline, 5-[{(3,4-dimethoxyphenyl)methyl]-5,6,7,8-tetrahydro-9-methoxy-6-(1-naphthalenylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 37 THERE ARE 37 CAPLUS RECORDS THAT CITE THIS RECORD (38 CITINGS)

L8 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1987:156735 CAPLUS
DOCUMENT NUMBER: 106:156735
ORIGINAL REFERENCE NO.: 106:25517a,25520a
TITLE: An asymmetric synthesis of (+)-ocoteine
AUTHOR(S): Dickman, Daniel A.; Meyers, A. I.

CORPORATE SOURCE:

Dep. Chem., Colorado State Univ., Fort Collins, CO,
80523, USA

SOURCE:

Tetrahedron Letters (1986), 27(13), 1465-8
CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE:

Journal


LANGUAGE:

English


OTHER SOURCE(S):

CASREACT 106:156735

GI



I



II

AB Asym synthesis of (+)-ocoteine (I) was achieved starting from 2-methoxy-3,4-methylenedioxy-β-phenethylamine via benzylation of chiral formamidine II with 3,4-(MeO)₂C₆H₃CH₂Br.


IT 107485-94-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 107485-94-9 CAPLUS

CN 1,3-Dioxolo[4,5-g]isoquinoline, 5-[(3,4-dimethoxyphenyl)methyl]-5,6,7,8-tetrahydro-9-methoxy-6-(1-naphthalenylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L8 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 1984:423295 CAPLUS

DOCUMENT NUMBER: 101:23295

ORIGINAL REFERENCE NO.: 101:3689a,3692a

TITLE: Chromatographic separation of the enantiomers of
N-acylated heterocyclic amines

AUTHOR(S): Pirkle, William H.; Welch, Christopher J.; Mahler,
 George S.; Meyers, A. I.; Fuentes, Lelia M.; Boes,
 Michael
 CORPORATE SOURCE: Sch. Chem. Sci., Univ. Illinois, Urbana, IL, 61801,
 USA
 SOURCE: Journal of Organic Chemistry (1984), 49(13), 2504-6
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 101:23295
 GI



AB Racemic heterocyclic amines were chromatog. resolved as their N- α -naphthoyl derivs. with chiral stationary phases derived from (R)-N-(3,5-dinitrobenzoyl)phenylglycine. Resolved by this technique were, e.g., pyrrolidines I ($n = 0$, R = Me, Bu), piperidines I ($n = 1$, R = Me, Et, Pr, Bu, Ph), isoindolines II ($n = 0$, R = Me, Et), tetrahydroisoquinolines II ($n = 1$, R = Me, Bu, Me₂CHCH₂, PhCO, PhCH₂CH₂), and tetrahydroquinolinolines III. Morphinan IV (R₁ = α -naphthoyl) and dibenzocoumarinolizinone V were also resolved; the latter required no prior derivatization.


| | | |
|----------------|-------------|-------------|
| IT 90133-02-1P | 90133-03-2P | 90133-04-3P |
| 90133-05-4P | 90133-06-5P | 90133-07-6P |
| 90133-08-7P | 90133-09-8P | 90133-10-1P |
| 90133-11-2P | 90192-91-9P | 90192-92-0P |

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 90133-02-1 CAPLUS


CN Isoquinoline, 1,2,3,4-tetrahydro-1-methyl-2-(1-naphthalenylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-03-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-1-methyl-2-(1-naphthalenylcarbonyl)-,
(1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-04-3 CAPLUS
CN Isoquinoline, 1-butyl-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-, (R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-05-4 CAPLUS
CN Isoquinoline, 1-butyl-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-, (S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-06-5 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-1-(2-methylpropyl)-2-(1-naphthalenylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-07-6 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-1-(2-methylpropyl)-2-(1-naphthalenylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-08-7 CAPLUS
CN Isoquinoline, 1-benzoyl-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-09-8 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-,
(S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-10-1 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-1-(2-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90133-11-2 CAPLUS
CN Isoquinoline, 1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)-1-(2-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90192-91-9 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-methyl-2-(1-naphthalenylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 90192-92-0 CAPLUS
 CN Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-methyl-2-(1-naphthalenylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 90132-80-2 90147-60-7
 RL: PROC (Process)
 (resolution of, by chiral stationary phase chromatog.)
 RN 90132-80-2 CAPLUS
 CN Methanone, (3,4-dihydro-6,7-dimethoxy-1-methyl-2(1H)-isoquinolinyl)-1-naphthalenyl- (CA INDEX NAME)






RN 90147-60-7 CAPLUS
 CN Morphinan, 3-methoxy-17-(1-naphthalenylcarbonyl)-, (±)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)

L8 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1983:452758 CAPLUS
 DOCUMENT NUMBER: 99:52758
 ORIGINAL REFERENCE NO.: 99:8233a,8236a
 TITLE: Nonoxidative photocyclization of
 2-aryl-1-methylene-1,2,3,4-tetrahydroisoquinolines
 AUTHOR(S): Naito, Takeaki; Katsumi, Kotomi; Tada, Yukiko;
 Ninomiya, Ichiya
 CORPORATE SOURCE: Kobe Women's Coll. Pharm., Kobe, 658, Japan
 SOURCE: Heterocycles (1983), 20(5), 775-8
 CODEN: HTCYAM; ISSN: 0385-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Nonoxidative photocyclization of enamides I [R = m-OMe, p-OMe, 3,4-(OMe)₂] in C₆H₆ at low temperature gave lactams II, which were readily transformed into the corresponding dehydrolactams III. Similar results were obtained with the N-β-naphthylcarbonyl analog of I.

IT 86425-89-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(nonoxidative photocyclization of)

RN 86425-89-0 CAPLUS

CN Methanone, (3,4-dihydro-6,7-dimethoxy-1-methylene-2(1H)-isoquinolinyl)-2-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L8 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1971:99903 CAPLUS

DOCUMENT NUMBER: 74:99903

ORIGINAL REFERENCE NO.: 74:16261a,16264a

TITLE: Hypoglycemic 2-acyl-7-(ureidosulfonyl)-1,2,3,4-tetrahydroisoquinolines

INVENTOR(S): Grell, Wolfgang; Griss, Gerhart; Kleemann, Manfred; Kutter, Eberhard

PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H.

SOURCE: Ger. Offen., 34 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|----------------------------|
| DE 1933388 | A | 19710121 | DE 1969-1933388 | 19690701 |
| FI 49828 | B | 19750630 | FI 1970-1712 | 19700617 |
| SE 357745 | B | 19730709 | SE 1970-8771 | 19700624 |
| SU 399122 | A3 | 19730927 | SU 1970-1452672 | 19700625 |
| RO 56857 | A1 | 19741215 | RO 1970-63739 | 19700625 |
| CH 536842 | A | 19730629 | CH 1970-9824 | 19700629 |
| BE 752760 | A | 19701230 | BE 1970-752760 | 19700630 |
| AT 301568 | B | 19720911 | AT 1970-5868 | 19700630 |
| GB 1313539 | A | 19730411 | GB 1970-31722 | 19700630 |
| IL 34820 | A | 19730829 | IL 1970-34820 | 19700630 |
| DK 127928 | B | 19740204 | DK 1970-3389 | 19700630 |
| NO 132094 | B | 19750609 | NO 1970-2575 | 19700630 |
| PL 81112 | B1 | 19750830 | PL 1970-141708 | 19700630 |
| NL 7009704 | A | 19710105 | NL 1970-9704 | 19700701 |
| ZA 7004523 | A | 19710428 | ZA 1970-4523 | 19700701 |
| FR 2059465 | A5 | 19710604 | FR 1970-24368 | 19700701 |
| FR 2059465 | B1 | 19740322 | | |
| RO 62631 | A2 | 19771025 | RO 1971-74524 | 19711208 |
| PRIORITY APPLN. INFO.: | | | | DE 1969-1933388 A 19690701 |
| | | | | DE 1970-2027436 A 19700604 |

GI For diagram(s), see printed CA Issue.


AB The hypoglycemic title compds. (I) were prepared from the corresponding 7-sulfamoyl compds. and R1NCO or from a 7-sulfonylcarbamate and R1NH2. Thus, II (R2 = Ac, X = Cl), prepared from 2-acetyl-1,2,3,4-tetrahydroisoquinoline and ClSO3H, was added to NH4OH to give II (R2 = Ac, X = NH2), which was hydrolyzed with HCl to give II (R2 = H, X = NH2 (III)). Reaction of III with PhCH2CH2COCl gave II (R2 = PhCH2CH2CO, X = NH2), which reacted with cyclohexyl isocyanate in PhNO2 to give I (R = PhCH2CH2, R1 = cyclohexyl). Among .apprx.40 I prepared were (R and R1 given): p-MeC6H4, cyclohexyl; Ph2CHCH2, cyclohexyl; EtPhCH, cyclohexyl; PhCH2CH2, Bu; PhCH2CH2, 1-adamantyl; PhCH2CH2, cycloheptyl.

IT 31398-54-6P 31581-46-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 31398-54-6 CAPLUS

CN 7-Isoquinolinesulfonamide, N-[(cyclohexylamino)carbonyl]-1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)- (CA INDEX NAME)



RN 31581-46-1 CAPLUS

CN 7-Isoquinolinesulfonamide, 1,2,3,4-tetrahydro-2-(1-naphthalenylcarbonyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

=>
Connecting via Winsock to STN

Welcome to STN International! Enter x::x

LOGINID:ssptajem1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

| Welcome to STN International | | | |
|------------------------------|--------|--|---|
| NEWS 1 | | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | APR 02 | | CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases |
| NEWS 3 | APR 02 | | PATIDPAFULL: Application and priority number formats enhanced |
| NEWS 4 | APR 02 | | DWPI: New display format ALLSTR available |
| NEWS 5 | APR 02 | | New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes |
| NEWS 6 | APR 02 | | EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948 |
| NEWS 7 | APR 07 | | CA/Caplus CLASS Display Streamlined with Removal of Pre-IPC 8 Data Fields |
| NEWS 8 | APR 07 | | 50,000 World Traditional Medicine (WTM) Patents Now Available in Caplus |
| NEWS 9 | APR 07 | | MEDLINE Coverage Is Extended Back to 1947 |
| NEWS 10 | JUN 16 | | WPI First View (File WPIFV) will no longer be available after July 30, 2010 |
| NEWS 11 | JUN 18 | | DWPI: New coverage - French Granted Patents |
| NEWS 12 | JUN 18 | | CAS and FIZ Karlsruhe announce plans for a new STN platform |
| NEWS 13 | JUN 18 | | IPC codes have been added to the INSPEC backfile (1969-2009) |
| NEWS 14 | JUN 21 | | Removal of Pre-IPC 8 data fields streamline displays in CA/Caplus, CASREACT, and MARPAT |
| NEWS 15 | JUN 21 | | Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN |
| NEWS 16 | JUN 28 | | Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol |
| NEWS 17 | JUN 29 | | Enhanced Batch Search Options in DGENE, USGENE, |

NEWS 18 JUL 19 and PCTGEN
Enhancement of citation information in INPADOC databases provides new, more efficient competitor analyses

NEWS 19 JUL 26 CAS coverage of global patent authorities has expanded to 61 with the addition of Costa Rica

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 20:55:53 ON 17 AUG 2010

=> FIL REGISTRY
COST IN U.S. DOLLARS

| | SINCE FILE
ENTRY | TOTAL
SESSION |
|---------------------|---------------------|------------------|
| FULL ESTIMATED COST | 0.22 | 0.22 |

FILE 'REGISTRY' ENTERED AT 20:56:12 ON 17 AUG 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 AUG 2010 HIGHEST RN 1236252-88-21
DICTIONARY FILE UPDATES: 16 AUG 2010 HIGHEST RN 1236252-88-21

New CAS Information Use Policies. enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=> Uploading C:\Program Files\STNEXP\Queries\10-542,759-2 isoquinoline open phenyl.str



chain nodes :

17 18

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

5-17 9-17 17-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16

13-14 14-15 15-16

exact/norm bonds :

7-8 7-12 8-9 9-10 9-17 10-11 11-12 11-13 12-16 13-14 14-15 15-16 17-18

exact bonds :

5-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
SAMPLE SEARCH INITIATED 20:56:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 81227 TO ITERATE

2.5% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

6 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1607559 TO 1641521
PROJECTED ANSWERS: 3937 TO 5809


L2 6 SEA SSS SAM L1

=> s 11 sss full
FULL SEARCH INITIATED 20:56:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1629323 TO ITERATE

100.0% PROCESSED 1629323 ITERATIONS 8732 ANSWERS
SEARCH TIME: 00.00.04

L3 8732 SEA SSS FUL L1

=>
Uploading C:\Program Files\STNEXP\Queries\10-542,759-2a isoquinoline open phenyl.str




chain nodes :
17 18 19 20 21 22 23 24 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
chain bonds :
5-17 7-23 7-24 8-21 8-22 9-17 10-19 10-20 11-25 12-26 17-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 11-13 12-16
13-14 14-15 15-16
exact/norm bonds :
7-8 7-12 8-9 9-10 9-17 10-11 11-12 11-13 12-16 13-14 14-15 15-16 17-18
exact bonds :
5-17 7-23 7-24 8-21 8-22 10-19 10-20 11-25 12-26
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

L4 STRUCTURE UPLOADED

=> d 14
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 14 sss sam

SAMPLE SEARCH INITIATED 21:01:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 81227 TO ITERATE

2.5% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
PROJECTED ITERATIONS: 1607559 TO 1641521
PROJECTED ANSWERS: 0 TO 0

L-5 0 SEA SSS SAM L-4

```
=> s 14 sss full
FULL SEARCH INITIATED 21:01:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1629323 TO ITERATE
```

100.0% PROCESSED 1629323 ITERATIONS 524 ANSWERS
SEARCH TIME: 00:00:04

16 524 SEA SSS FII J4

=> fil caplus
 COST IN U.S. DOLLARS

| | SINCE FILE | TOTAL |
|---------------------|------------|---------|
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 387.00 | 387.22 |

FILE 'CABLUIS' ENTERED AT 21:02:11 ON 17 AUG 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Aug 2010 VOL 153 ISS 8
FILE LAST UPDATED: 16 Aug 2010 (20100816/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2010

CPlus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 16
L7 57 L6

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 57 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1590349 CAPLUS
DOCUMENT NUMBER: 152:278601
TITLE: Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability
AUTHOR(S): Sellitti, Ian; Le Bourdonnec, Bertrand; Worm, Karin; Goodman, Allan; Savolainen, Markku A.; Chu, Guo-Hua; Ajello, Christopher W.; Saeui, Christopher T.; Leister, Lara K.; Cassel, Joel A.; DeHaven, Robert N.; LaBuda, Christopher J.; Koblish, Michael; Little, Patrick J.; Brogdon, Bernice L.; Smith, Steven A.; Dolle, Roland E.
CORPORATE SOURCE: Department of Chemistry, Adolor Corporation, Exton, PA, 19341, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2010), 20(1), 387-391
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 152:278601
AB A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB2 agonists was conducted to improve the in vitro metabolic stability profile in this series while retaining high potency and selectivity for the CB2 receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was


identified as a potent and selective CB₂ agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain.

IT 1021298-22-5

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sulfamoyl benzamides preparation as selective CB₂ agonists with improved in vitro metabolic stability)

RN 1021298-22-5 CAPLUS

CN Methanone, [4-(1-methylethyl)-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 20091329504 CAPLUS

DOCUMENT NUMBER: 151:508598

TITLE: Novel derivatives of benzimidazole and imidazo-pyridine as MCR receptors modulators and their preparation, pharmaceutical compositions and use in the treatment of MC4R

INVENTOR(S): Poitout, Lydie; Brault, Valerie; Sackur, Carole; Pierre, Roubert; Plas, Pascale

PATENT ASSIGNEE(S): Societe de Conseils de Recherches Et, Fr.

SOURCE: U.S. Pat. Appl. Publ., 206pp., Cont.-in-part of U.S. Ser. No. 504,033.

CODEN: USXKC0

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4



PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| US 20090270372 | A1 | 20091029 | US 2009-356964 | 20090121 |
| FR 2851563 | A1 | 20040827 | FR 2003-2320 | 20030226 |
| FR 2851563 | B1 | 20050422 | | |
| WO 2004075823 | A2 | 20040910 | WO 2004-FR418 | 20040225 |
| WO 2004075823 | A3 | 20041007 | | |
| W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20050065179 | A1 | 20050324 | US 2004-915920 | 20040811 |
| US 7501524 | B2 | 20090310 | | |
| US 20050267147 | A1 | 20051201 | US 2004-504033 | 20040928 |
| US 7355052 | B2 | 20080408 | | |
| PRIORITY APPLN. INFO.: | | | FR 2003-2320 | A 20030226 |
| | | | WO 2004-FR418 | W 20040225 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 151:508598

GI




AB A subject of the application is derivs. of benzimidazole and imidazopyridine of formula I, which have a good affinity for certain sub-types of melanocortin receptors, in particular the MC4 receptors. They are particularly useful for treating pathol. conditions and diseases in which one or more melanocortin receptors are involved. The invention also relates to pharmaceutical compns. containing said products. Compds. of formula I wherein A is CO, COCR_{Ab}; Ra and Rb are independently H, and C1-6 alkyl; R1 is H, (un)substituted C1-8 alkyl, (un)substituted C1-8 alkoxy, etc.; R2 is (un)substituted C1-8 alkoxy, C2-6 alkenyl, and (CH₂)₀₋₆-adamantyl, etc.; X is CH; R3 is C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, etc.; R4 is (CH₂)₀₋₄R'₄; R'₄ is guanidine, heterocycloalkyl, aralkyl, etc.; and racemic and enantiomeric forms or any combination of these forms, and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their MC4R modulatory activity.

IT 746660-21-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazole and imidazopyridine derivs. as MC4 receptor modulators useful in treatment of MC4R-mediated diseases)


RN 746660-21-9 CAPLUS

CN Methanone, [1-(3-aminopropyl)-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-6-yl]octahydro-2(1H)-isoquinolinyl- (CA INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L7 ANSWER 3 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1119833 CAPLUS
DOCUMENT NUMBER: 151:417502
TITLE: Discovery of 1-[4-(3-Chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK54418A), a Brain Penetrant 5-Azaindole CB2 Agonist for the Treatment of Chronic Pain
AUTHOR(S): Giblin, Gerard M. P.; Billinton, Andrew; Briggs, Michael; Brown, Andrew J.; Chesseil, Iain P.; Clayton, Nick M.; Eatherton, Andrew J.; Goldsmith, Paul; Haslam, Carl; Johnson, Matthew R.; Mitchell, William L.; Naylor, Alan; Perboni, Alcide; Slingsby, Brian P.; Wilson, Alex W.
CORPORATE SOURCE: Neurosciences CEDD, GlaxoSmithKline, Essex, CM19 5AW, UK
SOURCE: Journal of Medicinal Chemistry (2009), 52(19), 5785-5788
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 151:417502
GI



I



II


AB We report the synthesis and SAR of a series of novel azaindole CB2 agonists. 6-Azaindole 18 (I) showed activity in an acute pain model but was inactive in a chronic model. 18 Is a Pgp substrate with low brain penetration. The template was redesigned, and the resulting 5-azaindole 36 (II) was a potent CB2 agonist with high CNS penetration. This compound was efficacious in the acute model and the chronic joint pain model.

IT 1021298-13-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK54418A), a brain penetrant 5-Azaindole CB2 agonist for the treatment of chronic pain)

RN 1021298-13-4 CAPLUS

CN Methanone, [4-methyl-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:6177 CAPLUS

DOCUMENT NUMBER: 150:274891

TITLE: CB2 selective sulfamoyl benzamides: Optimization of the amide functionality

AUTHOR(S): Goodman, Allan J.; Ajello, Christopher W.; Worm, Karin; Le Bourdonnec, Bertrand; Savolainen, Markku A.; O'Hare, Heather; Cassel, Joel A.; Stabley, Gabriel J.; De Haven, Robert N.; La Buda, Christopher J.; Koblish, Michael; Little, Patrick J.; Brogdon, Bernice L.; Smith, Steven A.; Dolle, Roland E.

CORPORATE SOURCE: Department of Chemistry, Adolor Corporation, Exton, PA, 19341, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2009), 19(2), 309-313

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 150:274891


AB Previous research within our labs. identified sulfamoyl benzamides as novel cannabinoid receptor ligands. Optimization of the amide linkage led to the reverse amide 40. The compound exhibited robust antialloodynic activity in a rodent pain model when administered i.p. Efficacy after oral administration was observed only when ABT, a cytochrome P 450 suicide inhibitor, was coadministered.

IT 1046270-77-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CB2 selective sulfamoyl benzamides: optimization of amide functionality)


RN 1046270-77-2 CAPLUS

CN Methanone, [3-[1,1-dioxido-4-thiomorpholinyl)sulfonyl]-4-methylphenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)
 REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:5978 CAPLUS
 DOCUMENT NUMBER: 150:136095
 TITLE: Pyridine-3-carboxamides as novel CB2 agonists for analgesia
 AUTHOR(S): Mitchell, William L.; Giblin, Gerard M. P.; Naylor, Alan; Eatherton, Andrew J.; Slingsby, Brian P.; Rawlings, Anthony D.; Jandu, Karanjit S.; Haslam, Carl P.; Brown, Andrew J.; Goldsmith, Paul; Clayton, Nick M.; Wilson, Alex W.; Chessel, Iain P.; Green, Richard H.; Whittington, Andrew R.; Wall, Ian D.
 CORPORATE SOURCE: Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline PLC, Harlow, Essex, CM19 5AW, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2009), 19(1), 259-263
 CODEN: BMCL8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 150:136095
 GI



I

AB We describe herein the medicinal chemical approach which led to the discovery of a novel pyridine-3-carboxamide series of CB2 receptor agonists. The SAR of this new template was evaluated and culminated in the identification of analog 14a (I) which demonstrated efficacy in an in vivo model of inflammatory pain.

IT 1021298-13-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Pyridine-3-carboxamides as novel CB2 agonists for analgesia)

RN 1021298-13-4 CAPLUS

CN Methanone, [4-methyl-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-

isoquinolinyl)- (CA INDEX NAME)





OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)
REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 20081476533 CAPLUS
DOCUMENT NUMBER: 150:35377
TITLE: Benzamide derivatives as mGluR5 positive allosteric modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Conn, P. Jeffrey; Lindsley, Craig W.; Weaver, Charles David; Rodriguez, Alice L.; Niswender, Colleen M.; Jones, Carrie K.; Williams, Richard
PATENT ASSIGNEE(S): Vanderbilt University, USA
SOURCE: PCT Int. Appl., 324pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2008151184 | A1 | 20081211 | WO 2008-US65647 | 20080603 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SI, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| AU 2008259776 | A1 | 20081211 | AU 2008-259776 | 20080603 |
| AU 2008259776 | A2 | 20100128 | | |
| CA 2689282 | A1 | 20081211 | CA 2008-2689282 | 20080603 |
| US 2009042855 | A1 | 20090212 | US 2008-132289 | 20080603 |
| EP 2162136 | A1 | 20100317 | EP 2008-770045 | 20080603 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS | | | | |
| KR 2010033981 | A | 20100331 | KR 2009-727281 | 20080603 |
| CN 101795689 | A | 20100804 | CN 2008-80100770 | 20080603 |
| US 20090270362 | A1 | 20091029 | US 2008-263224 | 20081031 |
| MX 2009013169 | A | 20100430 | MX 2009-13169 | 20091203 |
| IN 2009DN08495 | A | 20100716 | IN 2009-DN8495 | 20091224 |
| PRIORITY APPLN. INFO.: | | | US 2007-941686P | P 20070603 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 150:35377
GI



AB The invention relates to compds. of formula I, which are useful as pos. allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5), to methods for making the compds., to pharmaceutical compns. comprising the compds., and to methods of treating neurol. and psychiatric disorders associated with glutamate dysfunction using the compds. and compns. Compds. of formula I wherein dotted line is an optional covalent bond; Y1 and Y2 are independently N and (un)substituted CH; R1 and R2 are independently H and (un)substituted C1-12 organic radical; R3 is (un)substituted C4-14 organic radical; L is C1-7 organic radical, ethynyl, (un)substituted (hetero)cyclic ring, 1,2,4-oxadiazolyl, and amido; and their pharmaceutically acceptable salts and N-oxides thereof, are claimed. Example compound II was prepared by amidation of 4(phenylethynyl)benzoic acid with 4-hydroxypiperidine. All the invention compds. were evaluated for their mGluR5 pos. allosteric modulating activity. From the assay, it was determined that II exhibited an EC50 value of 1.43E-08 nM.


IT 1092551-26-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(drug candidate; preparation of benzamide derivs. as mGluR5 pos. allosteric modulators useful in the treatment of diseases)

RN 1092551-26-2 CAPLUS


CN Methanone, (octahydro-2(1H)-isoquinolinyl)[4-(2-phenylethynyl)phenyl]-(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1384638 CAPLUS
 DOCUMENT NUMBER: 149:532793
 TITLE: Synthesis of cis-4a(S),8a(R)-perhydro-6(2H)-isoquinolinones from quinine:
 4a(S),8a(R)-2-benzoyloctahydro-6(2H)-isoquinolinone
 Hutchinson, Darrell R.; Khuu, Vien V.; Martinelli, Michael J.; Nayyar, Naresh K.; Peterson, Barry C.; Sullivan, Keven A.
 AUTHOR(S): Lilly Res. Lab., Indianapolis, IN, USA
 CORPORATE SOURCE: Organic Syntheses (1998), 75, No pp. given
 SOURCE: CODEN: OSRYAV
 URL: <http://www3.interscience.wiley.com/cgi-bin/mrwhome/104554793/HOME>
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal; General Review; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:532793
 AB A review of the article Synthesis of
 cis-4a(S),8a(R)-perhydro-6(2H)-isoquinolinones from quinine:
 4a(S),8a(R)-2-benzoyloctahydro-6(2H)-isoquinolinone.
 IT 52390-26-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Synthesis of cis-4a(S),8a(R)-perhydro-6(2H)-isoquinolinones from
 quinine: 4a(S),8a(R)-2-benzoyloctahydro-6(2H)-isoquinolinone)
 RN 52390-26-8 CAPLUS
 CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS,8aR)- (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 8 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2008:1383594 CAPLUS
 DOCUMENT NUMBER: 149:555100
 TITLE: The Baeyer-Villiger oxidation of ketones and aldehydes
 AUTHOR(S): Krow, Grant R.
 CORPORATE SOURCE: Temple Univ., Philadelphia, PA, USA
 SOURCE: Organic Reactions (Hoboken, NJ, United States) (1993),
 43, No pp. given
 CODEN: ORHNBA
 URL: <http://www3.interscience.wiley.com/cgi-bin/mrwhome/107610747/HOME>
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal; General Review; (online computer file)
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:555100
 AB A review of the article The Baeyer-Villiger oxidation of ketones and

aldehydes.
IT 52390-26-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(The Baeyer-Villiger Oxidation of Ketones and Aldehydes)
RN 52390-26-8 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS,8aR)- (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 9 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1223105 CAPLUS
DOCUMENT NUMBER: 149:448228
TITLE: Preparation of substituted azaspiro derivatives as histamine H3 receptors modulators
INVENTOR(S): Xu, Yuelian; Caldwell, Timothy M.; Xie, Linghong; Chenard, Bertrand L.
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 97 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| US 20080247964 | A1 | 20081009 | US 2007-745448 | 20070507 |
| AU 2007249925 | A1 | 20071122 | AU 2007-249925 | 20070508 |
| CA 2651654 | A1 | 20071122 | CA 2007-2651654 | 20070508 |
| WO 2007133561 | A3 | 20081002 | WO 2007-US1135 | 20070508 |
| W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AP, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, EA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, EP, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, OA, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 2021004 | A2 | 20090211 | EP 2007-756232 | 20070508 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| JP 2009536651 | T | 20091015 | JP 2009-509820 | 20070508 |
| IN 20080DN09302 | A | 20090612 | IN 2008-DN9302 | 20081106 |
| KR 2009015956 | A | 20090212 | KR 2008-729820 | 20081205 |
| CN 101466375 | A | 20090624 | CN 2007-80021760 | 20081211 |
| PRIORITY APPLN. INFO.: | | | US 2006-746680P | P 20060508 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 149:448228
GI



AB The title compds. I [Z = CHR3 or NR4; R1 = alkyl, alkenyl, cycloalkylalkyl, etc.; R2 = alkyl, haloalkyl; R3 = alkyl, alkoxy, alkylthio, etc.; R4 = alkyl, alkenyl, alkylsulfonyl, etc.; each m = 0-3] which may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals, were prepared E.g., a multi-step synthesis of II, starting from Et cyanoacetate and 1-benzyl-4-piperidone, was given. All over three-hundred compds. I listed in tables showed Ki of < 1 μ M when tested in chimeric human H3 receptor GTP binding assay. Compds. I may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compns. and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

IT 1067896-91-6P 1067896-93-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted azaspiro derivs. as histamine H3 receptors modulators)

RN 1067896-91-6 CAPLUS

CN Methanone, [4-(9-cyclobutyl-3,9-diazaspiro[5.5]undec-3-yl)phenyl][(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1067896-93-8 CAPLUS

CN Methanone, [4-(9-cyclobutyl-3,9-diazaspiro[5.5]undec-3-yl)phenyl](4aS,8aS)-octahydro-2(1H)-isoquinolinyl- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L7 ANSWER 10 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:974346 CAPLUS
DOCUMENT NUMBER: 149:259468
TITLE: Arylsulfonamide compounds which modulate the CB2 receptor
INVENTOR(S): Thomson, David; Riether, Doris; Zindell, Renee M.; Hickey, Eugene Richard; Ermann, Monika; Jenkins, James Edward; Mushi, Innocent; Taylor, Malcolm; Amouzegh, Patricia; Walker, Edward
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 98pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2008098025 | A1 | 20080814 | WO 2008-US53117 | 20080206 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: US 2007-888830P P 20070208
OTHER SOURCE(S): MARPAT 149:259468
GI



AB Compds. are provided which bind to and are agonists, antagonists or inverse agonists of the CB₂ receptor, the compds. having the general formula (I) and the formula (II) wherein, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈ and X have the meanings given in the specification, and the preparation and use thereof. The compds. are valuable CB₂ receptor modulators.

IT


| | | |
|---------------|---------------|---------------|
| 878593-76-1P | 1021298-08-7P | 1021298-11-2P |
| 1021298-12-3P | 1021298-13-4P | 1021298-14-5P |
| 1021298-15-6P | 1021298-16-7P | 1021298-17-8P |
| 1021298-19-0P | 1021298-22-5P | 1021298-23-6P |
| 1021298-24-7P | 1046270-69-2P | 1046270-70-5P |
| 1046270-71-6P | 1046270-72-7P | 1046270-73-8P |
| 1046270-74-9P | 1046270-75-0P | 1046270-76-1P |
| 1046270-77-2P | 1046270-78-3P | 1046270-79-4P |
| 1046270-80-7P | 1046270-81-8P | 1046270-82-9P |
| 1046270-83-0P | 1046270-84-1P | 1046270-85-2P |
| 1046270-86-3P | 1046270-87-4P | 1046270-88-5P |
| 1046270-89-6P | 1046270-90-9P | 1046270-91-0P |
| 1046270-92-1P | 1046270-93-2P | 1046270-94-3P |
| 1046270-95-4P | 1046270-96-5P | 1046270-97-6P |

RL: PAC (Pharmacological activity); **SPN:** (Synthetic preparation); **THU:** (Therapeutic use); **BIOL:** (Biological study); **PREP:** (Preparation); **USES:** (Uses)

(arylsulfonamide compds. which modulate the cb2 receptor)


RN 878593-76-1 CAPLUS

CN Methanone, [4-chloro-3-(1-piperidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-08-7 CAPLUS

CN Methanone, [4-methyl-3-(1-piperidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-11-2 CAPLUS

CN Benzenesulfonamide, 2-methyl-N-(1-methylethyl)-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)




RN 1021298-12-3 CAPLUS

CN Benzenesulfonamide, 2-methyl-N-(2-methylpropyl)-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)




RN 1021298-13-4 CAPLUS

CN Methanone, [4-methyl-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-14-5 CAPLUS

CN Methanone, [3-(1-azetidinylsulfonyl)-4-methylphenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-15-6 CAPLUS


CN Methanone, [3-[(hexahydro-1H-azepin-1-yl)sulfonyl]-4-methylphenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-16-7 CAPLUS
CN Methanone, [4-methyl-3-(4-morpholinylsulfonyl)phenyl](octahydro-2(1H)-isoquinoliny)- (CA INDEX NAME)




RN 1021298-17-8 CAPLUS
CN Methanone, [4-methyl-3-(4-thiomorpholinylsulfonyl)phenyl](octahydro-2(1H)-isoquinoliny)- (CA INDEX NAME)



RN 1021298-19-0 CAPLUS
CN Methanone, [3-[(4-hydroxy-1-piperidinyl)sulfonyl]-4-methylphenyl](octahydro-2(1H)-isoquinoliny)- (CA INDEX NAME)




RN 1021298-22-5 CAPLUS
CN Methanone, [4-(1-methylethyl)-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinoliny)- (CA INDEX NAME)




RN 1021298-23-6 CAPLUS


CN Methanone, [4-cyclohexyl-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-24-7 CAPLUS
CN Methanone, [4-chloro-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1046270-69-2 CAPLUS
CN Benzenesulfonamide, 2-methyl-N-(1-methylpropyl)-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)




RN 1046270-70-5 CAPLUS
CN Methanone, [3-[(3,3-difluoro-1-pyrrolidinyl)sulfonyl]-4-methylphenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1046270-71-6 CAPLUS
CN Methanone, [4-methyl-3-[(3-methyl-1-pyrrolidinyl)sulfonyl]phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1046270-72-7 CAPLUS
CN Benzenesulfonamide, N-(cyclopropylmethyl)-2-methyl-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)




RN 1046270-73-8 CAPLUS
CN Methanone, [3-[(4,4-difluoro-1-piperidinyl)sulfonyl]-4-methylphenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1046270-74-9 CAPLUS
CN Benzenesulfonamide, N-bicyclo[2.2.1]hept-2-yl-2-methyl-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)




RN 1046270-75-0 CAPLUS
CN Methanone, [4-methyl-3-(3-thiazolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1046270-76-1 CAPLUS


CN Methanone, [4-methyl-3-(1-pyrrolidinylsulfonyl)phenyl][(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1046270-77-2 CAPLUS


CN Methanone, [3-[(1,1-dioxido-4-thiomorpholinyl)sulfonyl]-4-methylphenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1046270-78-3 CAPLUS

CN Methanone, [4-methyl-3-(1-pyrrolidinylsulfonyl)phenyl][(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-79-4 CAPLUS

CN Methanone, [4-methyl-3-(1-piperidinylsulfonyl)phenyl][(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-80-7 CAPLUS

CN Methanone, [3-[(3*S*)-3-fluoro-1-pyrrolidinyl]sulfonyl]-4-methylphenyl](octahydro-2(1*H*)-isoquinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-81-8 CAPLUS

CN Methanone, [3-(4-morpholinylsulfonyl)-4-(trifluoromethyl)phenyl](4a*S*,8a*R*)-octahydro-2(1*H*)-isoquinolinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-82-9 CAPLUS


CN Methanone, [(4a*S*,8*aR*)-octahydro-2(1*H*)-isoquinolinyl](3-(1-pyrrolidinylsulfonyl)-4-(trifluoromethyl)phenyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1046270-83-0 CAPLUS


CN Methanone, [4-chloro-3-(4-thiomorpholinylsulfonyl)phenyl](octahydro-2(1*H*)-isoquinolinyl)- (CA INDEX NAME)



RN 1046270-84-1 CAPLUS

CN Methanone, [4-chloro-3-(4-thiomorpholinylsulfonyl)phenyl][(4aS,8aR)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-85-2 CAPLUS

CN Methanone, [4-chloro-3-(1-piperidinylsulfonyl)phenyl][(4aS,8aR)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-86-3 CAPLUS

CN Methanone, [4-chloro-3-(1-pyrrolidinylsulfonyl)phenyl][(4aS,8aR)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-87-4 CAPLUS

CN Methanone, [4-chloro-3-(4-morpholinylsulfonyl)phenyl][(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-88-5 CAPLUS


CN Benzenesulfonamide, 2-chloro-N-(2-methylpropyl)-5-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1046270-89-6 CAPLUS

CN Benzenesulfonamide, 2-chloro-N-(2-methylpropyl)-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)



RN 1046270-90-9 CAPLUS


CN Methanone, [4-(1-methylethyl)-3-(1-piperidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1046270-91-0 CAPLUS

CN Methanone, [4-(1-methylethyl)-3-(4-morpholinylsulfonyl)phenyl][(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1046270-92-1 CAPLUS


CN Benzenesulfonamide, 2-(1-methylethyl)-N-(2-methylpropyl)-5-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1046270-93-2 CAPLUS

CN Methanone, [3-[(hexahydro-1H-azepin-1-yl)sulfonyl]-4-(1-methylethyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1046270-94-3 CAPLUS


CN Methanone, [4-(1-methylethyl)-3-(4-morpholinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1046270-95-4 CAPLUS


CN Benzenesulfonamide, N-cyclohexyl-2-methyl-N-(1-methylethyl)-5-[(octahydro-

2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)



RN 1046270-96-5 CAPLUS


CN Methanone, [4-(1-methylethyl)-3-(4-thiomorpholinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1046270-97-6 CAPLUS

CN Methanone, [3-[(hexahydro-1H-azepin-1-yl)sulfonyl]-4-(1-methylethyl)phenyl][(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 1046271-25-3P 1046271-26-4P 1046271-27-5P

1046271-28-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(arylsulfonamide compds. which modulate the cb2 receptor)

RN 1046271-25-3 CAPLUS


CN Methanone, (4-methylphenyl)(octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1046271-26-4 CAPLUS


CN Methanone, [4-(1-methylethyl)phenyl][(4aS,8aR)-octahydro-2(1H)-isoquinolinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1046271-27-5 CAPLUS


CN Benzenesulfonyl chloride, 2-methyl-5-[(octahydro-2(1H)-isoquinolinyl]carbonyl]- (CA INDEX NAME)



RN 1046271-28-6 CAPLUS

CN Benzenesulfonyl chloride, 2-methyl-5-[[[4aS,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:708755 CAPLUS

DOCUMENT NUMBER: 149:53994

TITLE: Preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors

INVENTOR(S): Poitout, Lydie; Brault, Valerie; Sackur, Carole; Roubert, Pierre; Pias, Pascale

PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications (S.C.R.A.S.), Fr.

SOURCE: U.S. Pat. Appl. Publ., 204pp., Cont.-in-part of U.S. Ser. No. 504,033.

DOCUMENT TYPE: CODEN: USXXCO
 Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| US 20080139619 | A1 | 20080612 | US 2008-12184 | 20080131 |
| US 7501525 | B2 | 20090310 | | |
| FR 2851563 | A1 | 20040827 | FR 2003-2320 | 20030226 |
| FR 2851563 | B1 | 20050422 | | |
| WO 2004075823 | A2 | 20040910 | WO 2004-FR418 | 20040225 |
| WO 2004075823 | A3 | 20041007 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20050065179 | A1 | 20050324 | US 2004-915920 | 20040811 |
| US 7501524 | B2 | 20090310 | | |
| US 20050267147 | A1 | 20051201 | US 2004-504033 | 20040928 |
| US 7355052 | B2 | 20080408 | | |
| PRIORITY APPLN. INFO.: | | | FR 2003-2320 | A 20030226 |
| | | | WO 2004-FR418 | W 20040225 |
| | | | US 2004-915920 | A3 20040811 |
| | | | US 2004-504033 | A2 20040928 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 149:53994
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = CH₂, CO, (un)substituted COCH₂; X = CH, N; R₁, R₂ = independently H, alkyl optionally substituted by OH, alkenyl, etc.; or R₁R₂ = (un)substituted hetero(bi)cycloalkyl; R₃ = alkyl, alkoxy, alkylthio, heteroaryl, (un)substituted hetero(cyclo)alkyl, aryl, etc.; R₄ = (CH₂)_sR₅; R₅ = heterocycloalkyl, heteroaryl, etc.; s = 0-6] were prepared as melanocortin (MC), in particular MC4, receptor modulators (no data given). For example, II was prepared, in 2 steps, by amination of 3-fluoro-N,N-bis(3-methylbutyl)-4-nitrobenzamide (preparation given) with 3-(piperidino)propylamine in CH₃CN at reflux, followed by one-step hydrogenation/coupling with 4-acetylphenyl isothiocyanate. I are useful in the treatment of pathol. states and the diseases in which one or more melanocortin receptors are involved. The invention also relates to pharmaceutical compns. containing compds. I.


IT 746660-21-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors)

RN 746660-21-9 CAPLUS

CN Methanone, [(1-(3-aminopropyl)-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-6-yl](octahydro-2(1H)-isoquinolinyl)-(CA INDEX NAME)



OS.CITING REF COUNT: 0 THERE ARE 0 CAPLUS RECORDS THAT CITE THIS RECORD
(0 CITINGS)

L7 ANSWER 12 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:324799 CAPLUS
DOCUMENT NUMBER: 148:486374

TITLE: Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity

AUTHOR(S): Ermann, Monika; Riether, Doris; Walker, Edward R.; Mushi, Innocent F.; Jenkins, James E.; Noya-Marino, Beatriz; Brewer, Mark L.; Taylor, Malcolm G.; Amouzegh, Patricia; East, Stephen P.; Dymock, Brian W.; Gemkow, Mark J.; Kahrs, Andreas F.; Ebnet, Andreas; Loebbe, Sabine; O'Shea, Kathy; Shih, Daw-Tsun; Thomson, David

CORPORATE SOURCE: Evotec (UK) Ltd., Abingdon, Oxfordshire, OX14 4SA, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008),

18(5), 1725-1729

CODEN: BMCL8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:486374


AB A high-throughput screening campaign resulted in the discovery of a highly potent dual cannabinoid receptor 1 (CB1) and 2 (CB2) agonist. Following a thorough SAR exploration, a series of selective CB2 full agonists were identified.

| | | |
|------------------|---------------|---------------|
| IT 1021298-08-7P | 1021298-09-8P | 1021298-10-1P |
| 1021298-11-2P | 1021298-12-3P | 1021298-13-4P |
| 1021298-14-5P | 1021298-15-6P | 1021298-16-7P |
| 1021298-17-8P | 1021298-18-9P | 1021298-19-0P |
| 1021298-20-3P | | |

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity)

RN 1021298-08-7 CAPLUS


CN Methanone, [4-methyl-3-(1-piperidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1021298-09-8 CAPLUS


CN Methanone, [4-methyl-3-(1-piperidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1021298-10-1 CAPLUS

CN Benzenesulfonamide, 2-methyl-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]-N-phenyl- (CA INDEX NAME)




RN 1021298-11-2 CAPLUS

CN Benzenesulfonamide, 2-methyl-N-(1-methylethyl)-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)




RN 1021298-12-3 CAPLUS

CN Benzenesulfonamide, 2-methyl-N-(2-methylpropyl)-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)




RN 1021298-13-4 CAPLUS


CN Methanone, [4-methyl-3-(1-pyrrololidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-14-5 CAPLUS
CN Methanone, [3-(1-azetidinylsulfonyl)-4-methylphenyl] (octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-15-6 CAPLUS
CN Methanone, [3-[1-(hexahydro-1H-azepin-1-yl)sulfonyl]-4-methylphenyl] (octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1021298-16-7 CAPLUS
CN Methanone, [4-methyl-3-(4-morpholinylsulfonyl)phenyl] (octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-17-8 CAPLUS
CN Methanone, [4-methyl-3-(4-thiomorpholinylsulfonyl)phenyl] (octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-18-9 CAPLUS

CN 3,5-Thiomorpholinedione, 4-[(2-methyl-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl)sulfonyl]- (CA INDEX NAME)




RN 1021298-19-0 CAPLUS

CN Methanone, [3-[(4-hydroxy-1-piperidinyl)sulfonyl]-4-methylphenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



RN 1021298-20-3 CAPLUS

CN Methanone, [4-methyl-3-[(4-(1-methylethyl)-1-piperazinyl)sulfonyl]phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




IT 1021298-22-5 1021298-23-6 1021298-24-7
1021298-25-8 1021298-26-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arylsulfonamide CB₂ receptor agonists: SAR and optimization of CB₂ selectivity)


RN 1021298-22-5 CAPLUS

CN Methanone, [4-(1-methylethyl)-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-23-6 CAPLUS

CN Methanone, [4-cyclohexyl-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-24-7 CAPLUS
 CN Methanone, [4-chloro-3-(1-pyrrolidinylsulfonyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1021298-25-8 CAPLUS
 CN Methanone, [(4aR,8aS)-octahydro-2(1H)-isoquinolinyl][3-(1-pyrrolidinylsulfonyl)phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1021298-26-9 CAPLUS
 CN Methanone, [4-chloro-3-(1-pyrrolidinylsulfonyl)phenyl][(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




IT 1046271-25-3P 1046271-27-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2

selectivity)
RN 1046271-25-3 CAPLUS
CN Methanone, (4-methylphenyl)(octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 1046271-27-5 CAPLUS
CN Benzenesulfonyl chloride, 2-methyl-5-[(octahydro-2(1H)-isoquinolinyl)carbonyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:242525 CAPLUS
DOCUMENT NUMBER: 148:426671
TITLE: Solution phase synthesis of a 3,5,7-substituted indolin-2-one library as potential CDK2 inhibitor isosteres
AUTHOR(S): Tymoshenko, Dmytro O.; Gregg, Brian T.; Hirsch, Matthew J.; Butcher, Jennifer L.
CORPORATE SOURCE: Department of Medicinal Chemistry, AMRI, Albany, NY, 12203, USA
SOURCE: Letters in Drug Design & Discovery (2008), 5(1), 43-47
CODEN: LDDDAW; ISSN: 1875-628X
URL: <http://www.ingentaconnect.com/content/ben/lddd/2008/00000005/00000001>
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:426671
AB A set of 4-[N'-(2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazino]-benzamides focused on specific interactions at the ATP binding cleft of CDK2 was synthesized. The synthetic strategy towards potential inhibitors included the preparation of p-nitrophenyl activated esters and use of polymer scavengers to facilitate amide bond formation and purification. Using this methodol., a focused library of 352 compds. was prepared
IT 1007532-70-8P 1017799-00-6P 1017799-31-3P
1017800-51-9P 1017800-87-1P 1017801-24-9P
1017801-68-1P 1017802-15-1P
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(combinatorial preparation of library of oxodihydroindolylidenehydrazino benzamides via esterification of oxodihydroindolylidenehydrazino


benzoic acids with nitrophenyl trifluoroacetate followed by amidation)
RN 1007532-70-8 CAPLUS
CN 1H-Indole-2,3-dione, 5-bromo-, 3-[2-[4-[(octahydro-2(1H)-
isoquinolinyl)carbonyl]phenyl]hydrazone] (CA INDEX NAME)




RN 1017799-00-6 CAPLUS
CN 1H-Indole-2,3-dione, 3-[2-[4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]hydrazone] (CA INDEX NAME)




RN 1017799-31-3 CAPLUS
CN 1H-Indole-2,3-dione, 5-fluoro-, 3-[2-[4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]hydrazone] (CA INDEX NAME)




RN 1017800-51-9 CAPLUS
CN 1H-Indole-2,3-dione, 5,7-dichloro-,
3-[2-[4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]hydrazone] (CA INDEX NAME)




RN 1017800-87-1 CAPLUS
CN 1H-Indole-2,3-dione, 5,7-dimethyl-,
3-[2-[4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]hydrazone] (CA
INDEX NAME)




RN 1017801-24-9 CAPLUS
CN 1H-Indole-2,3-dione, 7-(trifluoromethyl)-,
3-[2-[4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]hydrazone] (CA
INDEX NAME)



RN 1017801-68-1 CAPLUS
CN 1H-Indole-2,3-dione, 5-methoxy-, 3-[2-[4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]hydrazone] (CA INDEX NAME)



RN 1017802-15-1 CAPLUS
CN 1H-Indole-2,3-dione, 5-(trifluoromethoxy)-,
3-[2-[4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]hydrazone] (CA
INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 20071454483 CAPLUS
 DOCUMENT NUMBER: 148:79076
 TITLE: Preparation of benzamide compounds containing heterocycle moiety as PARP inhibitors
 INVENTOR(S): Javaid, Muhammad Hashim; Gomez, Sylvie; Cockcroft, Xiao-Ling Fan; Menear, Keith Allan; Martin, Niall Morrison Barr
 PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2007144652 | A2 | 20071221 | WO 2007-GB2247 | 20070615 |
| WO 2007144652 | A3 | 20080410 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, LZ, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, IJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| EP 2035380 | A2 | 20090318 | EP 2007-733251 | 20070615 |
| R: AT, BS, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| JP 2009539963 | T | 20091119 | JP 2009-514909 | 20070615 |
| US 20090181951 | A1 | 20090716 | US 2008-304794 | 20081215 |
| IN 2008DN10453 | A | 20090320 | IN 2008-DN10453 | 20081217 |
| CN 101500997 | A | 20090805 | CN 2007-80030105 | 20090212 |
| PRIORITY APPLN. INFO.: | | | US 2006-804848P | P 20060615 |
| | | | WO 2007-GB2247 | W 20070615 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:79076; MARPAT 148:79076

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R2-R5 = H, alkoxy, amino, etc.; Y = -CR11R12-(CH₂)_m-; m = 0 or 1; R11 = CH₃ or CF₃; R12 = H or CH₃; or R11 and R12 together with the carbon atom to which they are attached form 1,1-cyclopropylene group; R21, R22 = H or R; R = (un)substituted alkyl, heterocycl or aryl; or R21 and R22 together with the carbon atom to which they are attached form a (un)substituted nitrogen containing heterocyclic ring; Het = Q₁, etc.; Y₁, Y₃ = CH or N; Y₂ = CX or N; X = H, Cl or F] and their pharmaceutically acceptable salts were prepared. Thus, a multi-step synthesis of compound II, starting from 2-fluoro-5-formylbenzonitrile, was given. In PARP (Poly(ADP-ribose) polymerase) inhibition assays, compound II exhibited the IC₅₀ value of less than 1 μ M. Compds. I are claimed useful for the treatment of vascular diseases, septic shock, etc.


IT 960244-72-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamide compds. containing heterocycle moiety as PARP inhibitors for treatment of vascular diseases, septic shock)

RN 960244-72-8 CAPLUS

CN Benzanide, 2-[1-[4-fluoro-3-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]ethoxy]- (CA INDEX NAME)



L7 ANSWER 15 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1454122 CAPLUS

DOCUMENT NUMBER: 148:79062

TITLE: Preparation of heterocyclcarbonylphenylalkoxybenzamides as poly(ADP-ribose) polymerase (PARP) inhibitors.

INVENTOR(S): Javайд, Muhammad Hashim; Gomez, Sylvie; Cockcroft, Xiao-Ling Fan; Menear, Keith Allan; Martin, Niall Morrison Barr

PATENT ASSIGNEE(S): Kudos Pharmaceuticals Limited, UK

SOURCE: PCT Int. Appl., 56pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2007144639 | A1 | 20071221 | WO 2007-GB2232 | 20070615 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, | | | | |


KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
 RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM

| | | | | |
|------------------------|--|----------|------------------|------------|
| EP 2041087 | A1 | 20090401 | EP 2007-733236 | 20070615 |
| R: | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
AL, BA, HR, MK, RS | | | |
| JP 2009541217 | T | 20091126 | JP 2009-514906 | 20070615 |
| US 20090209520 | A1 | 20090820 | US 2008-304636 | 20081212 |
| IN 2008DN10455 | A | 20090320 | IN 2008-DN10455 | 20081217 |
| CN 101484421 | A | 20090715 | CN 2007-80025119 | 20081231 |
| PRIORITY APPLN. INFO.: | | | US 2006-804849P | P 20060615 |
| | | | WO 2007-GB2232 | W 20070615 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 148:79062; MARPAT 148:79062

GI



AB Title compds. [I; R2-R5 = H, alkoxy, amino, halo, OH; Y = CR21R22(CH₂)_m; m = 0, 1; R21 = H, Me, CF₃; R22 = H, Me; R21R22C = 1,1-cyclopropane; R11, R12 = H, R; R = (substituted) alkyl, heterocycl, aryl; R11R12N = (substituted) 5-7 membered heterocycl; Y1, Y3 = CH, N; Y2 = CX, N; X = H, Cl, F], were prepared. Thus, 2-[2-[3-fluoro-4-[4-(2-phenoxypropionyl)piperazine-1-carbonyl]phenyl]ethoxybenzamide [multistep preparation from 2-(3-fluorophenyl)ethan-1-ol, salicylamide, Boc-piperazine, and 2-phenoxypropionyl chloride given] and other I inhibited mammalian PARP with IC₅₀ values of <10 μM.


IT 960250-15-1P 960250-28-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclcarbonylphenylalkoxybenzamides as PARP inhibitors)

RN 960250-15-1 CAPLUS

CN Benzamide, 2-[2-[3-fluoro-4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]ethoxy]- (CA INDEX NAME)



RN 960250-28-6 CAPLUS
 CN Benzamide, 5-fluoro-2-[(4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl)methoxy]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 20071874154 CAPLUS
 DOCUMENT NUMBER: 147:257665
 TITLE: Spirochromane derivatives as histamine H3 receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy
 INVENTOR(S): Butler, Todd William; Howard, Harry Ralph, Jr.; Wager, Travis T.
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 41pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2007088462 | A1 | 20070809 | WO 2007-IB235 | 20070122 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JE, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: US 2006-764230P P 20060201
 OTHER SOURCE(S): CASREACT 147:257665; MARPAT 147:257665
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to spirochromane derivs. of formula I, which are histamine H3 receptor antagonists. In compds. I, R1 is selected from (un)substituted Ph, (un)substituted naphthyl, (un)substituted 5- or 6-membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O, and S, and (un)substituted carbamoyl; and R2 is C1-4 alkyl. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound of formula I, and optionally a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of disorders or conditions that respond to H3 receptor antagonism, such as depression, anxiety disorders, and attention-deficit disorders. Cyclocondensation of 5'-bromo-2'-hydroxyacetophenone with N-Boc-piperidin-4-one followed by hydride reduction and deoxygenation yielded spirochromane II, which underwent alkylation with Et iodide and Suzuki coupling with 2-methoxypyridine-5-boronic acid to give spirochromane III. The compds. of the invention, e.g., III, are antagonists of histamine H3 receptors (no data).

IT 945723-21-7P 945723-25-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of spirochromane derivs. as histamine H3 receptor antagonists)

RN 945723-21-7 CAPLUS


CN Methanone, (1'-ethyl-3,4-dihydrospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl) [(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 945723-25-1 CAPLUS

CN Methanone, (1'-ethyl-3,4-dihydrospiro[2H-1-benzopyran-2,4'-piperidin]-6-yl) (octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)


ACCESSION NUMBER: 2007:817925 CAPLUS
 DOCUMENT NUMBER: 147:211730
 TITLE: Isoindole derivatives as cannabinoid receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases
 INVENTOR(S): Chackalannil, Samuel; Chelliah, Mariappan V.; Clasby, Martin C.; Eagen, Keith A.; Scott, Jack D.; Wang, Yuguang; Xia, Yan; Greenlee, William J.
 PATENT ASSIGNEE(S): Schering Corp., USA
 SOURCE: PCT Int. Appl., 406 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2007084450 | A2 | 20070726 | WO 2007-US1024 | 20070116 |
| WO 2007084450 | A3 | 20071108 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| AU 2007207706 | A1 | 20070726 | AU 2007-207706 | 20070116 |
| CA 2637565 | A1 | 20070726 | CA 2007-2637565 | 20070116 |
| US 20070197628 | A1 | 20070823 | US 2007-653558 | 20070116 |
| AR 59021 | A1 | 20080305 | AR 2007-100181 | 20070116 |
| EP 1973877 | A2 | 20081001 | EP 2007-716633 | 20070116 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, RS | | | | |
| JP 2009528266 | T | 20090806 | JP 2008-551309 | 20070116 |
| IN 2008CN03665 | A | 20090313 | IN 2008-CN3665 | 20080716 |
| ZA 2008006237 | A | 20090527 | ZA 2008-6237 | 20080717 |
| MX 2008009354 | A | 20080930 | MX 2008-9354 | 20080718 |
| NO 2008003562 | A | 20081020 | NO 2008-3562 | 20080815 |
| KR 2008097426 | A | 20081105 | KR 2008-720165 | 20080818 |
| CN 101405263 | A | 20090408 | CN 2007-80009372 | 20080916 |
| PRIORITY APPLN. INFO.: | | | US 2006-760007P | P 20060118 |
| | | | US 2006-846965P | P 20060925 |
| | | | WO 2007-US1024 | W 20070116 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 147:211730

GI



AB A compound having the general structure of formula I or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders. Compds. of formula I wherein m is 0 and 1; n is 1 and 2; and m + n is 1 and 2; dashed lines is single and double bonds; R1 is CONH2 and derivs., CO2-alkyl, and acyl; R2 is H, (un)substituted alkyl, and alkylen-NH2 and derivs.; R1R2 taken together to form a (un)substituted 5-membered heterocyclic ring; R15 is H, N3, halo, alkenyl, (un)substituted alkylene, OH, CN, etc.; Ar1 and Ar2 are independently (un)substituted (hetero)aryl; and their pharmaceutically acceptable salts, solvates and esters thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compds. were evaluated for their cannabinoid receptor modulatory activity. From the assay, it was determined that compound II exhibited Ki value in the range of 10 to 1 nM.

IT 944815-64-9P 944818-07-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoindole derivs. as cannabinoid receptor modulators useful in the treatment of diseases or conditions mediated by cannabinoid receptors)

RN 944815-64-9 CAPLUS

CN 1H-Isoindol-1-one, 5-[2-chloro-4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-4-(4-chlorophenyl)octahydro-3,7a-dimethyl-, (3R,3aS,4S,5R,7aR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 944818-07-9 CAPLUS

CN 1H-Isoindol-1-one, 5-[2-chloro-4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-4-(4-chlorophenyl)octahydro-3,7a-dimethyl-, (3R,3aS,4S,5R,7aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L7 ANSWER 18 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:512058 CAPLUS

DOCUMENT NUMBER: 146:481830

TITLE: Substituted benzamide and 11 β -hydroxysteroid dehydrogenase type 1 and their preparation and pharmaceutical use

INVENTOR(S): Andersen, Henrik Sune; Joergensen, Anker Steen;
Kilburn, John Paul; Kampen, Gita Camilla Tejlgaard;
Ebdrup, Soeren

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 185 pp.

DOCUMENT TYPE: CODEN: PIXDD2
Patent



LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2007051810 | A2 | 20070510 | WO 2006-EP68015 | 20061101 |
| WO 2007051810 | A3 | 20080124 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| AU 2006310518 | A1 | 20070510 | AU 2006-310518 | 20061101 |
| CA 2627306 | A1 | 20070510 | CA 2006-2627306 | 20061101 |
| EP 1948190 | A2 | 20080730 | EP 2006-819214 | 20061101 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| JP 2009514818 | T | 20090409 | JP 2008-537121 | 20061101 |
| MX 2008005322 | A | 20080718 | MX 2008-5322 | 20080424 |
| IN 2008DN04550 | A | 20080815 | IN 2008-DN4550 | 20080528 |
| KR 2008076916 | A | 20080820 | KR 2008-712901 | 20080529 |
| CN 101351209 | A | 20090121 | CN 2006-80050249 | 20080701 |
| US 20090124598 | A1 | 20090514 | US 2008-92230 | 20081023 |
| PRIORITY APPLN. INFO.: | | | EP 2005-110228 | A 20051101 |
| | | | EP 2006-116808 | A 20060707 |
| | | | WO 2006-EP68015 | W 20061101 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:481830; MARPAT 146:481830

GI



AB The use of substituted amides of formula I for modulating the activity of 11 β -hydroxysteroid dehydrogenase type 1 (11 β HSD1) and the use of these compds. as pharmaceutical compns., are described. Also a class of substituted amides of formula I, their use in therapy, pharmaceutical compns. comprising the compds., as well as their use in the manufacture of medicaments are described. Compound of formula I wherein R1 is H, acyl, (amino)sulfonyl, (amino)sulfinyl, etc.; R2 is H, C1-6 alkyl, and C3-6 cycloalkyl; R1R2 taken together with N to form (un)substituted (un)saturated 3- to 12-membered (mono/bi)heterocyclic ring; A is (un)substituted (un)saturated 5- to 12-membered (bi/tri)heterocyclic; R5 is H, C1-6 alkyl, C3-6 cycloalkyl, halo, OH, and CN; R6 and R7 is H, C1-6 alkyl, F, trihalomethyl, and trihalomethoxy; R6R7 taken together to give (un)substituted (un)saturated 3- to 8-membered (hetero)monocyclic; and their prodrugs, pharmaceutically acceptable acid and base salts, optical isomers, mixts. of optical isomers, racemic mixts., tautomeric forms thereof, are claimed. The compds. are modulators and more specifically inhibitors of the activity of 11 β HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. Example compound II was prepared by amidation at 4-(tert-butoxycarbonylaminomethyl)benzoic acid with 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane hydrochloride; the resulting [4-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octane-6-carbonyl)benzyl]carbamic acid tert-Bu ester underwent methylation with Me Iodide to give methyl-[4-(1,3,3-trimethyl-6-azabicyclo[3.2.1]octane-6-carbonyl)benzyl]carbamic acid tert-Bu ester, which underwent hydrolysis to give (4-methylaminomethylphenyl)-(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methanone, which underwent acetylation with acetyl chloride to give compound II. All the invention compds. were evaluated for their 11 β HSD1 inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 19 nM.


IT 936019-82-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzamide derivs. as 11 β -hydroxysteroid dehydrogenase type 1 inhibitors useful in the treatment of diseases)

RN 936019-82-8 CAPLUS

CN Methanone, [4-[(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)methyl]phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




IT 1153065-15-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzamide derivs. as 11 β -hydroxysteroid dehydrogenase type 1 inhibitors useful in the treatment of diseases)

RN 1153065-15-6 CAPLUS

CN Methanone, [4-(aminomethyl)phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)


L7 ANSWER 19 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:143519 CAPLUS
DOCUMENT NUMBER: 146:229382
TITLE: Preparation of dipiperazinyl ketones and related analogues as modulators of histamine H3 receptor binding
INVENTOR(S): Xie, Linghong; Ochterski, Joseph W.; Gao, Yang; Han, Bingsong; Caldwell, Timothy M.; Xu, Yuelian; Peterson, John M.; Ge, Ping; Ohliger, Robert
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 279pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2007016496 | A2 | 20070208 | WO 2006-US29761 | 20060728 |
| WO 2007016496 | A3 | 20090430 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| AU 2006275568 | A1 | 20070208 | AU 2006-275568 | 20060728 |
| CA 2606004 | A1 | 20070208 | CA 2006-2606004 | 20060728 |
| US 20070049571 | A1 | 20070301 | US 2006-495986 | 20060728 |
| EP 1909797 | A2 | 20080416 | EP 2006-788999 | 20060728 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| JP 2009506987 | T | 20090219 | JP 2008-525081 | 20060728 |
| PRIORITY APPLN. INFO.: | | | US 2005-704722P | P 20050802 |
| | | | WO 2006-US29761 | W 20060728 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 146:229382; MARPAT 146:229382
GI



I



II

AB Title compds. I [Z1 and Z2 independently = N or CRa wherein Ra = H, OH, halo, alkyl, etc.; Z3 = N or CRb wherein Rb = absent, H, OH, alkyl, etc.; bonds a and b independently represent single or double bond such that if Z3 = N, then bond a is single bond and at least one of bond a or bond b = single bond; W = CR3R4, NR5, COCR3R4, CO2R3R4; R3 and R4 independently = H, alkyl, haloalkyl, etc.; R5 = H, alkyl, haloalkyl, etc.; each m independently = 0-2, such that neither m = 0 if both Z2 and Z3 = N; n = 0-2; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = 0-4 substituents chosen from alkyl and groups that are taken together to form alkylene bridge; R6 = (un)substituted alkanoyl, alkoxy carbonyl, alkenyl, etc.; R7 = 0-4 substituents chosen from alkyl and groups that are taken together to form alkylene bridge], and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of histamine H3 receptor binding. Thus, e.g., II was prepared by acetylation of 1-cyclopentylpiperazine with bromoacetyl bromide followed by N-alkylation of 1-(4-piperazinyl-1-ylphenyl)ethanone. Details for bioassays are described (no data). I may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).


IT 923934-89-8P 923934-90-1P 923934-91-2P
923934-92-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dipiperazinyl ketones and related analogs as histamine H3 receptor modulators)

RN 923934-89-8 CAPLUS

CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[4-[3-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-1-piperazinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 923934-90-1 CAPLUS

CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[4-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-1-piperazinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 923934-91-2 CAPLUS


CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[4-[3-[(4aS,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-1-piperazinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 923934-92-3 CAPLUS
CN Ethanone, 1-(4-cyclobutyl-1-piperazinyl)-2-[4-[4-[(4aS,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-1-piperazinyl- (CA INDEX NAME)


Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L7 ANSWER 20 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:111510 CAPLUS
DOCUMENT NUMBER: 149:331755
TITLE: Product class 6: lactones
AUTHOR(S): Maier, M. E.
CORPORATE SOURCE: Institut fuer Organische Chemie, Universitaet
Tuebingen, Tuebingen, 72076, Germany
SOURCE: Science of Synthesis (2006), 20b, 1421-1551
CODEN: SSCYJ9
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review of methods to prepare lactones and their applications to organic synthesis.
IT 52390-25-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(review preparation of lactones and their applications to organic synthesis)
RN 52390-25-7 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 602 THERE ARE 602 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L7 ANSWER 21 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 20061206741 CAPLUS

DOCUMENT NUMBER: 145:489228

TITLE: Preparation of thiazole compounds for treating Hepatitis C virus infections

INVENTOR(S): Zhang, Suoming; Phadke, Avinash; Liu, Cuixian; Wang, Xiangzhu; Quinn, Jesse; Chen, Dawei; Gadhachanda, Venkat; Li, Shouming; Deshpande, Milind

PATENT ASSIGNEE(S): Achillion Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 254pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2006122011 | A2 | 20061116 | WO 2006-US17692 | 20060509 |
| WO 2006122011 | A3 | 20070503 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| AU 2006244203 | A1 | 20061116 | AU 2006-244203 | 20060509 |
| CA 2607617 | A1 | 20061116 | CA 2006-2607617 | 20060509 |
| US 20070004711 | A1 | 20070104 | US 2006-431155 | 20060509 |
| EP 1879575 | A2 | 20080123 | EP 2006-770077 | 20060509 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR | | | | |
| JP 2008540537 | T | 20081120 | JP 2008-511226 | 20060509 |
| BR 2006008910 | A2 | 20100217 | BR 2006-8910 | 20060509 |
| SG 159561 | A1 | 20100330 | SG 2010-1098 | 20060509 |
| IN 2007DN08346 | A | 20080704 | IN 2007-DN8346 | 20071029 |
| MX 2007013955 | A | 20080205 | MX 2007-13955 | 20071108 |
| NO 2007005723 | A | 20080205 | NO 2007-5723 | 20071109 |
| ZA 2007009751 | A | 20081126 | ZA 2007-9751 | 20071113 |
| KR 2008019213 | A | 20080303 | KR 2007-728496 | 20071206 |
| CN 101247807 | A | 20080820 | CN 2006-80025066 | 20080109 |
| PRIORITY APPLN. INFO.: | | | US 2005-679133P | P 20050509 |
| | | | WO 2006-US17692 | W 20060509 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 145:489228, MARPAT 145:489228

GI



AB The title compds. I [Ar1 = fluorenyl, Ph, naphthyl, etc.; R2 = halo, CO2H, CONH2, etc.; R3 = H, alkyl, C(OR5) (wherein R5 = alkyl, Ph, 5-6 membered heteroaryl); R4 = H, halo, OH, etc.; or R2 and R4 are taken together with the carbon atoms of the thiazole ring to which they are attached to form 5-7 membered carbocyclic ring which is aromatic or partially unsatd.; r = 0-2; q = 0-1; t = 0-1] that are potent and/ or selective inhibitors of Hepatitis C virus replication, were prepared. Thus, bromination of 3-acetylpyridine with Br2 followed by reacting 2-bromo-1-(pyridin-3-yl)ethanone with N-(4-pentyloxy-3-trifluoromethylphenyl)thiourea afforded II which showed EC50 of < 1 μ M when tested in a replicon based assay of HCV replication inhibition. Certain compds. I inhibit assembly of the HCV replication complex. The invention also provides pharmaceutical compns. containing one or more compds. I, or a salt, solvate, or acylated prodrug of such compds., and one or more pharmaceutically acceptable carriers, excipients, or diluents. The invention further comprises methods of treating patients suffering from certain infectious diseases by administering to such patients an amount of a compound I effective to reduce signs or symptoms of the disease. These infectious diseases include viral infections, particularly HCV infections. The invention particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease. Methods of treatment include administering a compound I as a single active agent or administering a compound I in combination with one or more other therapeutic agent.


IT 914667-43-9P 914668-24-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazole compds. for treating Hepatitis C virus infections)


RN 914667-43-9 CAPLUS

CN Methanone, [4-[4-(4-fluorophenyl)-2-thiazolyl]amino]-2-(trifluoromethyl)phenyl](octahydro-2(1H)-isoquinolinyl)-(CA INDEX NAME)



RN 914668-24-9 CAPLUS

CN Methanone, 4-[(4-(2-methoxy-5-pyrimidinyl)-2-thiazolyl]amino]-2-(trifluoromethyl)phenyl] (octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L7 ANSWER 22 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:213433 CAPLUS

DOCUMENT NUMBER: 144:274294

TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β -secretase for treating Alzheimer's disease and related disorders
Bishoff, Francois Paul; Bracken, Mireille; Pieters, Serge Marie Aloysius; Mercken, Marc Hubert; De Winter, Hans Louis Jos; Berthelot, Dieder Jean-Claude

PATENT ASSIGNEE(S): Janssen Pharmaceutica, N. V., Belg.

SOURCE: PCT Int. Appl., 369 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2006024932 | A1 | 20060309 | WO 2005-IB2595 | 20050808 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20060079686 | A1 | 20060413 | US 2005-197608 | 20050804 |
| US 20060079687 | A1 | 20060413 | US 2005-197669 | 20050804 |
| US 20060178383 | A1 | 20060810 | US 2005-197615 | 20050804 |
| EP 1789398 | A1 | 20070530 | EP 2005-780525 | 20050808 |

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU



CN 101035772 A 20070912 CN 2005-80034228 20050808
JP 2008509129 T 20080327 JP 2007-524423 20050808
IN 2007/KN00752 A 20070713 IN 2007-KN752 20070301

PRIORITY APPLN. INFO.: US 2004-599810P P 20040806
US 2004-599317P P 20040806
US 2004-599811P P 20040806
WO 2005-IB2595 W 20050808

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 144:274294

GI



AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [R0 = H, Me, CF3; R1 = H, OH, Me, Et, CF3, OEt, etc.; Al = (un)substituted alkyl; Q1= O, S, CO, CS, NHCO, CONH, etc.; R2 = (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl, etc.; m = 0-1; R3 = (un)substituted alk(en)yl, aryl, etc.; n = 0-3; each R10 = independently OH, halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β -secretase, also known as β -site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β -secretase in 3 different assays.


IT 876766-27-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-aminoquinazolines as β -secretase inhibitors for treating Alzheimer's disease and related disorders)

RN 876766-27-7 CAPLUS



CN Methanone, [3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]phenyl](octahydro-2(1H)-isoquinolinyl)-(CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
 (9 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2006:152738 CAPLUS
 DOCUMENT NUMBER: 144:254142
 TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β -secretase for treating Alzheimer's disease and related disorders
 INVENTOR(S): Baxter, Ellen; Bischoff, Francois Paul; Boyd, Robert; Braeken, Mireille; Coats, Steven; Huang, Yifang; Jordan, Alfonzo; Luo, Chi; Mercken, Marc Hubert; Reynolds, Charles H.; Ross, Tina Morgan; Touinge, Brett A.; Schulz, Mark; De Winte, Hans Louis Jos; Pieters, Serge Maria Aloysius; Reitz, Allen B.
 PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
 SOURCE: PCT Int. Appl., 385 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 2006017836 | A2 | 20060216 | WO 2005-US28191 | 20050808 |
| WO 2006017836 | A3 | 20060629 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TU, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| US 20060079686 | A1 | 20060413 | US 2005-197608 | 20050804 |
| US 20060079687 | A1 | 20060413 | US 2005-197669 | 20050804 |
| US 20060178383 | A1 | 20060810 | US 2005-197615 | 20050804 |
| EP 1776349 | A2 | 20070425 | EP 2005-785256 | 20050808 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| CN 101035771 | A | 20070912 | CN 2005-80034122 | 20050808 |
| JP 2008509165 | T | 20080327 | JP 2007-525074 | 20050808 |
| IN 2007KN00762 | A | 20070713 | IN 2007-KN762 | 20070301 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 2004-599811P | P 20040806 |
| | | | US 2004-599317P | P 20040806 |
| | | | US 2004-599810P | P 20040806 |



AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [$R_0 = H, Me, CF_3$; $R_1 = H, OH, Me, Et, CF_3, OEt$, etc.; $A_1 =$ (un)substituted alkyl; $Q_1 = O, S, CO, CS, NHCO, CONH$, etc.; $R_2 =$ (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl; $m = 0-1$; $L_1 = O, S, SO, SO_2$, etc.; $R_3 =$ (un)substituted alk(en)yl, aryl, etc.; $n = 0-3$; each $R_{10} =$ independently OH , halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β -secretase, also known as β -site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β -secretase in 3 different assays.


IT 876766-27-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-aminoquinazolines as β -secretase inhibitors for treating Alzheimer's disease and related disorders)

RN 876766-27-7 CAPLUS

CN Methanone, [3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]phenyl](octahydro-2(1H)-isoquinolinyl)-(CA INDEX NAME)



L7 ANSWER 24 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:149827 CAPLUS

DOCUMENT NUMBER: 144:254141

TITLE: Novel 2-aminoquinazoline derivatives, their preparation and use as inhibitors of β -secretase for treating Alzheimer's disease and related disorders
Baxter, Ellen; Boyd, Robert; Coats, Steve; Jordan, Alfonzo; Reitz, Allen; Reynolds, Charles H.; Scott, Malcolm; Schulz, Mark; De Winter, Hans Louis Jos

INVENTOR(S): Janssen Pharmaceutica, N.V., Belg.

PATENT ASSIGNEE(S): PCT Int. Appl., 382 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 2006017844 | A1 | 20060216 | WO 2005-US28340 | 20050808 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM | | | | |
| US 20060079686 | A1 | 20060413 | US 2005-197608 | 20050804 |
| US 20060079687 | A1 | 20060413 | US 2005-197669 | 20050804 |
| US 20060178383 | A1 | 20060810 | US 2005-197615 | 20050804 |
| EP 1776350 | A1 | 20070425 | EP 2005-786778 | 20050808 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU | | | | |
| CN 101035770 | A | 20070912 | CN 2005-80034011 | 20050808 |
| JP 2008509167 | T | 20080327 | JP 2007-525078 | 20050808 |
| IN 2007KN00792 | A | 20070713 | IN 2007-KN792 | 20070306 |
| PRIORITY APPLN. INFO.: | | | | |
| US 2004-599317P P 20040806 | | | | |
| US 2004-599810P P 20040806 | | | | |
| US 2004-599811P P 20040806 | | | | |
| WO 2005-US28340 W 20050808 | | | | |


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 144:254141; MARPAT 144:254141

GI



I



II

AB The invention is related to novel 2-amino-3,4-dihydro-quinazoline derivs. I [R0 = H, Me, CF3; R1 = H, OH, Me, Et, CF3, OEt, etc.; q = 0-1; A2 = (un)substituted alkyl; R = (un)substituted hetero/aryl, arylalkyl, hetero/cycloalkyl, partially unsatd. carbocyclyl, spiroheterocyclyl; provided that when q = 0; R is other than hetero/aryl; Q3 = O, S, CO, CS, COO, etc.; R2 = (un)substituted cyclo/alkyl, aryl, spiroheterocyclyl, etc.; m = 0-1; L1 = O, S, SO, SO2, CO, NH and derivs., etc.; R3 = (un)substituted cyclo/alkyl, alkenyl, hetero/aryl, etc.; n = 0-3; each R10 = independently OH, halo, alkyl, alkoxy, etc.; with provisos] pharmaceutical compns. containing them and their use as inhibitors of β -secretase, also known as β -site cleaving enzyme and BACE, in the treatment of Alzheimer's disease and related disorders. E.g., a multi-step synthesis starting from N-(tert-butoxycarbonyl)glycine Me ester and N,N,O-dimethylhydroxylamine•HCl was given for aminoquinazoline II. I inhibited β -secretase in 3 different assays.


IT 876766-27-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2-aminoquinazolines as β -secretase inhibitors for treating Alzheimer's disease and related disorders)

RN 876766-27-7 CAPLUS

CN Methanone, [3-[(2-amino-6-phenoxy-3(4H)-quinazolinyl)methyl]phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




| | | |
|----------------------|---|---|
| OS.CITING REF COUNT: | 9 | THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS) |
| REFERENCE COUNT: | 4 | THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS |

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1012143 CAPLUS
 DOCUMENT NUMBER: 143:398877
 TITLE: Perhydroquinolylbenzamides as Novel Inhibitors of 11 β -Hydroxysteroid Dehydrogenase Type 1
 AUTHOR(S): Coppola, Gary M.; Kukkola, Paivi J.; Stanton, James L.; Neubert, Alan D.; Marcopoulos, Nicholas; Bilci, Natalie A.; Wang, Hua; Tomaselli, Hollis C.; Tan, Jenny; Aicher, Thomas D.; Knorr, Douglas C.; Jeng, Arcu Y.; Dardik, Beatriz; Chatelain, Ricardo E.
 CORPORATE SOURCE: Department of Metabolic and Cardiovascular Diseases, Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, USA
 SOURCE: Journal of Medicinal Chemistry (2005), 48(21), 6696-6712
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:398877
 AB High-throughput screening identified 5 as a weak inhibitor of 11 β -HSD1. Optimization of the structure led to a series of perhydroquinolylbenzamides, some with low nanomolar inhibitory potency. A tertiary benzamide is required for biol. activity and substitution of the terminal benzamide with either electron-donating or -withdrawing groups is tolerated. The majority of the compds. show selectivity of >20 to >700-fold over 11 β -HSD2. Analogs which showed >50% inhibition of 11 β -HSD1 at 1 μ M in an cellular assay were screened in an ADX mouse model. A maximal response of >70% reduction of liver corticosterone levels was observed for three compds.; 9m, 25 and 49.
 IT 735348-72-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)
 RN 735348-72-8 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[4-[[[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



IT 867288-62-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (perhydroquinolylbenzamides as inhibitors of hydroxysteroid dehydrogenase)
 RN 867288-62-8 CAPLUS

CN Methanone, (4-nitrophenyl)[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]-, rel-
(CA INDEX NAME)

Relative stereochemistry.




IT 867288-63-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(perhydroquinolinylbenzamides as inhibitors of hydroxysteroid
dehydrogenase)

RN 867288-63-9 CAPLUS

CN Methanone, (4-aminophenyl)[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]-, rel-
(CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 34 THERE ARE 34 CAPLUS RECORDS THAT CITE THIS
RECORD (34 CITINGS)

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 26 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:347016 CAPLUS

DOCUMENT NUMBER: 142:411252

TITLE: Preparation of azabicyclooctane derivatives as CXCR3
antagonists

INVENTOR(S): Habashita, Hiromu; Suzuki, Ryo; Shibayama, Shiro;
Tanihiro, Tatsuya; Kaneko, Yousuke; Egashira, Hiromu;

Nishiyama, Eiji; Yamatsuta, Katsura; Fujita, Setsuko
Ono Pharmaceutical Co., Ltd., Japan

PATENT ASSIGNEE(S): PCT Int. Appl., 171 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2005035534 | A1 | 20050421 | WO 2004-JP14864 | 20041007 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, | | | | |

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 JP 2007015927 A 20070125 JP 2003-349033 20031008
 JP 2007015930 A 20070125 JP 2004-266040 20040913
 PRIORITY APPLN. INFO.: JP 2003-349033 A 20031008
 JP 2004-266040 A 20040913

OTHER SOURCE(S): MARPAT 142:411252
GI



AB Title compds. I [ring A = (un)substituted heterobicyclic, heterotricycle; ring B = (un)substituted cycle; Y = bond, spacer] were prepared. For example, 1,3,3-trimethyl-6-(2-naphthoyl)-6-azabicyclo[3.2.1]octane (II) was prepared from 1,3,3-trimethyl-6-azabicyclo[3.2.1]octane. In 11 β -HSD1 inhibition assays, the IC50 value of compound II was 29 nM. Compds. I are claimed useful for the treatment of inflammation, allergy, etc. Formulations are given.


IT 850366-88-0P 850367-02-1P 850367-07-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azabicyclooctane derivs. as CXCR3 antagonists for treatment of treatment of inflammation, allery, etc.)

RN 850366-88-0 CAPLUS


CN Methanone, [(octahydro-2(1H)-isoquinolinyl)[4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]phenyl]- (CA INDEX NAME)



RN 850367-02-1 CAPLUS

CN Methanone, [(4aR,8aS)-octahydro-2(1H)-isoquinolinyl][4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 850367-07-6 CAPLUS

CN Methanone, [(4aS,8aS)-octahydro-2(1H)-isoquinolinyl][4-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-yl)methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:283466 CAPLUS

DOCUMENT NUMBER: 142:355171

TITLE: Preparation of piperidine compounds as histamine H3 antagonists or inverse agonists

INVENTOR(S): Otake, Norikazu; Mizutani, Sayaka; Yoshimoto, Ryo; Tokita, Shigeru; Kanatani, Akio

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2005028438 | A1 | 20050331 | WO 2004-JP13768 | 20040921 |
| WO 2005028438 | A9 | 20050526 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |

| | | | | |
|--|----|----------|------------------|-------------|
| AU 2004274309 | A1 | 20050331 | AU 2004-274309 | 20040921 |
| AU 2004274309 | B2 | 20100408 | | |
| CA 2551037 | A1 | 20050331 | CA 2004-2551037 | 20040921 |
| EP 1669350 | A1 | 20060614 | EP 2004-787951 | 20040921 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1902177 | A | 20070124 | CN 2004-80027372 | 20040921 |
| US 20070105901 | A1 | 20070510 | US 2006-574087 | 20060321 |
| US 7547693 | B2 | 20090616 | | |
| IN 2006DN01894 | A | 20070713 | IN 2006-DN1894 | 20060407 |
| US 20090203710 | A1 | 20090813 | US 2009-381099 | 20090306 |
| PRIORITY APPLN. INFO.: | | | JP 2003-330758 | A 20030922 |
| | | | WO 2004-JP13768 | W 20040921 |
| | | | US 2006-574087 | A3 20060321 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:355171
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X1, X2 = N, CH; X3 = Os(CH₂)_m; s = 0, 1; m = an integer that (m+s) is 0 to 4; Y = II; j, k, l = 0, 1; L1 = alkylene, single bond; M = O, NR0; R0 = H, alkyl; Q1 = cyano, etc.] were prepared For example, HBTU mediated acylation of 1-cyclopentyl(3R)-methylinopyrrolidine with 4-(4-piperidin-1-yl)piperidin-1-ylbenzoic acid hydrochloride, e.g., prepared from 4-fluorobenzonitrile in 2 steps, afforded compound III in 44% yield. In histamine analog binding inhibition assays, the IC₅₀ value of compound III was 7.5 (sic). Compds. I are claimed useful for the treatment of obesity, diabetes, etc. Formulations are given.


IT 848822-88-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of piperidine compds. as histamine H₃ antagonists or inverse agonists for treatment of obesity, diabetes, etc.)

RN 848822-88-8 CAPPLUS

CN Methanone, (4-[1,4'-bipiperidin]-1'-ylphenyl)(octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:259680 CAPLUS

DOCUMENT NUMBER: 142:336356

TITLE: Preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular

INVENTOR(S): MC4, receptors
 Poitout, Lydie; Brault, Valerie; Sackur, Carole;
 Roubert, Pierre; Plas, Pascale
 PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'Applications
 Scientifiques (S.C.R.A.S.), Fr.
 SOURCE: U.S. Pat. Appl. Publ., 213 pp., Cont.-in-part of U.S.
 Ser. No. 504,033.
 DOCUMENT TYPE: CODEN: USXXCO
 Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|---|--|
| US 20050065179 | A1 | 20050324 | US 2004-915920 | 20040811 |
| US 7501524 | B2 | 20090310 | | |
| FR 2851563 | A1 | 20040827 | FR 2003-2320 | 20030226 |
| FR 2851563 | B1 | 20050422 | | |
| WO 2004075823 | A2 | 20040910 | WO 2004-FR418 | 20040225 |
| WO 2004075823 | A3 | 20041007 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20050267147 | A1 | 20051201 | US 2004-504033 | 20040928 |
| US 7355052 | B2 | 20080408 | | |
| US 20080139619 | A1 | 20080612 | US 2008-12184 | 20080131 |
| US 7501525 | B2 | 20090310 | | |
| US 20090270372 | A1 | 20091029 | US 2009-356964
FR 2003-2320
WO 2004-FR418
US 2004-504033
US 2004-915920 | 20090121
A 20030226
W 20040225
A2 20040928
A3 20040811 |
| PRIORITY APPLN. INFO.: | | | | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 142:336356; MARPAT 142:336356

GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = CH₂, CO, (un)substituted COCH₂; X = CH, N;
 R₁, R₂ = independently H, alkyl optionally substituted by OH, alkenyl,
 etc.; or R₁R₂ = (un)substituted hetero(bi)cycloalkyl; R₃ = alkyl, alkoxy,
 alkylthio, heteroaryl, (un)substituted hetero(cyclo)alkyl, aryl, etc.; R₄ =
 (CH₂)_sR₅; R₅ = heterocycloalkyl, heteroaryl, etc.; s = 0-6] were prepared as
 melanocortin (MC), in particular MC4, receptor modulators (no data given).
 For example, II was prepared, in 2 steps, by amination of
 3-Fluoro-N,N-bis(3-methylbutyl)-4-nitrobenzamide (preparation given) with
 3-(piperidino)propylamine in CH₃CN at reflux, followed by one-step
 hydrogenation/coupling with 4-acetylphenyl isothiocyanate. I are useful
 in the treatment of pathol. states and the diseases in which one or more
 melanocortin receptors are included such as pain, inflammatory conditions,
 etc.


IT 1057138-03-0

RL: PRPH (Prophetic)

(Preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors)
RN 1057138-03-0 CAPLUS
CN Methanone, [2-[(3-aminopropyl)(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-6-yl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



IT 746660-21-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors)
RN 746660-21-9 CAPLUS
CN Methanone, [1-(3-aminopropyl)-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-6-yl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L7 ANSWER 29 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:182640 CAPLUS
DOCUMENT NUMBER: 142:280220
TITLE: Preparation of quinazoline-2,4(1H,3H)-dione derivatives as gonadotropin-releasing hormone antagonists
INVENTOR(S): Hamamura, Kazumasa; Oda, Tsuneo; Kusaka, Masami;
Kanzaki, Naoyuki
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 541 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2005019188 | A1 | 20050303 | WO 2004-JP12322 | 20040820 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, | | | | |

| | |
|--|----------|
| GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, | |
| LR, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, | |
| NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, | |
| TJ, TM, TN, TR, TT, TZ, UA, US, UZ, VC, VN, YU, ZA, ZM, ZW | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, | |
| AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, | |
| EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, | |
| SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, | |
| SN, TD, TG | |
| 2536313 A1 20050303 CA 2004-2536313 | 20040820 |
| 2005097276 A 20050414 JP 2004-241721 | 20040820 |
| 1657238 A1 20060517 EP 2004-772278 | 20040820 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PI, | |
| IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, EL, SK | |
| 20070010537 A1 20070111 US 2006-569391 | 20060222 |
| APPLN. INFO. : JP 2003-298637 A 20030822 | |
| WO 2004-JP12322 W 20040820 | |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 142:280220

GI




$$\text{I} \quad \begin{array}{c} \text{NH} \\ | \\ \text{Cl} \end{array} \quad \begin{array}{c} \text{CH}_2=\text{CH}- \\ | \\ \text{CH}_2=\text{CH}- \end{array} \quad \text{Br} \quad \text{II}$$

AB The title quinazoline-2,4(1H,3H)-dione derivs. I (wherein R1 = H or (un)substituted hydrocarbyl; ring A = (un)substituted aromatic 6-membered ring; ring B = (un)substituted (hetero)cyclyl; W = O or S; X1 and X2 = independently H, (un)substituted hydrocarbyl, or heterocyclyl; or X1 and X2 together form =O, =S, or (un)substituted =NH; Y = a bond or (un)substituted alkylene), or salts or prodrugs thereof are prepared as gonadotropin-releasing hormone antagonists. For example, the compound II was prepared in a multi-step synthesis. I inhibited 75.4-99.9% of human gonadotropin releasing hormone at the concentration of 10 nM. I are useful for the treatment of prostatic hyperplasia, hysteromyoma, endometriosis, uterus fibroma, etc. (no data). Formulations containing I as an active ingredient were also described.

IT 847168-15-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of quinazoline-2,4(1H,3H)-dione derivs. as gonadotropin-releasing hormone antagonists)

RN 847168-15-4 CAPLUS
CN 2,4(1H,3H)-Quinazolinedione, 3-[2-chloro-5-[(octahydro-2(1H)-isouquinolinyl)carbonyl]phenyl]- (CA INDEX NAME)





OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 30 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:964830 CAPLUS
 DOCUMENT NUMBER: 141:410932
 TITLE: Preparation of benzo[1,2,5]thiadiazoles as CCK2 modulators for treatment of gastrointestinal disorders, pain, and other conditions
 INVENTOR(S): Allison, Brett; McAtee, Laura C.; Phuong, Victor K.; Rabinowitz, Michael H.; Shankley, Nigel P.
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: U.S. Pat. Appl. Publ., 81 pp.
 CODEN: USXKC0
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|----------|
| US 20040224983 | A1 | 20041111 | US 2004-811292 | 20040326 |
| US 7241759 | B2 | 20070710 | | |
| AU 2004261547 | A1 | 20050210 | AU 2004-261547 | 20040326 |
| CA 2520546 | A1 | 20050210 | CA 2004-2520546 | 20040326 |
| WO 2005012275 | A2 | 20050210 | WO 2004-US9589 | 20040326 |
| WO 2005012275 | A3 | 20060511 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG | | | | |
| BR 2004008899 | A | 20060418 | BR 2004-8899 | 20040326 |
| EP 1675837 | A2 | 20060705 | EP 2004-785868 | 20040326 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | |
| CN 1829704 | A | 20060906 | CN 2004-80014470 | 20040326 |
| JP 2006528241 | T | 20061214 | JP 2006-532352 | 20040326 |
| NZ 542491 | A | 20090430 | NZ 2004-542491 | 20040326 |
| MX 2005010484 | A | 20060310 | MX 2005-10484 | 20050928 |
| NO 2005005002 | A | 20051214 | NO 2005-5002 | 20051027 |
| ZA 2005008732 | A | 20070425 | ZA 2005-8732 | 20051027 |
| IN 2005KN02161 | A | 20061013 | IN 2005-KN2161 | 20051031 |
| US 20070276016 | A1 | 20071129 | US 2007-775535 | 20070710 |

OTHER SOURCE(S):
GI

MARPAT 141:410932




AB Title [(2,1,3-benzothiadiazol-4-yl)sulfonyl]amino]benzamides I [wherein R1, R2 = independently H, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, naphthyl, benzoylalkyl, Ph, etc.; or NR1R2 = (un)substituted 10-oxa-4-azatricyclo[5.2.1.0_{2,6}]dec-4-yl, heterocyclyl, 8-oxo-1,5,6,8-tetrahydro-2H-4H-1,5-methanopyrido[1,2-a][1,5]diazocin-3-yl; R1 = independently (cyclo)alkyl, alkenyl, Ph, furanyl, thienyl, benzyl, pyrrolyl, OH, alkoxy, SH, CN, NO₂, NH₂, halo, etc.; Rb = independently alkyl, halo; and enantiomers, diastereomers, hydrates, solvates, and pharmaceutically acceptable salts thereof] were prepared as cholecystokinin 2 (CCK2) receptor modulators. For example, 4-bromo-2-aminobenzoic acid piperidine amide (3-step preparation given) was coupled with 4-chlorosulfonyl-2,1,3-benzothiadiazole in pyridine to afford II (74%). The latter showed binding to CCK2R specific zinc finger proteins fused with the herpes simplex virus VP16 activation domain with pKi of 7.6 and behaved as a competitive antagonist in a guinea pig gastric corpus muscle assay with pKB of 8.8. Thus, I and their pharmaceutical compns. are useful for the treatment of CCK2 mediated conditions, such as pancreatic adenocarcinoma, pain, eating disorders, gastroesophageal reflux disease, gastroduodenal ulcers, reflux esophagitis, anxiety, colon cancer, peptic ulcers, pancreatic tumors, gastric tumors, Barrett's esophagus, antral G cell hyperplasia, pernicious anemia, and Zollinger-Ellison syndrome (no data).

IT 791099-27-9P, 2,1,3-Benzothiadiazole-4-sulfonic acid
N-[5-chloro-2-[(octahydroisoquinolin-2-yl)carbonyl]phenyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CCK2 modulator; preparation of [(benzo[1,2,5]thiadiazol-4-yl)sulfonyl]amino]benzamides as CCK2 modulators for treatment of gastrointestinal disorders, pain, and other conditions)

RN 791099-27-9 CAPLUS

CN 2,1,3-Benzothiadiazole-4-sulfonamide,
N-[5-chloro-2-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)
 REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 31 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2004:780704 CAPLUS
 DOCUMENT NUMBER: 141:296035
 TITLE: Preparation of oxopyrazolocinnolines as CD80
 inhibitors useful as immunomodulators
 INVENTOR(S): Mathews, Ian Richard
 PATENT ASSIGNEE(S): Avidex Limited, UK
 SOURCE: PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|----------|
| WO 2004081011 | A1 | 20040923 | WO 2004-GB1008 | 20040310 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BN, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG | | | | |
| AU 2004220310 | A1 | 20040923 | AU 2004-220310 | 20040310 |
| CA 2519063 | A1 | 20040923 | CA 2004-2519063 | 20040310 |
| EP 1603917 | A1 | 20051214 | EP 2004-719006 | 20040310 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| BR 2004008365 | A | 20060321 | BR 2004-8365 | 20040310 |
| CN 1761664 | A | 20060419 | CN 2004-80006886 | 20040310 |
| CN 100363365 | C | 20080123 | | |
| JP 2006520372 | T | 20060907 | JP 2006-505937 | 20040310 |
| NZ 541973 | A | 20090626 | NZ 2004-541973 | 20040310 |
| MX 2005009667 | A | 20060127 | MX 2005-9667 | 20050909 |
| ZA 2005007364 | A | 20061025 | ZA 2005-7364 | 20050913 |
| NO 2005004710 | A | 20051213 | NO 2005-4710 | 20051013 |

| | | | |
|------------------------|-------------|----------------|-------------|
| IN 2005CN02624 | A 20070406 | IN 2005-CN2624 | 20051013 |
| IN 229041 | A1 20090320 | | |
| US 20070021428 | A1 20070125 | US 2006-547448 | 20060620 |
| US 7276505 | B2 20071002 | | |
| HK 1090921 | A1 20080704 | HK 2006-111573 | 20061019 |
| US 20080045527 | A1 20080221 | US 2007-845837 | 20070828 |
| US 7598247 | B2 20091006 | | |
| US 20090312334 | A1 20091217 | US 2009-545902 | 20090824 |
| PRIORITY APPLN. INFO.: | | GB 2003-5876 | A 20030314 |
| | | GB 2003-19429 | A 20030819 |
| | | WO 2004-GB1008 | W 20040310 |
| | | US 2006-547448 | A3 20060620 |
| | | US 2007-845837 | A3 20070828 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:296035

GI



AB Title compds. [I; R1, R3 = H, F, Cl, Br, NO₂, cyano, alkyl, fluoroalkyl, chloroalkyl, alkoxy, fluoroalkoxy; R4 = CO₂H (ester), CONR₆R₇, NR₇COR₆, NR₇COOR₆, NHCONR₆R₇, NHCSNR₆R₇; R6 = H, (Alk)_mQ; m = 0, 1; Alk = (substituted) alkylene, alkenylene, alkynylene, carbocyclene which may contain ≥1 O, S, NR₈; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl; Q = H, NR₉R₁₀; R9, R10 = H, alkyl, alkenyl, alkynyl, cycloalkyl, ester group, (substituted) carbocyclyl, heterocyclyl; R9R10N = (substituted) heterocyclyl; R7 = H, alkyl; R6R7 = atoms to form (substituted) heterocyclyl; X = bond, (Z)n(Alk), (Alk)(Z)n; Z = O, S, NH; n = 0, 1], were prepared Thus, 4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzoic acid (preparation given) was stirred with DMF, diisopropylethylamine, 3-dimethylaminopropylamine, and HTBU at room temperature for 2 h to give 40% N-[(3-dimethylamino)propyl]4-(3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl)benzamide (AV1142005). The latter inhibited interleukin-2 production by human Jurkat T cells by 65% at 30 μM.


IT 763147-08-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxopyrazolocinnolines as CD80 inhibitors useful as immunomodulators)

RN 763147-08-6 CAPLUS

CN 3H-Pyrazolo[4,3-c]cinnolin-3-one, 6-fluoro-1,2-dihydro-2-[4-[(octahydro-2(1H)-isoquinoliny)carbonyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 32 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004700364 CAPLUS
DOCUMENT NUMBER: 141:225509
TITLE: Preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors
INVENTOR(S): Poitout, Lydie; Brault, Valerie; Sackur, Carole; Roubert, Pierre; Plas, Pascale
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques SCRAS, Fr.
SOURCE: Fr. Demande, 104 pp.
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| FR 2851563 | A1 | 20040827 | FR 2003-2320 | 20030226 |
| FR 2851563 | B1 | 20050422 | | |
| AU 2004216427 | A1 | 20040910 | AU 2004-216427 | 20040225 |
| AU 2004216427 | B2 | 20090625 | | |
| CA 2516660 | A1 | 20040910 | CA 2004-2516660 | 20040225 |
| WO 2004075823 | A2 | 20040910 | WO 2004-FR418 | 20040225 |
| WO 2004075823 | A3 | 20041007 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1599167 | A2 | 20051130 | EP 2004-714348 | 20040225 |
| EP 1599167 | B1 | 20071003 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2004007726 | A | 20060214 | BR 2004-7726 | 20040225 |
| CN 1753670 | A | 20060329 | CN 2004-80005413 | 20040225 |
| JP 2006519214 | T | 20060824 | JP 2006-502162 | 20040225 |
| AT 374754 | T | 20071015 | AT 2004-714348 | 20040225 |
| PT 1599167 | E | 20080109 | PT 2004-714348 | 20040225 |
| ES 2295826 | T3 | 20080416 | ES 2004-714348 | 20040225 |
| RU 2330023 | C2 | 20080727 | RU 2005-129738 | 20040225 |
| NZ 541632 | A | 20080926 | NZ 2004-541632 | 20040225 |

| | | | | |
|------------------------|----|----------|----------------|-------------|
| US 20050065179 | A1 | 20050324 | US 2004-915920 | 20040811 |
| US 7501524 | B2 | 20090310 | | |
| US 20050267147 | A1 | 20051201 | US 2004-504033 | 20040928 |
| US 7355052 | B2 | 20080408 | | |
| MX 2005009015 | A | 20051018 | MX 2005-9015 | 20050824 |
| US 20080139619 | A1 | 20080612 | US 2008-12184 | 20080131 |
| US 7501525 | B2 | 20090310 | | |
| US 20090270372 | A1 | 20091029 | US 2009-356964 | 20090121 |
| PRIORITY APPLN. INFO.: | | | FR 2003-2320 | A 20030226 |
| | | | WO 2004-FR418 | A 20040225 |
| | | | US 2004-915920 | A3 20040811 |
| | | | US 2004-504033 | A2 20040928 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 141:225509

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein A = CH₂, CO, CO-CH₂ and derivs., X = C or N; R₁, R₂ = independently H, alkyl optionally substituted by OH, alkenyl, etc.; or R₁R₂ = (un)substituted hetero(bi)cycloalkyl; R₃ = (CH₂)_p-Z₃ or CO-Z'₃; Z₃ = alkyl, alkenyl, alkoxy, alkoxy carbonyl, heteroaryl, (un)substituted hetero(cyclo)alkyl, aryl, etc.; Z'₃ = (un)substituted aryl; p = 0-4; R₄ = (CH₂)_s-R'₄; R'₄ = heterocycloalkyl, heteroaryl, NW'; W = H, alkyl; W' = (CH₂)_q-Z₄; Z₄ = H, alkenyl, (un)substituted cyclo/alkyl, aryl, etc.; q, s = independently 0-6] were prepared as melanocortin (MC), in particular MC4, receptor modulators. Two biol. protocols are given (no data). For example, II was prepared, in 2 steps, by amination of 3-Fluoro-N,N-bis(3-methylbutyl)-4-nitrobenzamide (preparation given) with 3-(piperidino)propylamine in CH₃CN at reflux, followed by one-step hydrogenation/coupling with 4-acetylphenyl isothiocyanate. I are useful in the treatment of pathol. states and the diseases in which one or more melanocortin receptors are implied, i.e. obesity, anxiety, pain, sex behavior, etc.


IT 746660-21-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of benzimidazoles and imidazopyridines having affinity for melanocortin (MC), in particular MC4, receptors)

RN 746660-21-9 CAPLUS

CN Methanone, [1-(3-aminopropyl)-2-[(3,4,5-trimethoxyphenyl)amino]-1H-benzimidazol-6-yl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 33 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:633903 CAPLUS

DOCUMENT NUMBER: 141:173975

TITLE: Preparation of amides as inhibitors of
11-beta-hydroxysteroid dehydrogenase type 1

INVENTOR(S): Coppola, Gary Mark; Damon, Robert Edson; Kukkola,
Paivi Jaana; Stanton, James Lawrence

PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH
SOURCE: PCT Int. Appl., 145 pp.

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|------------------|------------|
| WO 2004065351 | A1 | 20040805 | WO 2004-EP571 | 20040123 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ | | | | |
| CA 2513349 | A1 | 20040805 | CA 2004-2513349 | 20040123 |
| EP 1590319 | A1 | 20051102 | EP 2004-704554 | 20040123 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2004006938 | A | 20060103 | BR 2004-6938 | 20040123 |
| CN 1741986 | A | 20060301 | CN 2004-80002540 | 20040123 |
| JP 2006517199 | T | 20060720 | JP 2006-500009 | 20040123 |
| US 20060205772 | A1 | 20060914 | US 2005-542759 | 20050816 |
| PRIORITY APPLN. INFO.: | | | US 2003-442532P | P 20030124 |
| | | | WO 2004-EP571 | W 20040123 |

OTHER SOURCE(S): MARPAT 141:173975
GI



I



II

AB The title compds. [I; R1, R2 = H, CN, halo, NO₂, etc.; or R1 and R2 together with the carbon atoms they are attached to form an optionally

substituted 5-7 membered (hetero)aromatic ring; R3 = alkyl; or R3 and R2 together with the amide group to which R3 is attached and the carbon atoms to which R2 and the amide are attached form (un)substituted 5-7 membered carbocyclic or heterocyclic ring; R4 = alkyl, cycloalkyl, heterocyclyl, aryl, (hetero)aralkyl; or NR4R3 = (un)substituted 5-8 membered ring, 8-12 membered fused bicyclic ring (both ring systems may contain another heteroatom selected from O, N and S); W = NR5COR6, NR5CO2R6, NR5CONR6R7, etc.; R5, R7 = H, alkyl, aralkyl; R6 = alkyl, cycloalkyl, heterocyclyl, aryl, (hetero)aralkyl; X, Y = CH, N; or X:Y = CH2, O, S, NR10 (R10 = H, alkyl)] which lower intracellular glucocorticoid concns. in mammals, in particular, intracellular cortisol levels in humans, were prepared E.g., two alternative routes for preparation of the amide II were given. The compds. I were tested for inhibition of 11 β -HSD1 (specific data given for representative compds. I). The compds. I improve insulin sensitivity in the muscle and the adipose tissue, and reduce lipolysis and free fatty acid production in the adipose tissue. The compds. I lower hepatic glucocorticoid concentration in mammals, in particular, hepatic cortisol concentration

in humans, resulting in inhibition of hepatic gluconeogenesis and lowering of plasma glucose levels. Thus, the compds. I may be particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which hyperglycemia and/or insulin resistance are implicated, such as type-2 diabetes. The compds. I may also be used to treat other glucocorticoid associated disorders, such as Syndrome-X, dyslipidemia, hypertension and central obesity. The invention furthermore relates to the use of the compds. I for the preparation of medicaments, in particular of medicaments useful for the treatment and prevention of glucocorticoid associated disorders, by improving insulin sensitivity, reducing plasma glucose levels, reducing lipolysis and free fatty acid production, and by decreasing visceral adipose tissue formation.

| | | | |
|----|--------------|--------------|--------------|
| IT | 735348-52-4P | 735348-53-5P | 735348-54-6P |
| | 735348-55-7P | 735348-56-8P | 735348-57-9P |
| | 735348-58-0P | 735348-59-1P | 735348-60-4P |
| | 735348-61-5P | 735348-62-6P | 735348-63-7P |
| | 735348-64-8P | 735348-65-9P | 735348-66-0P |
| | 735348-67-1P | 735348-68-2P | 735348-69-3P |
| | 735348-70-6P | 735348-71-7P | 735348-72-8P |
| | 735348-73-9P | 735348-74-0P | 735348-75-1P |
| | 735348-76-2P | 735348-77-3P | 735348-78-4P |
| | 735348-79-5P | 735348-80-8P | 735348-81-9P |
| | 735348-82-0P | 735348-83-1P | 735348-84-2P |
| | 735348-85-3P | 735348-86-4P | 735348-87-5P |
| | 735348-88-6P | 735348-89-7P | 735348-90-0P |
| | 735348-91-1P | 735348-92-2P | 735348-93-3P |
| | 735348-94-4P | 735348-95-5P | 735348-96-6P |
| | 735348-97-7P | 735348-98-8P | 735348-99-9P |
| | 735349-00-5P | 735349-01-6P | 735349-02-7P |
| | 735349-03-8P | 735349-04-9P | 735349-05-0P |
| | 735349-06-1P | 735349-07-2P | 735349-08-3P |
| | 735349-09-4P | 735349-10-7P | 735349-11-8P |
| | 735349-12-9P | 735349-13-0P | 735349-14-1P |
| | 735349-15-2P | 735349-16-3P | 735349-17-4P |
| | 735349-18-5P | 735349-19-6P | 735349-20-9P |
| | 735349-21-0P | 735349-22-1P | 735349-23-2P |
| | 735349-24-3P | 735349-25-4P | 735349-26-5P |
| | 735349-27-6P | 735349-28-7P | 735349-29-8P |
| | 735349-30-1P | 735349-31-2P | 735349-32-3P |
| | 735349-33-4P | 735349-34-5P | 735349-35-6P |
| | 735349-36-7P | 735349-37-8P | 735349-38-9P |
| | 735349-39-0P | 735349-40-3P | 735349-41-4P |
| | 735349-42-5P | 735349-43-6P | 735349-44-7P |
| | 735349-45-8P | 735349-46-9P | 735349-47-0P |

| | | |
|--------------|--------------|--------------|
| 735349-48-1P | 735349-49-2P | 735349-50-5P |
| 735349-51-6P | 735349-52-7P | 735349-53-8P |
| 735349-54-9P | 735349-55-0P | 735349-56-1P |
| 735349-57-2P | 735349-58-3P | 735349-59-4P |
| 735349-60-7P | 735349-61-8P | 735349-62-9P |
| 735349-63-0P | 735349-64-1P | 735349-65-2P |
| 735349-66-3P | 735349-67-4P | 735349-68-5P |
| 735349-69-6P | 735349-70-9P | 735349-71-0P |
| 735349-72-1P | 735349-73-2P | 735349-74-3P |
| 735349-75-4P | 735349-76-5P | 735349-77-6P |
| 735349-78-7P | 735349-79-8P | 735349-80-1P |
| 735349-81-2P | 735349-82-3P | 735349-83-4P |
| 735349-84-5P | 735349-85-6P | 735349-86-7P |
| 735349-87-8P | 735349-88-9P | 735349-89-0P |
| 735349-90-3P | 735349-91-4P | 735349-92-5P |
| 735349-93-6P | 735349-94-7P | 735349-95-8P |
| 735349-96-9P | 735349-97-0P | 735349-98-1P |
| 735349-99-2P | 735350-00-2P | 735350-01-3P |
| 735350-02-4P | 735350-03-5P | 735350-04-6P |
| 735350-05-7P | 735350-06-8P | 735350-07-9P |
| 735350-08-0P | 735350-09-1P | 735350-10-4P |
| 735350-11-5P | 735350-12-6P | 735350-13-7P |
| 735350-14-8P | 735350-15-9P | 735350-16-0P |
| 735350-17-1P | 735350-18-2P | 735350-19-3P |
| 735350-20-6P | 735350-21-7P | 735350-22-8P |
| 735350-23-9P | 735350-24-0P | 735350-25-1P |
| 735350-26-2P | 735350-27-3P | 735350-28-4P |
| 735350-29-5P | 735350-30-8P | 735350-31-9P |
| 735350-32-0P | 735350-33-1P | 735350-34-2P |
| 735350-35-3P | 735350-36-4P | 735350-37-5P |
| 735350-38-6P | 735350-39-7P | 735350-40-0P |
| 735350-41-1P | 735350-42-2P | 735350-43-3P |
| 735350-44-4P | 735350-45-5P | 735350-46-6P |
| 735350-47-7P | 735350-48-8P | 735350-49-9P |
| 735350-50-2P | 735350-51-3P | 735350-52-4P |
| 735350-53-5P | 735350-54-6P | 735350-55-7P |
| 735350-56-8P | 735350-57-9P | 735350-58-0P |
| 735350-59-1P | 735350-60-4P | 735350-61-5P |
| 735350-62-6P | 735350-63-7P | 735350-64-8P |
| 735350-65-9P | 735350-66-0P | 735350-67-1P |
| 735350-68-2P | | |


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of amides as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1)

RN 735348-52-4 CAPLUS

CN Butanamide, 3,3-dimethyl-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-53-5 CAPLUS

CN Cyclopentaneacetamide, N-[4-[[((4aR,8aS)-octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-54-6 CAPLUS

CN Cyclopentanepropanamide, N-[4-[[((4aR,8aS)-octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-55-7 CAPLUS

CN Benzeneacetamide, N-[4-[[((4aR,8aS)-octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-56-8 CAPLUS


CN Benzeneacetamide, 4-methoxy-N-[4-[[((4aR,8aS)-octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-57-9 CAPLUS
 CN Benzenepropanamide, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-58-0 CAPLUS
 CN Benzamide, 4-fluoro-N-[4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-59-1 CAPLUS
 CN Benzamide, 4-fluoro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-60-4 CAPLUS
 CN 1,3-Benzodioxole-5-carboxamide, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-61-5 CAPLUS
 CN 2-Thiophenecarboxamide, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-62-6 CAPLUS
 CN 2-Furancarboxamide, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-63-7 CAPLUS

CN Benzamide, 2,4-difluoro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-64-8 CAPLUS

CN Urea, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-propyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-65-9 CAPLUS


CN Urea, N-(1-methylethyl)-N'-(4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-66-0 CAPLUS
CN Urea, N-(3-methoxyphenyl)-N'-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-67-1 CAPLUS
CN Urea, N-[(2-chlorophenyl)methyl]-N'-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-68-2 CAPLUS
CN Urea, N-methyl-N'-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-69-3 CAPLUS
CN Carbamic acid, [4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735348-70-6 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-71-7 CAPLUS

CN Benzamide, 2-methoxy-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-72-8 CAPLUS


CN Benzamide, 2,4-dichloro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-73-9 CAPLUS
 CN Carbamic acid, [4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735348-74-0 CAPLUS
 CN Carbamic acid, [4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735348-75-1 CAPLUS
 CN Carbamic acid, [4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735348-76-2 CAPLUS

CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-77-3 CAPLUS

CN Benzamide, 4-chloro-N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-78-4 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-79-5 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-4-cyano-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-80-8 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-4-(hexyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-81-9 CAPLUS
 CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(4-methoxyphenyl)methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-82-0 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(2,4-dichlorophenyl)methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-83-1 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(4-fluorophenyl)methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-84-2 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(2-ethoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-85-3 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(3-methoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-86-4 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-87-5 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-4-hexyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-88-6 CAPLUS

CN Butanamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 3,3-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-89-7 CAPLUS

CN Cyclohexanecarboxamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-90-0 CAPLUS

CN 1,3-Benzodioxole-5-carboxamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-91-1 CAPLUS

CN Benzanide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-4-(dimethylamino)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-92-2 CAPLUS

CN Benzanide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735348-93-3 CAPLUS


CN Benzanide, 4-butoxy-N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-94-4 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-95-5 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(trifluoromethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-96-6 CAPLUS
 CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(4-methoxyphenyl)methyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-97-7 CAPLUS
CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(2,4-dichlorophenyl)methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735348-98-8 CAPLUS
CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(4-fluorophenyl)methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735348-99-9 CAPLUS
CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isooquinolinyl]carbonyl]phenyl]-N'-(2,4-dimethoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry



RN 735349-00-5 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(2,4-difluorophenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-01-6 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(phenylmethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-02-7 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(2-chlorophenyl)methyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-03-8 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(2-phenylethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-04-9 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-cyclohexyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-05-0 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(2,4-dimethoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-06-1 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-3,4-difluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-07-2 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-2,4-difluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-08-3 CAPLUS


CN Cyclopentaneacetamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-09-4 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-10-7 CAPLUS
 CN Benzamide, 4-chloro-N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-11-8 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-fluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-12-9 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-2,4-difluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-13-0 CAPLUS

CN Benzamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-3,4-difluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-14-1 CAPLUS


CN Benzamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-15-2 CAPLUS
 CN Benzamide, 4-butoxy-N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-16-3 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-17-4 CAPLUS
 CN Benzamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(hexyloxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-18-5 CAPLUS
 CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(2,4-difluorophenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-19-6 CAPLUS
 CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-20-9 CAPLUS
 CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(2-phenylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-21-0 CAPLUS
CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-22-1 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-23-2 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-24-3 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-25-4 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, butyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-26-5 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-27-6 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-28-7 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-29-8 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-30-1 CAPLUS

CN Butanamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-3,3-dimethyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-31-2 CAPLUS

CN Cyclopentaneacetamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-32-3 CAPLUS

CN Cyclohexanecarboxamide, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-33-4 CAPLUS

CN Benzanide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-2-fluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-34-5 CAPLUS

CN Benzanide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-2-methoxy-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-35-6 CAPLUS

CN Benzamide, 2,6-dichloro-N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-36-7 CAPLUS

CN Benzeneacetamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-37-8 CAPLUS

CN Benzeneacetamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-methoxy-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-38-9 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-39-0 CAPLUS

CN Benzenepropanamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-40-3 CAPLUS


CN 2-Furancarboxamide, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-41-4 CAPLUS
CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-propyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-42-5 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-43-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-44-7 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-methylphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-45-8 CAPLUS
 CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-46-9 CAPLUS
 CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-47-0 CAPLUS
 CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-48-1 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-49-2 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 1-methylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-50-5 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-51-6 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-52-7 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, pentyloxy ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-53-8 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2,2-dimethylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-54-9 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-55-0 CAPLUS

CN Urea, N-butyl-N'-(3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-

isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-56-1 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-pentyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-57-2 CAPLUS

CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-propyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-58-3 CAPLUS


CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-59-4 CAPLUS
CN Urea, N-butyl-N'-(3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-60-7 CAPLUS
CN Urea, N-[3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-pentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-61-8 CAPLUS
CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(2-ethoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-62-9 CAPLUS
CN Urea, N-[3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(3-methoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-63-0 CAPLUS
 CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-64-1 CAPLUS
 CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, hexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-65-2 CAPLUS
 CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-66-3 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, (2-chlorophenyl)methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-67-4 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, hexyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-68-5 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, pentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-69-6 CAPLUS
CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 2-propynyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-70-9 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 2,2-dimethylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-71-0 CAPLUS

CN Carbamic acid, [3-chloro-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 2-butynyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-72-1 CAPLUS


CN Benzamide, 2,4-dichloro-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-73-2 CAPLUS
CN Benzamide, 4-chloro-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-74-3 CAPLUS
CN Benzamide, 4-cyano-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-75-4 CAPLUS
CN Benzamide, 4-fluoro-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735349-76-5 CAPLUS
CN Benzamide, 4-(hexyloxy)-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-77-6 CAPLUS

CN Benzamide, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-78-7 CAPLUS

CN Benzamide, 4-methoxy-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735349-79-8 CAPLUS


CN Benzamide, 2-methoxy-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-80-1 CAPLUS
 CN Benzamide, 4-butoxy-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-81-2 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-pentyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-82-3 CAPLUS
 CN Benzamide, 3,4-difluoro-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-83-4 CAPLUS
 CN Benzanide, 4-butoxy-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-84-5 CAPLUS
 CN 2-Furancarboxamide, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-85-6 CAPLUS
 CN Benzanide, 2,4-difluoro-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-86-7 CAPLUS
 CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-87-8 CAPLUS
 CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735349-88-9 CAPLUS
 CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-89-0 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-90-3 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-91-4 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735349-92-5 CAPLUS


CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, cyclopentyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735349-93-6 CAPLUS
 CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, (2-chlorophenyl)methyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-94-7 CAPLUS
 CN Benzamide, 4-(dimethylamino)-N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-95-8 CAPLUS
 CN Benzamide, 2,4-dichloro-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-96-9 CAPLUS
 CN Benzamide, 4-(hexyloxy)-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-97-0 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[(octahydro-2(1H)-isoquinolinyl)carbonyl]phenyl]-4-(pentyloxy)- (CA INDEX NAME)




RN 735349-98-1 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-4-(1-methylethoxy)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735349-99-2 CAPLUS
CN Benzamide, 2-chloro-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-00-2 CAPLUS
CN Benzamide, 2-methoxy-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-01-3 CAPLUS
CN Carbamic acid, [3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, methyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-02-4 CAPLUS
CN Carbamic acid, [3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, butyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-03-5 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 2-methoxyethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-04-6 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, phenyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-05-7 CAPLUS


CN Carbamic acid, [3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735350-06-8 CAPLUS
CN Carbanic acid, [3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 4-methylphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735350-07-9 CAPLUS
CN Carbanic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 4-methoxyphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 735350-08-0 CAPLUS
CN Carbanic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, 4-methylphenyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 735350-09-1 CAPLUS
CN Carbanic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, pentyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-10-4 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, phenylmethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-11-5 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, hexyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-12-6 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (1S,2R,5S)-5-methyl-2-(1-methylethyl)cyclohexyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-13-7 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-14-8 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2,2-dimethylpropyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-15-9 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-butynyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-16-0 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 2-propynyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-17-1 CAPLUS

CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-18-2 CAPLUS

CN Urea, N-ethyl-N'-(3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-19-3 CAPLUS

CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-propyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-20-6 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, 4-chlorophenyl ester, rel- (9CI) (CA)

INDEX NAME)


Relative stereochemistry.



RN 735350-21-7 CAPLUS

CN Carbamic acid, [3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, propyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 735350-22-8 CAPLUS

CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-23-9 CAPLUS

CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(4-methoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-24-0 CAPLUS

CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(2-methoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-25-1 CAPLUS

CN Urea, N-(4-fluorophenyl)-N'-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-26-2 CAPLUS


CN Urea, N-cyclohexyl-N'-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-27-3 CAPLUS
 CN Urea, N-hexyl-N'-(3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl)phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-28-4 CAPLUS
 CN Benzamide, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-29-5 CAPLUS
 CN Benzamide, 4-fluoro-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-30-8 CAPLUS
CN Benzanide, 4-chloro-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-31-9 CAPLUS
CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-32-0 CAPLUS
CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-1-naphthalenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-33-1 CAPLUS
CN Urea, N-[4-fluorophenylmethyl]-N'-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-34-2 CAPLUS
 CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(4-methoxyphenyl)methyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-35-3 CAPLUS
 CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-36-4 CAPLUS
 CN Urea, N-[3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(3-methoxyphenyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-37-5 CAPLUS

CN Urea, N-[(2,4-dichlorophenyl)methyl]-N'-(3-methoxy-4-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-38-6 CAPLUS

CN Urea, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-propyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-39-7 CAPLUS


CN Urea, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-(1-methylethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-40-0 CAPLUS
CN Urea, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-1-naphthalenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-41-1 CAPLUS
CN Urea, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-N'-(3-methoxyphenyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-42-2 CAPLUS
CN Benzamide, 4-methoxy-N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-43-3 CAPLUS
CN 1,3-Benzodioxole-5-carboxamide, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonylphenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-44-4 CAPLUS

CN Urea, N-[(4-fluorophenyl)methyl]-N'-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-45-5 CAPLUS

CN Urea, N-[3-methoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-N'-(4-methoxyphenyl)methyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-46-6 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-47-7 CAPLUS

CN Benzamide, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl]-4-(pentyloxy)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-48-8 CAPLUS

CN Benzamide, 4-(hexyloxy)-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-49-9 CAPLUS

CN Benzamide, 3,4-difluoro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-50-2 CAPLUS

CN Benzanide, 2,4-difluoro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphe nyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-51-3 CAPLUS

CN Benzanide, 4-fluoro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphe nyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-52-4 CAPLUS

CN Benzanide, 2-fluoro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphe nyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-53-5 CAPLUS

CN Benzamide, 2-methoxy-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-54-6 CAPLUS

CN Benzamide, 2,6-dichloro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-55-7 CAPLUS

CN Benzeneacetamide, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-56-8 CAPLUS

CN Benzeneacetamide, 4-methoxy-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-57-9 CAPLUS

CN Benzeneacetamide, 4-chloro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-58-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxypyhenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-59-1 CAPLUS

CN Benzamide, 4-chloro-N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-60-4 CAPLUS

CN Benzenepropanamide, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-61-5 CAPLUS

CN 2-Furancarboxamide, N-[4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]-3-propoxyphenyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-62-6 CAPLUS


CN Benzamide, 2,4-dichloro-N-[3-ethoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]phenyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-63-7 CAPLUS
 CN Benzamide, N-[3-ethoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-4-fluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 735350-64-8 CAPLUS
 CN Benzamide, N-[3-ethoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-3,4-difluoro-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 735350-65-9 CAPLUS
 CN Benzamide, 4-chloro-N-[3-ethoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-66-0 CAPLUS

CN Benzamide, N-[3-ethoxy-4-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]phenyl]-2,4-difluoro-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-67-1 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]carbonyl-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 735350-68-2 CAPLUS

CN 1H-Indole-1-carboxylic acid, 2,3-dihydro-5-[(4aR,8aR)-octahydro-2(1H)-isoquinolinyl]carbonyl-, 1,1-dimethylethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
 REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 34 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:376830 CAPLUS
 DOCUMENT NUMBER: 138:385441
 TITLE: Preparation of quinazolines as antitumor agents
 INVENTOR(S): Hennequin, Laurent Francois Andre; Kettle, Jason Grant; Pass, Martin; Bradbury, Robert Hugh
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 218 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2003040108 | A1 | 20030515 | WO 2002-GB4931 | 20021031 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2465068 | A1 | 20030515 | CA 2002-2465068 | 20021031 |
| AU 2002341156 | A1 | 20030519 | AU 2002-341156 | 20021031 |
| EP 1444210 | A1 | 20040811 | EP 2002-774960 | 20021031 |
| EP 1444210 | B1 | 20090218 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| BR 2002013842 | A | 20040831 | BR 2002-13842 | 20021031 |
| HU 2004001646 | A2 | 20041228 | HU 2004-1646 | 20021031 |
| CN 1585754 | A | 20050223 | CN 2002-826384 | 20021031 |
| CN 100343238 | C | 20071017 | | |
| JP 2005515176 | T | 20050526 | JP 2003-542154 | 20021031 |
| NZ 532924 | A | 20070223 | NZ 2002-532524 | 20021031 |
| AT 423104 | T | 20090315 | AT 2002-774960 | 20021031 |
| ES 2320980 | T3 | 20090601 | ES 2002-774960 | 20021031 |
| IN 2004DN01092 | A | 20050401 | IN 2004-DN1092 | 20040423 |
| MX 2004004219 | A | 20040910 | MX 2004-4219 | 20040503 |
| NO 2004002279 | A | 20040602 | NO 2004-2279 | 20040602 |
| US 20050043336 | A1 | 20050224 | US 2004-494137 | 20041006 |

HK 1066218
US 20070082921
PRIORITY APPLN. INFO.:


A1 20090626
A1 20070412

HK 2004-109119
US 2006-443208
GB 2001-26433
GB 2001-29059
WO 2002-GB4931
US 2004-494137


20041118
20060531
A 20011103
A 20011205
W 20021031
B1 20041006

OTHER SOURCE(S):
GI

MARPAT 138:385441



I




II

AB Anilino-, indolylamino-, and benzopyrazolylamino-substituted quinazolines I [wherein R1, R2, R3, and R6 = independently H or alkyl; Z = a bond, O, S, or NR2; Q1 = (un)substituted cycloalkyl(alkyl), cycloalkyl(alkenyl), cycloalkyl(alkynyl), or heterocyclyl(alkyl); with the proviso that alkylene chains within Q1Z are optionally interrupted by O, S, SO, SO2, NR3, CO, CHOR3, CONR3, NR3CO, SO2NR3, NR3SO2, CH=CH, or C.tpbond.C; Q2 = (un)substituted C6H4-4-X2Q2, 1-(X3Q4)indol-5-yl, 1-(X3Q4)indol-6-yl, 1-(X3Q4)-1H-benzopyrazol-5-yl, or 1-(X3Q4)-1H-benzopyrazol-6-yl; X2 = a bond, O, S, SO, SO2, NR6, CHOR6, CONR6, NR6CO, SO2NR6, NR6SO2, OC(R6)2, C(R6)2O, SC(R6)2, C(R6)2S, CO, C(R6)2NR6, or NR6C (R6)2; or X2Q3 = heterocyclylcarbonyl; X3 = a bond, SO2, CO, SO2NR7, or C(R7)2; Q3 and Q4 = independently (un)substituted (heteroaryl); and pharmaceutically acceptable salts thereof] were prepared for use in the prevention or treatment of tumors which are sensitive to inhibition of erbB receptor tyrosine kinases. For example, coupling of 4-hydroxy-1-methylpiperidine with 5-fluoro-3,4-dihydroquinazolin-4-one using NaH in DMA gave the ether (91%). Reaction with POC13 and di-isopropylethylamine in DCM provided 4-chloro-5-(1-methylpiperidin-4-yloxy)quinazoline (62%), which was coupled with 5-amino-1-benzylindole in the presence of IPA containing HCl in ether to afford II-HCl (46%). The biol. activity of the example compds. was assessed in five assays. Thus, I inhibited the phosphorylation of a tyrosine-containing polypeptide substrate by epidermal growth factor receptor (EGFR) kinase, erbB2 kinase, and erbB4 kinase with IC50 values in the range of 0.001 μ M - 10 μ M. I also inhibited the proliferation of both human naso-pharyngeal carcinoma KB cells and non-neoplastic epithelial H16N-2 cells with IC50 values in the range 0.001 μ M - 20 μ M. In addition, I inhibited the growth of colorectal adenocarcinoma LoVo and human mammary carcinoma BT-474 tumor cell xenografts in vivo with activities in the range of 1 mg/kg/day to 200 mg/kg/day with no physiol. unacceptable toxicity at the ED.

IT 524954-38-9P, 4-[3-Chloro-4-(decahydroisoquinolin-2-ylcarbonyl)anilino]-5-(1-methylpiperidin-4-yloxy)quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor agent; preparation of quinazolines as erbB receptor tyrosine kinase inhibitors for treatment of cancer)

RN 524954-38-9 CAPLUS
 CN Methanone, [2-chloro-4-[[5-[(1-methyl-4-piperidinyl)oxy]-4-quinazolinyl]amino]phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 35 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2003:319904 CAPLUS
 DOCUMENT NUMBER: 138:321428
 TITLE: Preparation of himbacine analogues as thrombin receptor antagonists
 INVENTOR(S): Chackalannil, Samuel; Chelliah, Mariappan V.; Clasby, Martin C.; Xia, Yan
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2003033501 | A1 | 20030424 | WO 2002-US32936 | 20021016 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2463628 | A1 | 20030424 | CA 2002-2463628 | 20021016 |
| AU 2002335031 | A1 | 20030428 | AU 2002-335031 | 20021016 |
| AU 2002335031 | B2 | 20050630 | | |
| US 20030203927 | A1 | 20031030 | US 2002-271715 | 20021016 |
| US 7037920 | B2 | 20060502 | | |
| EP 1436298 | A1 | 20040714 | EP 2002-801732 | 20021016 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |


| | IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | |
|------------------------|--|-----------------|-------------|
| CN 1571789 | A 20050126 | CN 2002-820666 | 20021016 |
| CN 100369917 | C 20080220 | | |
| HU 2005000443 | A2 20050829 | HU 2005-443 | 20021016 |
| HU 2005000443 | A3 20091228 | | |
| BR 200213967 | A 20050830 | BR 2002-13967 | 20021016 |
| JP 2005529841 | T 20051006 | JP 2003-536240 | 20021016 |
| JP 4307260 | B2 20090805 | | |
| NZ 531869 | A 20061130 | NZ 2002-531869 | 20021016 |
| RU 2319704 | C2 20080320 | RU 2004-115114 | 20021016 |
| KR 960170 | B1 20100526 | KR 2004-705435 | 20021016 |
| ZA 2004002849 | A 20050114 | ZA 2004-2849 | 20040415 |
| MX 2004003610 | A 20040727 | MX 2004-3610 | 20040416 |
| IN 2004CN00793 | A 20060113 | IN 2004-CN793 | 20040416 |
| IN 218259 | A1 20080523 | | |
| NO 2004002021 | A 20040514 | NO 2004-2021 | 20040514 |
| US 20060106050 | A1 20060518 | US 2005-311083 | 20051219 |
| IN 2007CN01003 | A 20070831 | IN 2007-CN1003 | 20070308 |
| JP 2009029820 | A 20090212 | JP 2008-238716 | 20080917 |
| PRIORITY APPLN. INFO.: | | US 2001-330359P | P 20011018 |
| | | JP 2003-536240 | A3 20021016 |
| | | US 2002-271715 | A3 20021016 |
| | | WO 2002-US32936 | W 20021016 |
| | | IN 2004-CN793 | A3 20040416 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:321428
GI



I




II

AB Heterocyclic-substituted tricyclics of formula I [R = H, alkyl, halo, OH, amino, aryl, etc.; R1-R7 = H, OH, alkyl, cycloalkyl, etc.; R8 = acyl, carboxy, amino, etc.; X = (CH2)n; Y = (CH2)m; n, m = 0-3; B = alkyl, (substituted) alkenyl; Het = (substituted) mono-, bi- or tricyclic heteroarom. group] are prepared for treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer. Pharmaceutical compns. containing I are described. Thus, II was prepared in several steps. The prepared compds. were found to have IC50 values from 1 to 2000 nM in in vivo antitumor tests against human breast carcinoma in nude mice.

IT 514203-24-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of himbacine analogs as thrombin receptor antagonists)
RN 514203-24-8 CAPLUS
CN Furo[3,4-g]isoquinolin-3(1H)-one, 6-benzoyldecahydro-1-methyl-9-[(1E)-2-[5-
[3-(trifluoromethyl)phenyl]-2-pyridinyl]ethenyl]-,
(1R,3aR,4aS,8aS,9S,9aS)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 36 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:282524 CAPLUS
DOCUMENT NUMBER: 138:304064
TITLE: Preparation of phenylurea derivatives as vanilloid
receptor agonists
INVENTOR(S): Matsumoto, Takahiro; Yamamoto, Masataka; Nagabukuro,
Hiroshi; Mochizuki, Manabu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---------------|------|----------|-----------------|----------|
| WO 2003029199 | A1 | 20030410 | WO 2002-JP9995 | 20020927 |
| WO 2003029199 | A9 | 20030925 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
 UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002332331 A1 20030414 AU 2002-332331 20020927
 EP 1437344 A1 20040714 EP 2002-768103 20020927
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2004339061 A 20041202 JP 2002-282514 20020927
 US 20040259912 A1 20041223 US 2004-489621 20040312
 PRIORITY APPLN. INFO.: JP 2001-300564 A 20010928
 WO 2002-JP9995 W 20020927

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:304064

GI



AB The title compds. I [R1, R4 and R6 are each independently hydrogen, halogeno, or hydrocarbyl; R2 is hydrocarbyl or a heterocyclic group; R3 is hydrocarbyl, etc.; R5 is hydrocarbyl or a heterocyclic group (except quinolyl) and R51 is hydrogen or hydrocarbyl, or R5 and R51 together with the nitrogen atom adjacent thereto may form a ring; and R52 is hydrogen or hydrocarbyl] are prepared I are useful for the treatment of pain, urinary incontinence, etc. In a tail flick test using mice, one compound of this invention showed a min. ED of 1 mg/kg.


IT 508216-96-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylurea derivs. as vanilloid receptor agonists)


RN 508216-96-4 CAPLUS

CN Urea, N-[4-(diphenylmethoxy)-3-[(octahydro-2(1H)-isoquinolinyl]carbonyl]phenyl]-N'-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1998:630299 CAPLUS
 DOCUMENT NUMBER: 129:343401
 ORIGINAL REFERENCE NO.: 129:69945a
 TITLE: Synthesis of cis-4a(S),8a(R)-perhydro-6(2H)-
 isoquinolinones from quinine:
 4a(S),8a(R)-2-benzoyloctahydro-6(2H)-isoquinolinone
 AUTHOR(S): Hutchinson, Darrell R.; Khau, Vien V.; Martinelli,
 Michael J.; Nayyar, Naresh K.; Peterson, Barry C.;
 Sullivan, Keven A.
 CORPORATE SOURCE:
 SOURCE: USA Organic Syntheses (1998), 75, 223-234
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 129:343401
 GI



AB Perhydroisoquinolinone I is prepared in 5 steps from quinine as a single enantiomer. Quinine is oxidized with benzophenone and potassium tert-butoxide in toluene to give quinone II in 98% yield. II is oxidized with oxygen and potassium tert-butoxide in tert-butanol/THF to give meroquinone tert-Bu ester, which is protected with benzoyl chloride in pyridine, cyclized with sulfuric acid, and reduced with hydrogen over palladium on carbon to give I in 51% yield.


IT 52390-26-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of a nonracemic N-benzoylperhydroisoquinolinone from quinine)

RN 52390-26-8 CAPLUS


CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS,8aR)- (CA INDEX NAME)

Absolute stereochemistry.




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 38 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1994:244862 CAPLUS
 DOCUMENT NUMBER: 120:244862
 ORIGINAL REFERENCE NO.: 120:43405a,43408a
 TITLE: A new method for the preparation of tetrazoles from
 nitriles using trimethylsilyl azide/trimethylaluminum
 Huff, Bret E.; Staszak, Michael A.
 AUTHOR(S):
 CORPORATE SOURCE: Lilly Res. Lab., Indianapolis, IN, 46285-4813, USA
 SOURCE: Tetrahedron Letters (1993), 34(50), 8011-14
 DOCUMENT TYPE: CODEN: TELEAY; ISSN: 0040-4039
 LANGUAGE: Journal
 English
 OTHER SOURCE(S):
 CASREACT 120:244862
 GI



AB Tetrazoles are prepared in good yields from alkyl and aryl nitriles by treatment with equimolar trimethylaluminum and trimethylsilylazide. Yields, substrate compatibility, and reaction temperature are comparable with the use of other metal azides such as Al(N3)3 and Bu3SnN3. The reactions are run in toluene or with added THF at 80°. Thus, reaction of C1CH2CH2CN with Me3Al in the presence of Me3SiN3 in PhMe gave 89% tetrazole I.
 IT 154373-21-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 154373-21-4 CAPLUS
 CN Methanone, [octahydro-6-(2H-tetrazol-5-ylmethylene)-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)



IT 154373-19-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with trimethylsilyl azide in presence of
 trimethylaluminum, tetrazole by)
 RN 154373-19-0 CAPLUS
 CN Acetonitrile, 2-(2-benzoyloctahydro-6(2H)-isoquinolinylidene)- (CA INDEX
 NAME)



OS.CITING REF COUNT: 43 THERE ARE 43 CAPLUS RECORDS THAT CITE THIS
 RECORD (43 CITINGS)


L7 ANSWER 39 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1994:134304 CAPLUS
 DOCUMENT NUMBER: 120:134304
 ORIGINAL REFERENCE NO.: 120:23651a,23654a
 TITLE: Antipsychotic nitrogen-containing bicyclic compounds
 INVENTOR(S): Gilligan, Paul Joseph
 PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
 SOURCE: PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 9316050 | A1 | 19930819 | WO 1993-US1384 | 19930216 |
| W: AU, CA, CZ, JP, KR, PL, SK | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| US 5532243 | A | 19960702 | US 1992-836230 | 19920214 |
| AU 9337200 | A | 19930903 | AU 1993-37200 | 19930216 |
| EP 626949 | A1 | 19941207 | EP 1993-905996 | 19930216 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| JP 07505142 | T | 19950608 | JP 1993-514332 | 19930216 |
| PRIORITY APPLN. INFO.: | | | US 1992-836230 | A 19920214 |
| | | | WO 1993-US1384 | A 19930216 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 120:134304

GI



AB The title compds. I [R1 = H, C1-6 alkyl, C3-6 cycloalkyl, C3-6 alkenyl, heterocyclyl, etc.; R2 = H, OH, C1-6 alkoxy, etc.; R3 = C1-6 alkyl, (un)substituted Ph, heteroaryl, naphthyl, etc.; R4, R5 = H, C1-6 alkyl; m, n, p, q = 1, 2; such that m = n ≠ 2 or p = q ≠ 2], useful in the treatment of physiol. or drug-induced psychosis and as antidysskinetic agents, and which are not expected to produce the extrapyramidal symptoms that are typical of those produced by other antipsychotics that are dopamine receptor antagonists, are prepared Thus, cis-2-benzoyl-6-(4'-fluorophenyl)-6-hydroxydecahydroisoquinoline was reduced with LiAlH₄, producing cis-2-benzyl-6-(4'-fluorophenyl)-6-hydroxydecahydroisoquinoline, which demonstrated potent binding affinity for guinea pig striatum-isolated sigma receptors and for dopamine D2 receptors.

IT 52346-10-8P 152620-57-0P 152620-93-4P


152620-95-6P 152620-96-7P

RL: BAC (Biological activity or effector, except adverse); BSU (biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antipsychotic activity of)


RN 52346-10-8 CAPLUS

CN Methanone, [octahydro-6-hydroxy-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)




RN 152620-57-0 CAPLUS

CN Methanone, [6-(4-fluorophenyl)octahydro-6-hydroxy-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)




RN 152620-93-4 CAPLUS


CN Methanone, [6-[4-[(1,1-dimethylethyl)dimethylsilyloxy]phenyl]octahydro-6-hydroxy-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)




RN 152620-95-6 CAPLUS
 CN Methanone, [octahydro-6-hydroxy-6-(4-methoxyphenyl)-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)



RN 152620-96-7 CAPLUS
 CN Methanone, [6-(4-fluorophenoxy)octahydro-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)




IT 52346-10-8P 152620-72-9P 152620-73-0P
 152620-96-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antipsychotic activity of, reaction of)
 RN 52346-10-8 CAPLUS
 CN Methanone, [octahydro-6-hydroxy-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)




RN 152620-72-9 CAPLUS
 CN 6-Isoquinolinol, 2-benzoyl-6-(4-fluorophenyl)decahydro-,
 (4aa,6a,8aβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 152620-73-0 CAPLUS
 CN 6-Isoquinolinol, 2-benzoyl-6-(4-fluorophenyl)decahydro-,
 (4aa,6beta,8ab)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 152620-96-7 CAPLUS
 CN Methanone, [6-(4-fluorophenoxy)octahydro-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)




IT 152620-97-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of antipsychotic agents)
 RN 152620-97-8 CAPLUS
 CN Methanone, [octahydro-6-[(methylsulfonyl)oxy]-2(1H)-isoquinolinyl]phenyl-
 (CA INDEX NAME)




IT 27875-48-5 52346-10-8 152620-57-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of antipsychotic agents)
RN 27875-48-5 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 52346-10-8 CAPLUS
CN Methanone, (octahydro-6-hydroxy-2(1H)-isoquinolinyl)phenyl- (CA INDEX NAME)



RN 152620-57-0 CAPLUS
CN Methanone, [6-(4-fluorophenyl)octahydro-6-hydroxy-2(1H)-isoquinolinyl]phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 40 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1993:539584 CAPLUS
DOCUMENT NUMBER: 119:139584
ORIGINAL REFERENCE NO.: 119:25059a,25062a
TITLE: Synthesis and κ-opioid antagonist selectivity of
a norbinalorphimine congener. Identification of the
address moiety required for κ-antagonist
activity
AUTHOR(S): Lin, Chia En; Takemori, Akira E.; Portoghese, Philip
S.
CORPORATE SOURCE: Coll. Pharm., Univ. Minnesota, Minneapolis, MN, 55455,
USA

SOURCE:

Journal of Medicinal Chemistry (1993), 36(16), 2412-15

DOCUMENT TYPE:



CODEN: JMCMAR; ISSN: 0022-2623

LANGUAGE:

Journal

GI

English




AB Compound I, which represents a structurally simplified congener of norbinaltorphimine (II), was synthesized in order to evaluate the role of its second basic nitrogen in conferring κ -opioid receptor antagonist selectivity. Congener I was found to be at least twice as selective as II as a κ antagonist, while its N-carbobenzoxy derivative was inactive at κ -receptors. The importance of the second basic nitrogen of II for κ -receptor recognition was established. It is proposed that this basic group mimics the guanidinium moiety of Arg, which may be the key κ -address component of dynorphin.

IT 58406-84-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction and benzyloxycarbonylation of)

RN 58406-84-1 CAPLUS

CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)




OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)

ACCESSION NUMBER: 1993:517276 CAPLUS
 DOCUMENT NUMBER: 119:117276
 ORIGINAL REFERENCE NO.: 119:21099a,21102a
 TITLE: Novel 4-arylpiperazines and 4-arylpiperidines
 INVENTOR(S): Reitz, Allen B.
 PATENT ASSIGNEE(S): McNeilab, Inc., USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|-------------|
| WO 9304682 | A1 | 19930318 | WO 1992-US7754 | 19920911 |
| W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MG, MW, NO, RO, RU, SD | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, | | | | |
| BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG | | | | |
| ZA 9109629 | A | 19931206 | ZA 1991-9629 | 19911205 |
| HU 68963 | A2 | 19950828 | HU 1993-1362 | 19911220 |
| HU 217068 | B | 19991129 | | |
| AU 9226599 | A | 19930405 | AU 1992-26599 | 19920911 |
| AU 657799 | B2 | 19950323 | | |
| EP 563345 | A1 | 19931006 | EP 1992-920313 | 19920911 |
| EP 563345 | B1 | 20020703 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE | | | | |
| HU 64535 | A2 | 19940128 | HU 1993-1361 | 19920911 |
| JP 06502870 | T | 19940331 | JP 1993-505525 | 19920911 |
| JP 2919495 | B2 | 19990830 | | |
| RU 2139867 | C1 | 19991020 | RU 1993-41055 | 19920911 |
| SG 70980 | A1 | 20000321 | SG 1996-5506 | 19920911 |
| AT 219938 | T | 20020715 | AT 1992-920313 | 19920911 |
| ES 2179822 | T3 | 20030201 | ES 1992-920313 | 19920911 |
| NO 9301695 | A | 19930527 | NO 1993-1695 | 19930510 |
| NO 9301694 | A | 19930630 | NO 1993-1694 | 19930510 |
| NO 303780 | B1 | 19980831 | | |
| FI 111639 | B1 | 20030829 | FI 1993-2104 | 19930510 |
| US 5569659 | A | 19961029 | US 1995-442600 | 19950517 |
| PRIORITY APPLN. INFO.: | | | US 1991-757881 | A 19910911 |
| | | | US 1992-944006 | B1 19920911 |
| | | | WO 1992-US7754 | A 19920911 |
| | | | WO 1992-US9082 | W 19921220 |
| | | | US 1994-365978 | B1 19941228 |

OTHER SOURCE(S): MARPAT 119:117276
 GI



AB Title compds. 4-RX(CH₂)_nCR1R2X1WNR3R4 [X = (un)substituted piperazine, piperidino; X1 = (un)substituted Ph; R = aryl; CR1R2 = CH₂, CO, 1,1-alkanediyl, CHOH; W = CO, CS, SO₂; NR3R4 = amino; n = 0-4] (113 compds.) were prepared as antipsychotic agents. Thus, 3-C1CH₂C₆H₄COCl was treated with piperidine and N-(2-isopropoxyphenyl)piperazine to give the

piperazine I which had an ED50 against apomorphine-induced emesis in dogs of 0.038mg/kg orally in dogs 1h before treatment with apomorphine..


IT 148827-10-5P 148853-90-1P 148888-36-2P
 148888-37-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antipsychotic activity of)

RN 148827-10-5 CAPLUS

CN Isoquinoline, decahydro-2-[3-[(4-[2-(1-methylethoxy)phenyl]-1-piperazinyl)methyl]benzoyl]-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 148853-90-1 CAPLUS
 CN Isoquinoline, decahydro-2-[3-[(4-[2-(1-methylethoxy)phenyl]-1-piperazinyl)methyl]benzoyl]-, cis-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 148827-10-5
 CMF C30 H41 N3 O2

Relative stereochemistry.




CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 148888-36-2 CAPLUS
CN Isoquinoline, decahydro-2-[3-[(4-[2-(1-methylethoxy)phenyl]-1-piperazinyl)methyl]benzoyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 148888-37-3 CAPLUS
CN Isoquinoline, decahydro-2-[3-[(4-[2-(1-methylethoxy)phenyl]-1-piperazinyl)methyl]benzoyl]-, trans-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 148888-36-2
CMF C30 H41 N3 O2

Relative stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4




OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 42 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1993:495555 CAPLUS
DOCUMENT NUMBER: 119:95555
ORIGINAL REFERENCE NO.: 119:17241a,17244a
TITLE: Novel 4-arylpiperazines and 4-arylpiperidines
INVENTOR(S): Reitz, Alan B.
PATENT ASSIGNEE(S): McNeilab, Inc., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 9304684 | A1 | 19930318 | WO 1991-US9082 | 19911220 |
| W: AU, BB, BG, BR, CA, FI, HU, JP, KP, KR, LK, MG, MW, NO, RO, SD, SU
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG | | | | |
| ZA 9109629 | A | 19931206 | ZA 1991-9629 | 19911205 |
| AU 9213633 | A | 19930405 | AU 1992-13633 | 19911220 |
| EP 562049 | A1 | 19930929 | EP 1992-906123 | 19911220 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE | | | | |
| JP 06502183 | T | 19940310 | JP 1992-506154 | 19911220 |
| HU 68963 | A2 | 19950828 | HU 1993-1362 | 19911220 |

| | | | | |
|------------------------|----|----------|----------------|-------------|
| HU 217068 | B | 19991129 | | |
| HU 64535 | A2 | 19940128 | HU 1993-1361 | 19920911 |
| SG 70980 | A1 | 20000321 | SG 1996-5506 | 19920911 |
| ES 2179822 | T3 | 20030201 | ES 1992-920313 | 19920911 |
| NO 9301695 | A | 19930527 | NO 1993-1695 | 19930510 |
| US 5569659 | A | 19961029 | US 1995-442600 | 19950517 |
| PRIORITY APPLN. INFO.: | | | US 1991-757881 | A 19910911 |
| | | | WO 1991-US9082 | A 19911220 |
| | | | US 1992-944006 | B1 19920911 |
| | | | WO 1992-US9082 | W 19921220 |
| | | | US 1994-365978 | B1 19941228 |

OTHER SOURCE(S): MARPAT 119:95555
GI




AB Piperazines and piperidines I [X = N, CH; Z = CO, CS, SO2; R = (un)substituted Ph, heteroaryl; R1, R2 = H, C1-C8 alkyl, (un)substituted Ph, aralkyl, acyl, C4-C10 cycloalkyl, NR1R2 may form a ring; R3, R4 = H, C1-C8 alkyl or alkoxy, NO2, halo, amino, etc.] were prepared as novel antipsychotic agents (dopamine D2 binding activities tabulated for 82 synthesized compds.). Thus, m-ClCH2C6H4COCl was treated with piperidine in THF, then piperidine and N-(2-isopropoxyphenyl)piperazine fumarate, to give 1-[3-[(4-(2-isopropoxyphenyl)-1-piperazinyl)methyl]benzoyl]piperidine, which is isolated as the HCl salt.

IT 148583-20-4P 149270-82-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and affinity for dopamine-2 receptor)

RN 148583-20-4 CAPLUS

CN Methanone, [3-[(4-[2-(1-methylethoxy)phenyl]-1-piperazinyl)methyl]phenyl](octahydro-2(1H)-isoquinolinyl)- (CA INDEX NAME)




RN 149270-82-6 CAPLUS

CN Methanone, [3-[(4-[2-(1-methylethoxy)phenyl]-1-piperazinyl)methyl]phenyl](octahydro-2(1H)-isoquinolinyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 148583-20-4

CMF C30 H41 N3 O2



CM 2


CRN 144-62-7
CMF C2 H2 O4



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 43 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1988:38172 CAPLUS
DOCUMENT NUMBER: 108:38172
ORIGINAL REFERENCE NO.: 108:6399a,6402a
TITLE: A general synthesis of
cis-perhydro-3,6-isocouquinoline diones related to the
alloyohimbane alkaloids
AUTHOR(S): Stork, Gilbert; Livingston, Douglas A.
CORPORATE SOURCE: Dep. Chem., Columbia Univ., New York, NY, 10027, USA
SOURCE: Chemistry Letters (1987), (1), 105-8
CODEN: CMLTAG; ISSN: 0366-7022
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:38172
GI



AB The intramol. annulation of malonic acid derivs. of 4-(aminomethyl)cyclohexenones, e.g. I, is an efficient route to cis-perhydroisoquinolininedione derivs., e.g. II. (\pm)-Alloyohimbone (III) was prepared from the imine of 4-methoxybenzaldehyde and tryptamine.


IT 58620-31-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 58620-31-8 CAPLUS

CN Spiro[1,3-dioxolane-2,6' (2'H)-isoquinoline], 2'-benzoyloctahydro-, cis-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L7 ANSWER 44 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1987:515469 CAPLUS

DOCUMENT NUMBER: 107:115469

ORIGINAL REFERENCE NO.: 107:18711a,18711a


TITLE: Synthesis and biological properties of some
6H-pyrido[4,3-b]carbazoles

AUTHOR(S): Archer, Sydney; Ross, Bruce S.; Pica-Mattoccia, Livia;
Cioli, Donato

CORPORATE SOURCE: Dep. Chem., Rensselaer Polytech. Inst., Troy, NY,
12180-3590, USA

SOURCE: Journal of Medicinal Chemistry (1987), 30(7), 1204-10
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:115469
GI



AB The effect of Me substitution on the biol. properties of ellipticines was reexamnd. 9-Hydroxy-pyridocarbazole I was synthesized and shown to be devoid of antitumor activity in murine P-388 lymphocytic leukemia in mice. The (hydroxymethyl)methylpyridocarbazole II (R = H) and its N-methylcarbamate II (R = CONHMe) were prepared from 3-acetylpyridine and Me indolylacetate III, via the intermediate [(pyridylvinylidene)indolyl]acetate IV, in 5 and 6 steps resp. The effect of II (R = H, CONHMe) on macromol. synthesis in HeLa cells and their antitumor properties were compared with those of ellipticine (V). In contrast to V and the hydroxymethyl derivative I (R = H), which produced partially reversible inhibition of [³H]thymidine incorporation, the carbamate ester I (R = CONHMe) irreversibly blocked incorporation of the tritiated pyrimidine. I (R = CONHMe) was also a more potent antitumor agent in P-388 lymphocytic leukemia than V or I (R = H).


IT 27875-47-4P 27875-48-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, ketalization and hydride reduction of)

RN 27875-47-4 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 27875-48-5 CAPLUS


CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L7 ANSWER 45 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1984:5546 CAPLUS
 DOCUMENT NUMBER: 100:5546
 ORIGINAL REFERENCE NO.: 100:951a,954a
 TITLE: Fischer indole synthesis from cis- and trans-hexahydro-7-methyl-6-isoquinolones. Proton NMR determination of the configuration and conformation of products
 AUTHOR(S): Freter, Kurt; Fuchs, Victor; Pitner, T. Phil
 CORPORATE SOURCE: Res. Dev., Boehringer Ingelheim, Ltd., Ridgefield, CT, 06877, USA
 SOURCE: Journal of Organic Chemistry (1983), 48(24), 4593-7
 DOCUMENT TYPE: CODEN: JOCEAH; ISSN: 0022-3263
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 100:5546
 GI




AB Acid-catalyzed ring closure of cis-fused heterocycle (I) gave either indoline (II) or the indole (III) depending on the acidity of the reaction medium. The trans isomer (IV) forms only indoline derivative (V). Anal. of vicinal 1H-1H coupling consts. in terms of dihedral angles yields the conformation and relative configuration of key intermediates and

products. Factors influencing the stereochem. course of these reactions are discussed.

IT 87682-34-6P 87682-35-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and Fischer indole synthesis with)


RN 87682-34-6 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-7-methyl-, 6-(phenylhydrazone),
(4 α ,7 β ,8 $\alpha\alpha$)- (9CI) (CA INDEX NAME)



RN 87682-35-7 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-7-methyl-, 6-(phenylhydrazone),
(4 $\alpha\alpha$,7 α ,8 $\alpha\beta$)- (9CI) (CA INDEX NAME)




IT 87682-36-8P 87727-56-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 87682-36-8 CAPLUS


CN 1H-Pyrido[4,3-b]carbazole, 2-benzoyl-2,3,4,4a,5,10b,11,11a-octahydro-10b-methyl-, (4 $\alpha\alpha$,10b β ,11a α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 87727-56-8 CAPLUS

CN Methanone, (1,3,4,4a,5,10b,11,11a-octahydro-10b-methyl-2H-pyrido[4,3-b]carbazol-2-yl)phenyl- (CA INDEX NAME)




IT 87682-32-4P 87682-33-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, phenylhydrazone from)
RN 87682-32-4 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzyloctahydro-7-methyl-,
(4aa,7 β ,8aa)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 87682-33-5 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzyloctahydro-7-methyl-,
(4aa,7 α ,8a β)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L7 ANSWER 46 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1981:462477 CAPLUS
DOCUMENT NUMBER: 95:62477
ORIGINAL REFERENCE NO.: 95:10563a,10566a
TITLE: Synthesis, DNA intercalation and antitumor activity of
9-hydroxy-11-demethylellipticine and some derivatives.
Comparison with the corresponding ellipticines
AUTHOR(S): Gouyette, Alain; Reynaud, Rene; Sadet, Jacqueline;
Baillarge, Michele; Gansser, Charles; Cros, Suzanne;
Le Goffic, Francois; Le Pecq, Jean Bernard; Paoletti,
Claude; Viel, Claude
CORPORATE SOURCE: Cent. Etudes Rech. Chim. Org. Appl., CNRS, Thiais,
94320, Fr.
SOURCE: European Journal of Medicinal Chemistry (1980), 15(6),
503-10
DOCUMENT TYPE: CODEN: EJMCA5; ISSN: 0009-4374
LANGUAGE: Journal
English
GI




AB 11-Demethylellipticines were prepared by 3 synthetic routes. Thus, 5-methoxygramine was treated with N-benzyl-4-piperidinone to give 1-benzyl-3-(5-methoxy-3-indolyl)-4-piperidinone, which underwent ethynylation and cyclization followed by debenzylation-aromatization to give demethylellipticine I. 9-Methoxy-11-demethylellipticine and 9-hydroxy-11-demethylellipticine as well as their quaternary ammonium salts were compared with the corresponding ellipticine derivs. concerning their DNA affinity, their *in vitro* cytotoxic action and their *in vivo* antitumor activity. 11-Demethylellipticines have less DNA affinity but possess a lower toxicity than the corresponding ellipticines and are also less active on L 1210 leukemia. The presence of a Me group on the intercalating ring (at C-11) plays a major role in determining the biol. activity. A similar observation has been made in the actinomycin series.

IT 77528-42-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclization with methoxyphenylhydrazine)

RN 77528-42-8 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-5-methyl- (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(5 CITINGS)

L7 ANSWER 47 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1980:76313 CAPLUS
DOCUMENT NUMBER: 92:76313
ORIGINAL REFERENCE NO.: 92:12567a,12570a
TITLE: Isoquinoline derivatives
INVENTOR(S): Hauth, Hartmut; Pfäffli, Paul
PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Switz.
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|----------|
| DE 2907461 | A1 | 19790920 | DE 1979-2907461 | 19790226 |
| CH 636859 | A5 | 19830630 | CH 1978-2643 | 19780310 |
| DK 7900882 | A | 19790911 | DK 1979-882 | 19790301 |

| | | | | |
|------------------------|----|----------|----------------|------------|
| FI 7900701 | A | 19790911 | FI 1979-701 | 19790301 |
| SE 7901848 | A | 19790911 | SE 1979-1848 | 19790301 |
| NL 7901764 | A | 19790912 | NL 1979-1764 | 19790306 |
| GB 2016012 | A | 19790919 | GB 1979-7868 | 19790306 |
| GB 2016012 | B | 19820721 | | |
| FR 2419286 | A2 | 19791005 | FR 1979-5753 | 19790306 |
| FR 2419286 | B1 | 19820305 | | |
| BE 874704 | A4 | 19790910 | BE 1979-193914 | 19790308 |
| AU 7944956 | A | 19790913 | AU 1979-44956 | 19790308 |
| AU 529350 | B2 | 19830602 | | |
| CA 1118775 | A1 | 19820223 | CA 1979-323128 | 19790308 |
| ZA 7901107 | A | 19801029 | ZA 1979-1107 | 19790309 |
| JP 54128585 | A | 19791005 | JP 1979-28183 | 19790310 |
| PRIORITY APPLN. INFO.: | | | CH 1978-2643 | A 19780310 |
| | | | CH 1978-6283 | A 19780608 |

OTHER SOURCE(S): CASREACT 92:76313
GI



AB The isoquinoline derivs. I (R = H, aliphatic group, cycloalkyl- or furylalkyl, optionally substituted phenylalkyl; R1 = R2 = H, alkyl, alkoxy, CF3, halogen) were prepared for use as analgesics (no data). Thus, 1,3,4,7,8,8a-hexahydro-2-benzoyl-6(2H)-isoquinolinone reacted with BuLi and 3-BrC6H4OMe, and the product was successively treated with NaBH4, Ac2O, and KOH in aqueous MeOH to give II. This was treated successively with MeSO2Cl and NaN3, followed by treatment with HCl-BuOH to give I (R = R1 = H, R2 = 3-MeO).


IT 27875-47-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with bromoanisole)

RN 27875-47-4 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L7 ANSWER 48 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1978:152822 CAPLUS

DOCUMENT NUMBER: 88:152822
 ORIGINAL REFERENCE NO.: 88:24097a,24100a
 TITLE: Total synthesis of Cinchona alkaloids. 1. Synthesis
 of meroquinene
 AUTHOR(S): Uskokovic, Milan R.; Henderson, Thomas; Reese,
 Charles; Lee, Hsi Lin; Grethe, Guenter; Gutzwiller,
 Juerg
 CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ,
 USA
 SOURCE: Journal of the American Chemical Society (1978),
 100(2), 571-6
 DOCUMENT TYPE: CODEN: JACSAT; ISSN: 0002-7863
 JOURNAL: Journal
 LANGUAGE: English
 GI



AB Meroquinene (I), the key intermediate in several total syntheses of Cinchona alkaloids, was synthesized by three methods. Starting from cis-2-benzoyloctahydro-6(2H)-isoquinolone, the acetic acid and the vinyl side chains of I were formed by either Baeyer-Villiger oxidation, opening of the lactone II to the hydroxy ester, and elimination, or by Schmidt rearrangement, nitrosation of the lactam III, and pyrolysis. A stereospecific preparation of I was effected by catalytic hydrogenation of 3-ethyl-4-pyridineacetic acid Me ester, followed by conversion of the Et group of IV into the vinyl group by Loffler-Freytag rearrangement and elimination.


IT 27875-47-4

RL: RCT (Reactant); RACT (Reactant or reagent)
 (Baeyer-Villiger oxidation of)

RN 27875-47-4 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




OS.CITING REF COUNT: 17 **THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)**

L7 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1976:135912 CAPLUS


DOCUMENT NUMBER: 84:135912
 ORIGINAL REFERENCE NO.: 84:22107a, 22110a
 TITLE: Intermediates for quinine, quinidine, isomers and derivatives
 INVENTOR(S): Gutzwiler, Juerg A. W.; Uskokovic, Milan Radoje
 PATENT ASSIGNEE(S): Hoffmann-La Roche, Inc., USA
 SOURCE: U.S., 44 pp. Division of U.S. 3,772,302.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------------|-----------------|----------|
| US 3929795 | A | 19751230 | US 1973-384525 | 19730801 |
| CA 954517 | A2 | 19740910 | CA 1971-126550 | 19711101 |
| CA 974994 | A2 | 19750923 | CA 1971-126549 | 19711101 |
| US 3772302 | A | 19731113 | US 1971-212774 | 19711227 |
| ZA 7200010 | A | 19720927 | ZA 1972-10 | 19720103 |
| CH 565793 | A5 | 19750829 | CH 1975-6540 | 19720103 |
| CH 565794 | A5 | 19750829 | CH 1975-6541 | 19720103 |
| GB 1347802 | A | 19740227 | GB 1972-629 | 19720106 |
| US 3869461 | A | 19750304 | US 1973-354838 | 19730426 |
| AT 7405754 | A | 19761115 | AT 1974-5754 | 19740711 |
| AT 337913 | B | 19770725 | | |
| AT 7405752 | A | 19770215 | AT 1974-5752 | 19740711 |
| AT 339510 | B | 19771025 | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 1968-741914 | A2 19680702 | |
| | | US 1969-837354 | A2 19690627 | |
| | | US 1971-104784 | A2 19710107 | |
| | | US 1971-212774 | A3 19711227 | |
| | | CA 1969-55886 | A3 19690702 | |
| | | US 1971-212648 | A3 19711227 | |
| | | AT 1972-73 | A 19720105 | |
| | | US 1972-104785 | A 19720107 | |

GI



I




II


AB Antimalarial and antiarrhythmic Cinchona alkaloid derivs. I and II ($R = H$, $R1 = Et$, $CH:CH2$; $R = Et$, $CH:CH2$, $R1 = H$; $R2 = H$, $R3 = OH$; $R2 = OH$, $R3 = H$; $R2R3 = H2$, O ; $R4 = H$, $6'-Cl$, $7'-Cl$, $7'-F3C$, $6',8'-(MeO)2$, $6',8'-C12$, $6',7'-OCH2O$) (59 comps.) were prepared. Thus, condensation of 6-methoxylepidine with N-benzoylmeroquinene Et ester followed by reductive debenzylation, acetylation, and cyclization gave a mixture of deoxyquinidine (I, $R = CH:CH2$, $R1-R3 = H$, $R4 = 6\text{-MeO}$) and deoxyquinidine (II, $R = CH:CH2$, $R1-R3 = H$, $R4 = 6\text{-MeO}$), which were hydroxylated using O in $Me2SO\text{-}Me3COH\text{-}KOCMe3$ to yield quinine (I, $R2 = H$, $R3 = OH$) and quinidine

(II, R₂ = OH, R₃ = H).
IT 26599-55-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Removal and Schmidt reaction of)
RN 26599-55-3 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 58406-84-1P 58846-10-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 58406-84-1 CAPLUS
CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)




RN 58846-10-9 CAPLUS
CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)



IT 27875-48-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and ketalization of)
RN 27875-48-5 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 26695-57-8P 27875-47-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 26695-57-8 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 27875-47-4 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)

L7 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1976:90387 CAPLUS

DOCUMENT NUMBER: 84:90387

ORIGINAL REFERENCE NO.: 84:14765a,14768a

TITLE: Processes and intermediates for quinine, quinidine, isomers and derivatives

INVENTOR(S): Gutzwiller, Juerg A. W.; Uskokovic, Milan R.

PATENT ASSIGNEE(S): Hoffmann-La Roche, Inc., USA

SOURCE: U.S., 44 pp. Division of U.S. 3,772,302.

CODEN: USXAM

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|----------|-----------------|----------|
| US 3914235 | A | 19751021 | US 1973-384556 | 19730801 |
| CA 954517 | A2 | 19740910 | CA 1971-126550 | 19711101 |
| CA 974994 | A2 | 19750923 | CA 1971-126549 | 19711101 |
| US 3772302 | A | 19731113 | US 1971-212774 | 19711227 |
| ZA 7200010 | A | 19720927 | ZA 1972-10 | 19720103 |
| CH 565793 | A5 | 19750829 | CH 1975-6540 | 19720103 |
| CH 565794 | A5 | 19750829 | CH 1975-6541 | 19720103 |
| GB 1347802 | A | 19740227 | GB 1972-629 | 19720106 |
| US 3869461 | A | 19750304 | US 1973-354838 | 19730426 |
| AT 7405754 | A | 19761115 | AT 1974-5754 | 19740711 |
| AT 337913 | B | 19770725 | | |
| AT 7405752 | A | 19770215 | AT 1974-5752 | 19740711 |
| AT 339510 | B | 19771025 | | |

PRIORITY APPLN. INFO.:

| | | |
|----------------|----|----------|
| US 1968-741914 | A2 | 19680702 |
| US 1969-837354 | A2 | 19690627 |
| US 1971-104784 | A2 | 19710107 |
| US 1971-212774 | A3 | 19711227 |
| CA 1969-55886 | A3 | 19690702 |
| US 1971-212648 | A3 | 19711227 |
| AT 1972-73 | A | 19720105 |
| US 1972-104785 | A | 19720107 |

GI For diagram(s), see printed CA Issue.

AB Cinchonidines I and cinchonines II [R = 6-MeO, 7-Cl, 7-F3C, R1 = H; RR1 = 6,8-(MeO)2, 6,8-C12, 6,7-OCH2O; R2 = H, OH; R3 = CH:CH2, Et, R4 = H; R3 = H, R4 = CH:CH2, Et] (58 compds.) and their salts, useful as antiarrhythmics, hypotensives, and antimalarials (no data), were prepared by condensation of lepidines III with cis- and trans-piperidineacetates IV (R5 = H, acyl, R6 = lower alkyl) followed by deacylation, when R5 = acyl, NaBH4 reduction, cyclization, and hydroxylation. The preparation of IV

also

was described.

IT 26599-55-3P 26695-57-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and Schmidt reaction of)

RN 26599-55-3 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 26695-57-8 CAPLUS


CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 27875-47-4P 27875-48-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and Schmidt rearrangement of)
 RN 27875-47-4 CAPLUS
 CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 27875-48-5 CAPLUS
 CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)


Relative stereochemistry.



IT 28888-47-3P 58406-84-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and hydrolysis of)
 RN 28888-47-3 CAPLUS
 CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
 2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)




RN 58406-84-1 CAPLUS
 CN Spiro[1,3-dioxolane-2,6'-(2'H)-isoquinoline],
 2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)


L7 ANSWER 51 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1976:89975 CAPLUS
 DOCUMENT NUMBER: 84:89975
 ORIGINAL REFERENCE NO.: 84:14677a,14680a
 TITLE: Synthesis of 1-azatwistane
 AUTHOR(S): Deslongchamps, Pierre; Ruest, Luc; Dube, Serge
 CORPORATE SOURCE: Lab. Synth. Org., Univ. Sherbrooke, Sherbrooke, QC, Can.
 SOURCE: Canadian Journal of Chemistry (1975), 53(23), 3613-19
 DOCUMENT TYPE: CODEN: CJCHAG; ISSN: 0008-4042
 LANGUAGE: Journal
 French
 OTHER SOURCE(S): CASREACT 84:89975
 GI For diagram(s), see printed CA Issue.
 AB 1-Azatwistane (I) was prepared by reducing the decahydroisoquinolinone II ($R = \text{COPh}$, $Z = O$), mesylating the benzylisoquinolinol II ($R = \text{CH}_2\text{Ph}$, $Z = H$, HO), cyclizing the mesylate II ($R = \text{CH}_2\text{Ph}$, $Z = H$, MeSO_3), hydrogenating the resulting quaternary ammonium salt III ($R = \text{CH}_2\text{Ph}$) over Pd-C, and treating III ($R = H$) with NH_3 .
 IT 58620-33-0P 58620-34-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and mesylation of)
 RN 58620-33-0 CAPLUS
 CN 6-Isoquinolinol, 2-benzoyldecahydro-, (4aa,6aa,8aa)-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 58620-34-1 CAPLUS
 CN 6-Isoquinolinol, 2-benzoyldecahydro-, (4 α ,6 β ,8 $\alpha\alpha$)- (9CI)
 (CA INDEX NAME)

Relative stereochemistry.




IT 27875-47-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reduction of)
 RN 27875-47-4 CAPLUS
 CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




IT 27875-48-5P 58620-31-8P 58620-32-9P
 58620-35-2P 58620-36-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 27875-48-5 CAPLUS
 CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 58620-31-8 CAPLUS
 CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline], 2'-benzoyloctahydro-, cis-
 (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 58620-32-9 CAPLUS
 CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline], 2'-benzoyloctahydro-, trans-
 (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 58620-35-2 CAPLUS
 CN 6-isoquinolinol, 2-benzoyldecahydro-, methanesulfonate (ester),
 (4aa,6a,8aa)- (9CI) (CA INDEX NAME)



RN 58620-36-3 CAPLUS
 CN 6-Isoquinolinol, 2-benzoyldecahydro-, methanesulfonate (ester),
 (4aa,6b,8aa)- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)

L7 ANSWER 52 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1974:121160 CAPLUS

DOCUMENT NUMBER: 80:121160

ORIGINAL REFERENCE NO.: 80:19510h,19511a

TITLE: Stereoselectivity of ketone reduction with Sporotrichum exile. Resolution of cis- and trans-2-benzoyloctahydro-6(2H)-isoquinolones

AUTHOR(S): Uskokovic, M. R.; Pruess, D. L.; Despreaux, C. W.; Shuey, S.; Pizzolato, G.; Gutzwiler, J.

CORPORATE SOURCE: Chem. Res. Dep., Hoffmann-La Roche Inc., Nutley, NJ, USA

SOURCE: Helvetica Chimica Acta (1973), 56(8), 2834-44
CODEN: HCACAV; ISSN: 0018-019X

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.

AB cis-Octahydroquinolones I and II were resolved by anaerobic incubation with *S. exile* which preferentially reduced II to give cis-octahydroquinolinol III of 70% optical purity. This was oxidized by chromic acid and recrystd. to yield optically pure II. The trans-octahydroquinolones IV and V were resolved by recrystn. of their (R,R)-2,3-butanediol ketal derivs. Cinchonidine was oxidized by treatment with Ph₂CO in the presence of KOCMe₃ and then ring cleaved by O in Me₃COH containing KOCMe₃ to give the meroquinene ester VI, which underwent successive N-benzoylation, ester hydrolysis, polyphosphoric acid catalyzed cyclization, and hydrogenation to give a mixture of II and IV.

IT 26599-54-2P 26599-55-3P 26695-57-8P


28888-47-3P 52346-10-8P 52390-25-7P

52390-26-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 26599-54-2 CAPLUS


CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 26599-55-3 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 26695-57-8 CAPLUS


CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 28888-47-3 CAPLUS

CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 52346-10-8 CAPLUS


CN Methanone, (octahydro-6-hydroxy-2(1H)-isoquinolinyl)phenyl- (CA INDEX NAME)



RN 52390-25-7 CAPLUS


CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 52390-26-8 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS,8aR)- (CA INDEX NAME)

Absolute stereochemistry.




IT 27875-48-5
RL: PROC (Process)
(resolution of, by ketalization with (RR)-2,3-butanediol)
RN 27875-48-5 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



IT 27875-47-4
RL: PROC (Process)
(resolution of, by stereoselective reduction with Sporotrichum exile)
RN 27875-47-4 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L7 ANSWER 53 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1974:37350 CAPLUS

DOCUMENT NUMBER: 80:37350

ORIGINAL REFERENCE NO.: 80:6135a,6138a

TITLE: Intermediates for quinine, quinidine, isomers and derivatives

INVENTOR(S): Gutzwiller, Juerg A. W.; Uskokovic, Milan R.

PATENT ASSIGNEE(S): Hoffman-La Roche Inc.

SOURCE: U.S., 35 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------------|-----------------|-----------|
| US 3772302 | A | 19731113 | US 1971-212774 | 197111227 |
| CA 954517 | A2 | 19740910 | CA 1971-126550 | 19711101 |
| CA 974994 | A2 | 19750923 | CA 1971-126549 | 19711101 |
| ZA 7200010 | A | 19720927 | ZA 1972-10 | 19720103 |
| CH 565793 | A5 | 19750829 | CH 1975-6540 | 19720103 |
| CH 565794 | A5 | 19750829 | CH 1975-6541 | 19720103 |
| GB 1347802 | A | 19740227 | GB 1972-629 | 19720106 |
| US 3869461 | A | 19750304 | US 1973-354838 | 19730426 |
| US 3857837 | A | 19741231 | US 1973-384523 | 19730801 |
| US 3857847 | A | 19741231 | US 1973-384557 | 19730801 |
| US 3864347 | A | 19750204 | US 1973-384765 | 19730801 |
| US 3869462 | A | 19750304 | US 1973-384767 | 19730801 |
| US 3872129 | A | 19750318 | US 1973-384766 | 19730801 |
| US 3873549 | A | 19750325 | US 1973-384781 | 19730801 |
| US 3875171 | A | 19750401 | US 1973-384524 | 19730801 |
| US 3914235 | A | 19751021 | US 1973-384556 | 19730801 |
| US 3929795 | A | 19751230 | US 1973-384525 | 19730801 |
| AT 7405754 | A | 19761115 | AT 1974-5754 | 19740711 |
| AT 337913 | B | 19770725 | | |
| AT 7405752 | A | 19770215 | AT 1974-5752 | 19740711 |
| AT 339510 | B | 19771025 | | |
| PRIORITY APPLN. INFO.: | | | | |
| | | US 1968-741914 | A2 19680702 | |
| | | US 1969-837354 | A2 19690627 | |
| | | US 1971-104784 | A2 19710107 | |
| | | CA 1969-55886 | A3 19690702 | |
| | | US 1971-108784 | A2 19710107 | |
| | | US 1971-212648 | A3 19711227 | |
| | | US 1971-212774 | A3 19711227 | |
| | | AT 1972-73 | A 19720105 | |
| | | US 1972-104785 | A 19720107 | |


GI For diagram(s), see printed CA Issue.

AB Alkaloidal analogs I ($R = H, Cl, MeO$; $R1 = H, Cl, F3C$; $R2 = H, MeO$; $R1R2 = CH2O2$; $R3 = H, OH$; $R4 = H$; $R3R4 = O$; $R5 = Et, CH:CH2$) (68 compds.), useful as antimalarials and antiarrhythmics, were prepared as isomer mixts., which were resolved into cinchonidine and cinchonine analogs. Thus methyl-quinoline II ($R = Cl, R1 = R2 = H$) condensed with piperidine acetate III ($R5 = CH:CH2$) to give IV ($R3R4 = O$) which was reduced, O-acetylated, cyclized and hydroxylated successively to an epimeric mixture of I ($R3 = H, R4 = OH$) (chlorocinchonidine and chlorocinchonine).
 IT 26599-54-2P 26599-55-3P 26695-57-8P
 2'875-47-4P 27875-48-5P 28888-47-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 26599-54-2 CAPLUS
 CN Spiro[1,3-dioxolane-2,6'-(2'H)-isoquinoline],
 2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)




RN 26599-55-3 CAPLUS
 CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 26695-57-8 CAPLUS
 CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 27875-47-4 CAPLUS
 CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 27875-48-5 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 28888-47-3 CAPLUS
CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L7 ANSWER 54 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1973:29651 CAPLUS
DOCUMENT NUMBER: 78:29651
ORIGINAL REFERENCE NO.: 78:4679a, 4682a
TITLE: New synthesis of 6H-pyrido[4,3-b]carbazoles
AUTHOR(S): Rastogi, Shri Nivas; Bindra, Jasjit S.; Rai, S. N.; Anand, Nitya
CORPORATE SOURCE: Cent. Drug Res. Inst., Lucknow, India
SOURCE: Indian Journal of Chemistry (1972), 10(6), 673-4
CODEN: IJOCAP; ISSN: 0019-5103
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB A new synthesis of 6H-pyrido[4,3-b]-carbazoles (I, R = Me, MeO, F) and the corresponding 4a,11acis- and trans-1,2,3,4,4a,5,11,11a-octahydro derivs.

is described. The starting compds. cis- and trans-2-benzoyl-1,3,4,4a,5,7,8,8a-octahydro-6(2H)-isoquinolones are condensed with arylhydrazines to give the corresponding hydrazones (II), which on indolization and dehydrogenation afford the desired compds. A number of ring-A substituted compds. have been prepared for anticancer screening.

IT 39112-36-2P 39112-37-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 39112-36-2 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, 6-(phenylhydrazone), cis- (9CI)
(CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




RN 39112-37-3 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, 6-(phenylhydrazone), trans-
(9CI) (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




IT 27875-47-4 27875-48-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with arylhydrazines)

RN 27875-47-4 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 27875-48-5 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

L7 ANSWER 55 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1970:90698 CAPLUS
DOCUMENT NUMBER: 72:90698
ORIGINAL REFERENCE NO.: 72:16497a,16500a
TITLE: Quinoline and quinine derivatives
INVENTOR(S): Gutzwiller, Juerg A. W.; Uskokovic, Milan R.
PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co., A.-G.
SOURCE: Ger. Offen., 122 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-------------|------|----------|-----------------|----------|
| DE 1933600 | A | 19700108 | DE 1969-1933600 | 19690702 |
| CH 533622 | A | 19730330 | CH 1969-9861 | 19690627 |
| CH 559181 | A5 | 19750228 | CH 1971-14523 | 19690627 |
| CH 559183 | A5 | 19750228 | CH 1971-14524 | 19690627 |
| CH 559184 | A5 | 19750228 | CH 1971-14525 | 19690627 |
| BE 735451 | A | 19700102 | BE 1969-735451 | 19690701 |
| FR 2012152 | A5 | 19700313 | FR 1969-22136 | 19690701 |
| FR 2012152 | B1 | 19730810 | | |
| AT 300813 | B | 19720810 | AT 1971-494 | 19690701 |
| AT 319482 | B | 19741227 | AT 1969-6270 | 19690701 |
| AT 323338 | B | 19750710 | AT 1969-49371 | 19690701 |
| NL 6910136 | A | 19700106 | NL 1969-10136 | 19690702 |
| NL 162384 | B | 19791217 | | |
| NL 162384 | C | 19800516 | | |
| GB 1280201 | A | 19720705 | GB 1969-1280201 | 19690702 |
| GB 1280202 | A | 19720705 | GB 1969-1280202 | 19690702 |
| GB 1280203 | A | 19720705 | GB 1969-1280203 | 19690702 |
| SE 364044 | B | 19740211 | SE 1969-9413 | 19690702 |
| CA 954516 | A1 | 19740910 | CA 1969-55886 | 19690702 |
| DK 129235 | B | 19740916 | DK 1969-3590 | 19690702 |
| SE 375776 | B | 19750428 | SE 1972-12265 | 19690702 |
| IL 32535 | A | 19750522 | IL 1969-32535 | 19690702 |
| SE 376612 | B | 19750602 | SE 1972-12266 | 19690702 |
| JP 49007160 | B | 19740219 | JP 1971-56691 | 19710728 |
| FR 2108178 | A5 | 19720519 | FR 1971-35510 | 19711001 |
| FR 2108178 | B1 | 19740322 | | |
| CA 954517 | A2 | 19740910 | CA 1971-126550 | 19711101 |
| CA 974994 | A2 | 19750923 | CA 1971-126549 | 19711101 |
| US 3869461 | A | 19750304 | US 1973-354838 | 19730426 |

GI For diagram(s), see printed CA Issue.

AB The title compds. (I), quinine related, were prepared. Thus a solution of 151 g racemic 2-benzoyl-1,3,4,7,8,8a-hexahydro-6(2H)isoquinolone (II) in 300 ml absolute EtOH and 300 ml 3N HCl was hydrogenated over 30 g 5% Rh-Al203 to give a product containing 61.9% racemic cis-2-benzoyloctahydro-6(2H)isoquinolone (III) and 13% of the racemic trans isomer (IV); III m. 147-8.5°. Hydrogenation of 25.5 g II in 1 l 1.95% EtOH over 2.5 g 10% Pd-C at 3 atm gave racemic IV, m. 157.5-59° (absolute EtOH). IV (23.4 g), 2.24 g 4-MeC6H4-SO3H, and 9.83 g (-)-butane-2(R), 3(R)-diol in 2 l. anhydrous C6H6 was refluxed 3 hr with azeotropic sepn. of H2O to give 12.95 g 2'-benzoyl-4(R),5(R)-dimethyl-1',2',3',4',4a'(R),7',8',8a'(R)-octahydrospiro[1,3-dioxolane-2,6'(5'H)isoquinolone] (V), m. 182-4° (Et2O), [α]25D -8.75° (0.96, MeOH), and 12.45 g 2'-benzoyl-4(R),5(R)-dimethyl-1',2',3',4',4a'('S),7',8',8a'('S)-octahydrospiro[1,3-dioxolane-2,6'(5'H)isoquinolone] (VI), m. 147-8.5° (1:l EtOH-H2O), [α]25D 9.95° (c 1.005, MeOH). Treatment of 0.329 g V with 50 ml 70% HOAc 4.67 hr at 100-5° gave 0.256 g 4a(R),8a(R)-2-benzoyloctahydro-6(2H)isoquinolone (VII), m. 151-3° (absolute EtOH), [α]25D -62.6° (c 1.005, CHCl3). VI (2.5 g) and 100 ml 70% HOAc heated 1.5 hr at 100-5° gave 2 g 4a(S),-8a(S)-2-benzoyloctahydro-6(2H)isoquinolone (VIII), m. 151-3° (absolute EtOH), [α]26D 61.8° (c 1.01, CHCl3). To 20.6 g III in 800 g polyphosphoric acid was added 10 g NaN3, and the mixture stirred 16 hr at 55-60° to give racemic cis-7-benzoyldecahydro-2H-pyrido[3,4-d]azepin-2-one (IX), m. 167-8.5° (Me2CO). From 2.57 g VIII and 1.3 g NaN3 in 100 g polyphosphoric acid was prepared 2.72 g 5a(S),9a(S)-7-benzoyldecahydro-2H-pyrido-[3,4-d]azepin-2-one (X); alcoholate m. 200-3° (absolute EtOH), [α]25D 37.83° (c 1.0547, CHCl3). Similarly prepared from 5.15 g IV and from 1.02 g II, resp., were: 5.45 g trans-7-benzoyldecahydro-2H-pyrido[3,4-d]azepin-2-one (XI), m. 187-9° (EtOH/Et2O); and racemic 2-benzoyl-1,2,3,4,7,8,9,9a-octahydro-6H-pyrido[3,4-d]azepin-6-one (XII), m. 219-21° (Me2CO). Hydrogenation of 5.4 g XII over 5.4 g 5% Rh-Al203 in 450 ml absolute EtOH and 10 ml 3N HCl gave IX. Alcoholytic of 2.8 g IX by 500 ml 5% aq. HCl, under reflux 100 hr, gave racemic Et cis-1-benzoyl-3-(2-aminoethyl)piperidine-4-acetate (XIII), oil. Alcoholytic of XI gave the trans isomer (XIV). A mixture of 1.91 g XIII, 1.38 g HCO2H, and 1.05 g 37% CH2O was heated 1 hr at 100° to give Et cis-1-benzoyl-3-(2-dimethylaminoethyl)piperidine-4-acetate, which in 10 ml MeOH was treated with 2ml 30% H2O2 at 0°, and the mixture stirred 16 hr at room temperature to give racemic Et cis-1-benzoyl-3-(2-dimethylaminoethyl)piperidine-4-acetate N-oxide, which was converted into racemic Et cis-1-benzoyl-3-vinylpiperidine-4-acetate (XV), m. 66-8° (C6H14) by heating 25 min at 90-125°. The racemic trans isomer (XVI), glass, was similarly prepared from XIV. To a mixture of 5.521 g N2O4 and 9.84 g anhydrous NaOAc in 360 ml CC14 (prepared at -70°) was added at 0° 10.88 g IX in 40 ml CH2Cl2 to give racemic cis-7-benzoyl-1-nitrosodecahydro-2H-pyrido[3,4-d]azepin-2-one (XVII); the racemic trans analog (XVIII) was similarly prepared from XI. Heating XVII at 120° 1 hr under N gave racemic cis-1-benzoyl-3-vinylpiperidine-4-acetic acid (XIX), oil. By similar methods XVIII was converted into the racemic trans isomer (XX), oil, and 3.86 g X was converted into 2.34 g 1-benzoyl-3(S)-vinylpiperidine-4(S)-acetic acid (XXI), oil. Action of 1 g CH2N2 in 50 ml Et2O on 5.29 g XIX in 500 ml Et2O gave the racemic cis Me ester (XXII), oil; 0.476 g XX in 4ml MeOH and 9 ml CH2N2 solution in Et2O (3 g/130 ml) gave 0.201 g racemic trans Me ester (XXIII), oil; and 2.34 g XXI gave 1.059 g Me 1-benzoyl-3(S)-vinylpiperidine-4(S)-acetate (XXIV), [α]25D -1.61° (c 1.1193, CHCl3). Addition of 22.4 g KOCMe3 in

300 ml anhydrous THF to 37.24 g di-Et glutaconate and 70.08 g NCCH₂CO₂CH₂Ph in 100 ml THF over 4 hr, and refluxing 12 hr gave 42.55 g racemic Ph-CH₂CO₂CH(CN)CH(CH₂CO₂Et)₂ (XXV), b₀.15 167-74°. Ethylation of 18 g XXV by 15.6 g EtI and 6.72 g KOCMe₂ in 200 ml-THF 3 hr gave 11.35 g racemic PhCH₂CO₂CEt(CN)CH(CH₂CO₂Et)₂ (XXVI), b₀.025 154-9°. Hydrogenolysis of 23.4 g XXVI in 600 ml 95% EtOH over 3 g 10%Pd-C gave 14.17 g NCCHEt(CH₂CO₂Et)₂ (XXVII), b₀.0284-6°. XXVII (101.23 g) was hydrogenated over 31.8 g Raney Ni in 1200 ml absolute EtOH at 110 atm to give 57.6 g racemic cis-4-ethoxycarbonylmethyl-5-ethyl-2-piperidone (XXVIII), m. 89-91° (CH₂Cl₂-Et₂O), and 16 g racemic trans isomer, oil. XXVIII (0.64 g) was treated with 0.684 g Et₃O+BF₄⁻ in 20 ml anhydrous CH₂Cl₂ at room temperature 65 hr, evaporated, the residue dissolved in 20 ml EtOH, 0.25 g NaBH₄ was added at 0°, and the mixture kept 23 hr at room temperature to give 0.591 g racemic Et cis-3-ethylpiperidine-4-acetate (XXIX), b₀.5 91-2°. To 0.032 mole (Me₂CH)₂NLi in 7:3 C₆H₆-Et₂O was added 5.6 g 6-methoxylepidine in 60 ml THF, the mixture kept 20 min, 4.6 g XXII in 60 ml THF added, and the mixture stirred 1 hr at 20° to give racemic cis-6-methoxy-4-[3-(1-benzoyl-3-vinyl-4-piperidyl)-2-oxopropyl]quinoline. This (2.8 g) in 150 ml PhMe at 0° was reduced by 12 ml 25% (Me₂CH)2AlH in PhMe. To the racemic product in 40 ml Me₂CO was added 1 g dibenzoyl-d-tartaric acid in 10 ml MeOH. Recrystn. 4 times from MeOH-Me₂CO gave the epimeric cis-6-methoxy-4-[3-(R)-vinyl-4-(S)-piperidyl]-2-hydroxypropyl quinoline (XXX) dibenzoyl-d-tartrate, m. 189-90°, [α]_{25D} -27.4° (c 0.82, MeOH); XXX, oil, [α]_{25D} 39.6° (c 1.425, CHCl₃). Acetylation of 1.15 g XXX by 40 ml HOAc and 4 ml BF₃.Et₂O 18 hr at 50° gave 6-methoxy-4-[3-(R)-vinyl-4-(S)-piperidyl]-2-acetoxypropyl quinoline (XXXI), glass, [α]_{25D} 21.4° (c 0.835, CHCl₃). Dehydration of 0.6 g XXX in 20 ml C₅H₅N by 1 ml SOC₁₂ 4 hr at 0-20° gave 6-methoxy-4-[3-(R)-vinyl-4(R)-piperidyl]prop-1-enyl quinoline (XXXII). To 1.241 g XXXI in 150 ml C₆H₆ and 7.5 ml HOAc was added 17g NaOAc.3H₂O and the mixture refluxed 14 hr to give a mixture (mixt.A) of deoxyquinine and deoxyquinidine. A solution of 0.826 g mixture A in 40 ml 4:1 Me₂SO-Me₂COH was treated 10 min at 20° with dry O, 0.6 g KOCMe₃ added, and the oxidn. continued until 71.5 ml O was taken up to give a mixture (I) [(R1)m = 6-MeO, R2 = vinyl] of quinine and quinidine. Other examples were given.


IT 26599-54-2 26599-55-3P 26695-57-8P

27875-47-4P 27875-48-5P 28888-47-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 26599-54-2 CAPLUS


CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 26599-55-3 CAPLUS


CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aS-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 26695-57-8 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 27875-47-4 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 27875-48-5 CAPLUS
CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 28888-47-3 CAPLUS
CN Spiro[1,3-dioxolane-2,6'(2'H)-isoquinoline],
2'-benzoyloctahydro-4,5-dimethyl-, stereoisomer (9CI) (CA INDEX NAME)



L7 ANSWER 56 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1959:56454 CAPLUS

DOCUMENT NUMBER: 53:56454

ORIGINAL REFERENCE NO.: 53:10223d-i,10224a-e

TITLE: Stereochemistry of the catalytic hydrogenation of some bicyclic α,β -unsaturated ketones

AUTHOR(S): Augustine, Robert L.

CORPORATE SOURCE: Univ. of Texas, Austin

SOURCE: Journal of Organic Chemistry (1958), 23, 1853-6

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB Catalytic hydrogenation of 1,9-octahydronaphthalen-2-one (I) and Δ 4,5-hexahydro-6-isooquinolone (II) under a variety of conditions was studied. The cis-isomer was obtained as the predominant product under acidic conditions. I (500 mg.), 10 ml. solvent, and 50 mg. catalyst was hydrogenated at room temperature under one atmospheric H (after 1 mole H was absorbed the reaction ceased), the catalyst removed, the solvent distilled in vacuo, and the residue subjected directly to vapor phase chromatography. The temperature was kept at 215-20° and helium used as the eluent gas at 80 ml./min. In acidic or neutral medium, 500 mg. I, 9 ml. alc., 50 mg. 10% Pd-C, and 1 ml. either 3N HCl or 10% aqueous NaOH was subjected to hydrogenation at room temperature under one atmospheric of H, after 1 mole H uptake the reaction stopped, the catalyst removed, the solvent evaporated, and the residue taken up in Et₂O. Evaporation of the solvent and vapor phase chromatography was then carried out. At 3 atmospheric, 500 mg. I, 10 ml.

MeOH, and 50% mg. 10% Pd-C was shaken 2 hrs. under 40 lb./sq. in. and worked up as above. The residue showed no unsatn. nor OH peaks in the infrared. It was subjected to vapor phase chromatography as described above. Liquid NH₃ (2 l.) added to 55 g. I in 500 ml. Et₂O, 3 g. Li added in small pieces, left 15 min., treated with a further 150 mg. Li, the solution stirred 1 hr., decomposed by 80 g. NH₄Cl, the NH₃ evaporated overnight, the residue taken up with H₂O, and extracted with Et₂O gave 35 g. trans- β -decalone (III), b₂₈ 127-8°, n_{23D} 1.4820; semicarbazone m. 191-2°; 2,4-dinitrophenylhydrazone m. 165-6°. I (50 g.), 5 g. 10% Pd-C, 250 ml. alc., and 25 ml. 3N HCl hydrogenated at 27° under H gave 35 g. cis- β -decalone (IV), b₂₃ 120-1°, n_{25D} 1.4904; semicarbazone m. 182-3°; 2,4-dinitrophenylhydrazone m. 154-5°. The following hydrogenation results were obtained with I (solvent, catalyst, % IV and % III given): alc., 10% Pd-C, 53, 47; MeOH, 10% Pd-C, 59, 41; MeOH, 10% Pd-C (3 atmospheric pressure), 63, 37; dioxane, 10% Pd-C, 50, 50; alc., 2% Pd-SrCO₃, 64, 36; alc., PtO₂, 72, 28; AcOH, PtO₂, 70, 30; alc., 30% Pd-C. 82, 18; alc.-aqueous NaOH, 10% Pd-C, 62, 38; alc.-aqueous HCl, 10% Pd-C, 93, 7; liquid NH₃, Li, -, 100. II was reduced as the 2-benzoyl-1,2,3,4,8a-hexahydro-6(7)-isoquinolone (V). 1-Benzoyl-4-piperidone (89 g.) and 36 g. pyrrolidine in 400 ml. C6H₆

refluxed 12 hrs. under N, the H₂O formed collected, the C₆H₆ removed, the residue taken up in 400 ml. dioxane, treated with 21 g. Me vinyl ketone, the solution left 45 min. at room temperature, refluxed 3 hrs., then refluxed 1 hr.

with 90 ml. AcOH, 45 g. NaOAc, and 90 ml. H₂O, poured into 2 l. H₂O, extracted with CHCl₃, the CHCl₃ washed with 10% NaOH and saturated NaCl, dried, and evaporated gave a dark oily residue, crystallized to give 36 g. V, m. 144-5° (C₆H₆-cyclohexane), λ 242 m μ , ϵ 12,000;

2,4-dinitrophenylhydrazone m. 226-7° (CHCl₃-alc.). I (5 g.), 100 ml. alc., 10 ml. 3N HCl, and 500 mg. 10% Pd-C hydrogenated at room temperature under 1 atmospheric H, reduction stopped after 1 mole H uptake, filtered, the residue washed with CHCl₃, the combined solns. evaporated, and the residue purified gave 2.7 g. cis-2-benzoyl-1,2,3,4,4a,7,8,8a-octahydro-6(5)-

isoquinolone (VI), m. 148-9° (C₆H₆-cyclohexane); 2,4-dinitrophenylhydrazone m. 200-1°. V (5 g.), 100 ml. alc., and 500 mg. 10% Pd-C hydrogenated at room temperature gave 1.3 g.

trans-2-benzoyloctahydro-6(5H)-isoquinolone (VI), m. 159-60° (95% alc.); 2,4-dinitrophenylhydrazone m. 205-6°. V (0.5 g.), 20 ml. alc., and 50 mg. catalyst hydrogenated at room temperature under 1 atmospheric

H, after

1 mole H uptake the catalyst removed, and the combined solns. evaporated gave mixts. of products with bands at 7.6, 7.7, and 9.1 μ . V (500 mg.), 18 ml. alc., 50 mg. catalyst, and 2 ml. 3N HCl or 10% aqueous NaOH hydrogenated as above, the solution filtered, the residue washed with CHCl₃, the solution evaporated, the residue taken up in CHCl₃, washed with 3N HCl and saturated NaHCO₃, dried, and evaporated gave a mixture of isomers. V (0.5 g.), 20 ml. alc., and 50 mg. 10% Pd-C was shaken at room temperature 1 hr. under 41 lb./sq. in. and worked up as above. The infrared spectrum showed no unsatn. nor OH peaks. The isomer ratio was determined as described. The following product ratio was obtained from the hydrogenation of V as follows (solvent, catalyst, % cis, and % trans forms obtained): alc., 10% Pd-C, 30, 70; alc., 10% Pd-C, 25, 75; alc., 2% Pd-SrCO₃, 40, 60; alc., PtO₂, 65, 35; alc., 30% Pd-C, 55, 45; alc.-aqueous NaOH, 10% Pd-C, 50, 50; alc.-aqueous HCl,

10%

Pd-C, 85, 15; alc.-aqueous HCl, 30% Pd-C, 85, 15. V (4.5 g.) in 250 ml. dioxane added to 500 ml. NH₃, stirred 0.5 hr. with 0.7 g. Li, another 0.7 g. Li added, the solution stirred 3 hrs., the mixture decomposed by the addition of

50 g. NH₄Cl, the NH₃ allowed to evaporate overnight, the residue dissolved in 500 ml. H₂O, the aqueous solution made acidic, saturated with NaCl, extracted with CHCl₃,

the CHCl₃ washed, dried, and evaporated gave 1 g. oil which smelled strongly of BzH. The aqueous solution from the extraction evaporated to a small volume, 500 ml.

CHCl₃ added, then sufficient Na₂CO₃ to neutralize the solution plus 10 g., the mixture refluxed 2 hrs. with 10 g. BzCl, 10 ml. alc. added, refluxed an addnl. 0.5 hr., cooled, H₂O added, the CHCl₃ separated, washed, dried, and distilled gave 200 mg. product not identical with VI, the nature of which was not determined. The mechanism of the above reactions is discussed.


IT 27875-47-4P 27875-48-5P 1089714-61-3P

RL: SPN (Synthetic preparation); PRP (Properties); PREP (Preparation) (Stereochemistry of the catalytic hydrogenation of some bicyclic α,β -unsaturated ketones)

RN 27875-47-4 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aS)-rel- (CA INDEX NAME)


Relative stereochemistry.



RN 27875-48-5 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-, (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.




RN 1089714-61-3 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-,
6-[2-(2,4-dinitrophenyl)hydrazone], (4aR,8aR)-rel- (CA INDEX NAME)

Relative stereochemistry.

Double bond geometry unknown.




IT 102757-27-7P, 6(2H)-Isoquinolinone, 2-benzoyloctahydro-,
(2,4-dinitrophenyl)hydrazone

RL: PREP (Preparation)
(preparation of)

RN 102757-27-7 CAPLUS


CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro-,
6-[2-(2,4-dinitrophenyl)hydrazone] (CA INDEX NAME)



IT 7511-21-9, 6(2H)-Isoquinolone, 2-benzoyloctahydro-
(stereoisomers)

RN 7511-21-9 CAPLUS

CN 6(2H)-Isoquinolinone, 2-benzoyloctahydro- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

L7 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1950:3133 CAPLUS

DOCUMENT NUMBER: 44:3133

ORIGINAL REFERENCE NO.: 44:640i,641a-g

TITLE: Stereochemistry of yohimbine

AUTHOR(S): Witkop, Bernhard

SOURCE: Journal of the American Chemical Society (1949), 71, 2559-66

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB A method is described by which yohimbine can be degraded to an optically active 2-methyl-trans-decahydroisoquinoline (I). The identification of this base with synthetic resolved material subsequently established the stereochemical relationship of C atoms 12 and 20 in yohimbine. The previous method of preparation of chano-desoxyyohimbol (II) (earlier designation, desoxyyohimbol) (C.A. 37, 5407.3) is modified to give 8-12% from yohimbic acid (III); not more than 3-5 g. III should be employed for 1 distillation, the ratio of III to Ti2O should be 5:1, and the temperature should be below 300°; in a 2nd method, 2 g. III and 0.4 g. Ti2CO3 were distilled at 0.01 mm. and 280°; 70 g. III yields 1.9 g. II, m. 151°. The MeOH mother liquors from II by the 1st method yielded further II and chano-isodesoxyyohimbol, m. 206°; it forms 2 methiodides, chars about 280°, and m. 254°, the latter being more soluble in MeOH. Reduction of II over Pt oxide in AcOH (15 min.) gives the dihydro derivative (IV), m. 130°, [α]D -2.5°; it yields 2.18% N-Me in the Herzig-Meyer determination; picrate, red, m. 190°. The methiodide of II, converted to the amorphous quaternary base and heated in vacuo at 170°, gives 1-methyl-trans-octahydroisoquinoline, whose picrate, yellow, m. 229-31° (the needles are transformed into prisms at 210°). IV yields an amorphous methiodide (V), which was converted to the picrate, m. 223-5°; the carbonate from V and Ti2CO3, heated at 180°/30 mm., gives 79% I, isolated as the HCl salt, m. 225-7°, [α]D 1.4° (H2O, c 4.9); picrate, yellow, m.

234-7°; picrolonate, golden, m. 199-201°; chloroaurate, m. 90-2°; bis(dibenzoyl-L-tartrate), m. 167-8° (decomposition), $[\alpha]_D$ 82.2° (MeOH, c 2.02); α -bromo-camphor- π -sulfonate, m. 170-2° $[\alpha]_D$ 71.4° (MeOH). Isoquinoline (VI) yields a bioxalate, m. 148°. VI, hydrogenated with Pt oxide in AcOH to the pyr-tetrahydro derivative, acetylated (1-Ac derivative, m. 45°), and reduced in EtOH over Raney Ni 17 hrs. at 164°/3000 lb./sq. in., gives 0.7 g. 1-ethyldecahydroisoquinoline, whose picrate, yellow, m. 154° (presumably the trans compound). VI (55 g.) in 400 cc. methylcyclohexane, hydrogenated (15 hrs.) with 15 g. Raney Ni at 180°/4000 lb./sq. in., the hydrogenated base (58 g.) refluxed 24 hrs. with 1 g. Pd black, and the distilled product (b2 75-105°) acetylated, extracted with dilute acid, hydrolyzed, and benzoylated, gives benzoyl-trans-decahydroisoquinoline, m. 97-9°. dl-I (1.53 g.) and 1.5 g. D-tartaric acid in hot ETOH give 1.41 g. of d-I D-bitartrate, m. 167-9° $[\alpha]_D$ 14.6° (H2O, c 2.05). dl-I gives a bis(dibenzoyl-L-tartrate), m. 154-5° (decomposition); the salt is suitable for characterization but not for resolution; picrolonate, m. 216-19°; HCl salt, m. 164-5°. These results indicate that in yohimbine rings D and E are trans-locked. No curariform activity was observed for the methochlorides (in doses of 12.5 mg./kg. frog) of II, IV, and quebrachamine.

IT 879276-56-9P, Isoquinoline, 2-benzoyldecahydro-, trans-


RL: PREP (Preparation)

(preparation of)

RN 879276-56-9 CAPLUS

CN Methanone, [(4aR,8aS)-octahydro-2(1H)-isoquinolinyl]phenyl-, rel- (CA INDEX NAME)

Relative stereochemistry.



=>